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Introduction
1 Introduction
1.1 Lung cancer 
Lung cancer can be induced by inhalation of irritants such as tobacco smoke, asbestos or 
radon gas [47]. In addition, individuals with genetic predisposition can develop lung cancer 
without  being  exposed  to  these  exogenous  irritants  [74].  Lung  cancer  is  a  result  of 
transformation and uncontrolled growth of lung tissue cells referred to as cancer cells. This 
can be caused by changes in the regulation of genes involved in the control of cell cycle and 
cell  death [41].  Although the immune system normally removes abnormal cells  from the 
body, some cancer cells are able to hide from the immune system [64].
In a first step of cancer development, the high proliferation rate of cancer cells leads 
to  the  formation  of  cell  clusters,  called  tumors.  Tumors  can  interfere  with  normal  lung 
functions, which provide oxygen to the body via the blood circulation. The treatment options 
such as  surgery, radiation and chemotherapy are quite invasive for the patients [123]. The 
understanding  of  lung  cancer  biology  grows  exponentially  leading  to  the  generation  of 
targeted  drugs  such  as  small  molecule  inhibitors  and  blocking  antibodies  against  the 
activation  of  growth  factor  receptors  [49;139;162].  However,  only  15%  of  lung  cancer 
patients will live for five years after diagnosis [44]. This is due to the fact that lung cancer 
has a high probability to spread into other tissues or organs caused by cancer cells that leave 
the primary tumor and enter the blood or lymph circulation [128]. Cancer cells form new 
tumors at other sites in the body and the new tumor is referred to as metastasis [56]. The 
process of tumor metastasis is depicted in figure 1.
In order to spread through the body, cancer cells rearrange their cytoskeleton, increase 
their motility and adhere to other cells as well as the extracellular matrix (ECM) via adhesion 
molecules.  Cancer  cells  also  secret  proteases  to  degrade  substrates  such  as  membrane 
junctions which helps them to invade into other tissues [140]. All these processes are critical 
parameters in metastasis formation [140]. Cancer research identified a collection of genes 
related to cell motility [136;178]. However, only a few drugs were specifically designed to 
target  cell  motility  related  pathways  [23;31].  Therefore,  further  understanding  and 
improvement of drug targets against cancer cell motility is needed.
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Figure  .  Process  of 
cancer metastasis.
Cancer  cells  from  a 
proliferative,  primary 
tumor can migrate to blood vessels where the cancer cell adheres and in a further step invades.  
The cancer cell circulates through the blood and adheres at another location in the blood vessel. Again, the  
cancer cell invades through the blood vessel and migrates into the surrounding tissue. In this distant tissue, the 
cancer cell proliferates and forms a new tumor, called metastasis [140].
1.2 The mechanisms of cell motility 
The mechanisms of cell motility allow cancer cells to change their location not only within 
the  tissue  but  also  throughout  the  whole  body to  form metastases.  To spread within  the 
tissues, cancer cells use mechanisms similar to those used in normal physiological processes 
such as embryogenesis,  development,  wound healing and immune cell  recruitment  [186]. 
These processes include mechanisms of adhesion, migration and invasion. Adhesion is the 
reversible attachment of a cell, either to another cell (cell-cell adhesion) or to a substrate such 
as  the  extracellular  matrix  (cell-matrix  adhesion).  This  process  is  mediated  by  adhesion 
molecules [133]. Cells have the ability to move from one location to another which is called 
cell  migration.  It  involves  several  adhesive  processes,  cytoskeletal  reorganization  and 
signaling pathways. In principle, invasion requires the same processes as cell migration and 
additionally the ability to permeate to the ECM or to enter neighboring tissues [25].
1.3 Steps in cell motility
Interaction with the extracellular matrix and the remodeling and reorganization of specialized 
adhesions sites are essential processes in cell movement. This adhesion sides are formed by a 
structural  link  between  the  actin  cytoskeleton  and  the  extracellular  matrix  components 
through adhesion molecules. The constant assembly and disassembly of adhesions must be 
tightly regulated.  This is  accompanied by the activation of surface receptors upstream of 
intracellular signaling, cell polarization and the constant rearrangement of the cytoskeleton 
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[27]. These dynamics are involved in the four steps of cell movement including polarization, 
protusion,  adhesion  and  translocation  (Figure  ).  First,  polarization in  cell  movement  is 
induced by extracellular or intracellular signals and is characterized through the formation of 
front  and rear  ends  that  coordinate  the  direction  of  cell  movement  [85].  Afterwards,  the 
process of protusion takes place and drives the actin assembly to extend flat (referred to as 
lamellipodia ) and fingerlike (referred to as filopodia) cellular membranes [108]. In the next 
step  called  adhesion,  the  cellular  membrane  extensions  form  connections  via  adhesion 
molecules. These connections comprise small and highly transient connections and are less 
stable so that they can be disassembled for further movement. This type of adhesion is called 
nascent adhesion [172]. The movement of a cell in the direction of a newly formed adhesion 
and  the  detachment  of  older  adhesions  leads  to  cell  body translocation.  This  process  is 
characterized by a high degree of actin-mysin contractile activity [5].
Polarization
Protusion
Adhesion
Translocation
Direction of movement
Lamellipodia/filopodia
nascent adhesion
actin
cytoskeleton
nucleus
adhesion sites
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Figure . Model of cell movement.
Polarization: after signal induction for motility processes, the actin filaments reorganize and start to define front 
and rear ends to coordinate cell movement. Protrusion: in the next step, the reorganization of actin filaments 
leads to membrane extensions. Adhesion: the membrane protrusion facilitates the binding to the surface by the 
generation of new attachments sites. Translocation of the cell body: the cell uses contractile force to move into  
the direction of new adhesion sites (modified from [168]).
The cellular adhesion sites include different types of adhesions such as nascent adhesions and 
focal adhesions. The nascent adhesions are small and highly transient while focal adhesions 
are  mature  adhesions  that  developed  slowly  over  time.  Focal  adhesions  are  specialized 
structures and include numerous regulatory proteins [172].
1.4 Focal adhesions
Focal adhesions are dynamic, multi-protein complexes that form links between intracellular 
cytoskeleton proteins and the extracellular substrates and are found at the protrusion edges of 
a cell [121]. In general, focal adhesions consist of adaptor proteins, paxillin, Scr and the focal 
adhesion kinase (Figure  ).  The formation of  focal  adhesions  is  initiated upon binding of 
adhesion molecules such as integrins to ECM ligands [147]. The components of the focal 
adhesion  complex  are  explained  in  detail  in  the  following  and  depicted  in  figure3. The 
integrin family is  the best  studied family of adhesion receptors.  They are expressed in  a 
distinct manner on different cell  types  including immune cells,  endothelial  and epithelial 
cells. Integrins are transmembrane heterodimeric receptors consisting of an alpha (α) and a 
beta (β) subunit. The two subunits comprise 18 α and 8 β subunits to form at least 24 specific 
integrin receptors. Via their extracellular domain, integrins bind specifically to the ECM such 
as  laminins,  collagens  and  fibronectin  [22].  Binding  to  fibronectin  is  mediated  by  α5β1 
integrin subunits, also called fibronectin receptors whereas α2β1 integrins bind to collagen 
[83]. Upon binding to ECM ligands, a signal transduction cascade is initiated and is mediated 
by the cytoplasmic domain of integrins, which are linked to actin microfilaments via adaptor 
proteins such as talin, tensin, vinculin, and paxillin (Figure ) [76]. Integrins have been shown 
to play major roles in cancer progression and metastasis by influencing adhesion dynamics, 
cell  movement  and  signaling  pathways  [51;122;172;183].  For  example, blocking  of  β1 
integrin  in  human  lung  cancer  cells  was  shown to  decrease  adhesion  to  fibronectin  and 
depends on p38 signaling [187]. Moreover, α1β1 integrin-dependent murine endothelial cell 
migration was shown to be mediated by p38 and Akt activation [2]. Further, integrin α5β1 in 
fibroblasts were demonstrated to be essential  for invasion mediated by the small GTPase 
RhoA [63]. Paxillin is an important adaptor protein in focal adhesions that allows interactions 
of different structural and signaling molecules. The binding domains of paxillin are located at 
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the C- and N- terminus. The C-terminus of paxillin is responsible for paxillin anchoring at 
the plasma membrane. The N-terminus of paxillin comprises five leucine-rich domains (LD), 
which act as binding site for tyrosine kinases. Upon phosphorylation by tyrosine kinases such 
as  c-Src  and  focal  adhesion  kinase  (FAK),  paxillin  was  shown  to  induce  cytoskeleton 
rearrangement  by  different  signal  transduction  pathways  [17;153;170].  In  addition, 
overexpression of paxillin increased human squamous cancer cell migration and invasion on 
type IV collagen which was shown to be dependent on the mitogen activated protein kinase 
(MAPK) pathway [45].
FAK is a cytoplasmic tyrosine kinase that is exclusively localized in focal adhesions. FAK 
consists of an N-terminal FERM (4.1 protein, ezrin-radixin-moesin) domain, a central kinase 
domain and a C-terminal domain containing the focal adhesion targeting (FAT) sequence, 
which  guides  FAK to  focal  adhesions.  Upon FAK activation,  a  specific  tyrosine  residue 
becomes phosphorylated. It was demonstrated that FAK is activated by autophosphorylation 
at  tyrosine 397 due  to  adhesion  molecule  engagement  [121].  Further,  clustering of  focal 
adhesions  enhances  autophosphorylation  at  tyrosine  397  [75].  In  addition, 
autophophorylation of FAK leads to further phosphorylation of tyrosine residues by Src and 
enhances  FAK  activity  [121].  In  contrast,  FAK  was  found  to  be  excluded  from  focal 
adhesions by Src mediated phosphorylation at tyrosine 925 located in the FAT sequence [99]. 
FAK-deficient mice showed an embryonic lethal phenotype. However, embryonic fibroblast-
like cells from FAK deficient mice showed reduced cell motility, but interestingly enhanced 
focal adhesions. This indicates that FAK is involved in the turnover of focal adhesions during 
cell  motility [87].  Further,  FAK activity is  linked  to  signaling pathways involved in cell 
motility. For example, the inhibition of FAK expression via siRNA led to decreased adhesion 
and phosphorylation of ERK in human pancreatic cells [152]. In addition, activation of the 
PI3-K/Akt signaling pathway dependent cell migration is blocked by FAK knockdown in 
colorectal cancer cells [169]. Moreover, FAK knockdown led to decreased activation of p38 
and reduced cell migration [179].
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Figure . Composition of focal adhesions.
Upon binding of integrins to ECM ligands, adaptor proteins such as vinculin, tensin and paxillin are recruited.  
These  proteins  stabilize the  complex formation and mediate signals  to  talin  which  is  coupled to  the actin 
filament.  Actinin  serves  as  connecting molecule  between the  different  actin  filaments.  The  focal  adhesion 
components and the Src kinase increase the activation and regulation of recruited proteins for focal adhesion 
assembly and disassembly [46;98].
1.5 Induction of cell motility 
The induction of cell motility is important in physiological and pathophysiological processes 
such as homeostasis, wound healing, inflammation and cancer. In homeostasis, the constant 
renewal of tissue cells within the adult organism is induced by the release of mediators to 
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recruit stem cells which replace the old tissue cell [62]. In cancer progression, the abnormal 
production of  migratory signals (e.g.  transforming growth factor-β (TGF-β))  induces  cell 
motility of the cancer cells to the distant tissues [50;60;61]. The induction of cell motility 
involves various types of soluble mediators and surface expressed molecules, which include 
growth  factors,  chemokines,  and  proteoglycans.  Growth  factors are  soluble  signaling 
polypeptides  produced  by  various  cell  types  and  involved  in  the  maintenance  of 
physiological and pathophysiological processes such as skin regeneration, wound healing and 
cancer  [23;182].  Major  regulatory  molecules  include  fibroblast  growth  factor  (FGF), 
transforming growth factor (TGF) and epithelial growth factor (EGF) [16;79;180]. Growth 
factors  play a  critical  role  in  cancer  cell  proliferation  and also  regulate  cell  motility  by 
decreasing  or  increasing  expression  of  proteins  involved in  cell  adhesion,  migration  and 
invasion [70;182]. For example, TGF-β was found to stimulate the expression of integrins 
and ECM degrading enzymes [67]. Moreover, focal adhesion complex formation in epithelial 
cells  was shown to be induced by TGF-β [88].  Cancer cells  migrate  along a gradient  of 
growth  factors,  which  guide  cancer  cells  into  distant  tissues  and  leads  to  cancer  cell 
metastasis formation [182]. Chemotactic cytokines called chemokines belong to the family of 
small, secreted proteins that bind to specific chemokine receptors belonging to the group of 
heptahelical G-protein-coupled receptors (GPCR) [3]. Chemokines are important mediators 
responsible  for  recruiting  immune  cells  to  the  site  of  inflammation  by  binding  to 
proteoglycans  [72].  In  cancer  cells,  chemokines  including  [C  X  C  motif]  ligand  12 
(CXCL12)  and  [C  C  motif]  ligand  18  (CCL18)  play  a  critical  role  for  cancer  cells  by 
modulating of proliferation and migration [24;188].
Proteoglycans bind extracellular ligands such as growth factors and chemokines to 
allow the interaction with the cognate receptor, which leads to the regulation or induction of 
processes involved in cell motility. They were found to be upregulated in tumor cells and 
play  a  critical  role  in  metastasis  by  changing  the  tumor  microenvironment  [89;90].  In 
general, proteoglycans are expressed in cellular or extra cellular compartments as membrane 
expressed or soluble or form. Proteoglycans are highly glycosylated and consist of a core 
protein, which carries covalently attached glycosaminoglycan (GAG) chains. GAGs are long 
unbranched polysaccharidesbuilt of disaccharide repeats. The GAGs can be further modified 
by chondroitin sulfate, keratin sulfate, dermatan sulfate, heparin sulfate, and heparan sulfate, 
whereby  different  types  of  proteoglycans  are  defined  [91].  Especially  heparan  sulfate 
proteoglycans  have  been  shown  to  regulate  cancer  cell  motility  by  acting  as  signal 
transduction mediators and binding sites for chemokines, growth factors or ECM proteins 
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[89;90]. Heparan sulfate proteoglycans (HSPGs) contain covalently attached heparan sulfated 
GAG chains. There are three classes of HSPGs: perlecan and agrin, glypicans and syndecans. 
Perlecan and agrin are present as non-anchored HSPGs in the basement membrane whereas 
the class of cell surface HSPGs including glypicans and syndecans are anchored to the cell 
membrane.  Syndecans  are  type  I  transmembrane  proteins  and  have  been  shown  to  be 
critically involved in cancer development [9;20;151].
1.6. Syndecans
The syndecans are a family of transmembrane heparan sulfate proteoglycans. The syndecan 
family in vertebrates comprises four members:  syndecan-1, -2,  -3, and -4.  Syndecan-1 is 
predominantly  expressed  in  epithelial  cells,  whereas  syndecan-2  is  found  in  fibroblasts. 
Syndecan-3 is mainly expressed by cells of the nervous system. In contrast, syndecan-4 is 
found in various cell types including epithelial cells, endothelial cells, fibroblasts and cells of 
the nervous system. In general, changes in syndecan expression occur during embryogenesis 
and  development,  but  also  under  pathological  conditions  such  as  inflammation,  wound 
healing and tumor development [68;100;126].
The four syndecans share a common structure.  Each syndecan core consists of an 
extracellular domain with covalently attached sulfated heparan and chondroitin GAG chains, 
a single transmembrane domain, and a short cytoplasmic domain (Figure ). The extracellular 
domain of  each syndecan differs in  the composition of  GAG chains.  Syndecan-2 and -4 
contain only heparan GAG chains, while syndecan-1 and -3 also carry chondroitin chains 
[167].
12
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Figure . Structure of syndecans.
Syndecans consist of an extracellular domain with attached heparan sulfated GAG chains, a transmembrane 
domain  and a short cytoplasmic domain containing the C1, V (Variable) and C2 region.  Syndecan-2 and -4 
contain only heparan sulfated GAGs while syndecan-1 and syndecan-4 also contain chondroitin sulfate chains 
(modified from [167]).
The transmembrane domain of all syndecan family members has a typical type I membrane 
protein architecture. The short cytoplasmic domain of all syndecans contains one variable (V) 
region flanked by two regions: a membrane proximal region C1 and the C-terminal region C2 
(Figure ). Homology analyses of the different regions showed that the C1 and C2 region is 
conserved  across  all  syndecans.  In  contrast,  the  V region  is  unique  for  each  syndecan 
[126;167].
C1 V C2
RMKKDEGSY
RMKKDEGSY
RMKKDEGSY
RMKKDEGSY
SLEEPKQANGGAYQKPTKQE
DLGERKPSXSAAYQKAPTKX
TLEEPKQASXVTYQKPDKQE
DLGXKKPXXXXIYKKAPTNX
EFYA
EFYA
EFYA
EFYA
Syndecan-1
Syndecan-2
Syndecan-3
Syndecan-4
Figure . The cytoplasmic domains of syndecans.
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The short cytoplasmic domain of all syndecans contains one variable (V) region flanked by two conserved 
regions: C1 and C2 (red crosses indicate gaps) (modified from [167]).
Within  the  syndecan  family,  syndecan-1  and  -4  have  been  studied  most  intensively.  As 
explained below, both syndecans are implicated in cell motility regulation.
1.6.2 Syndecan-1
Syndecan-1 is expressed by epithelial cells, endothelial cells and plasma cells. Syndecan-1 
can interact with components of the extracellular matrix via the glycosaminoglycan chains, 
but also binds various extracellular ligands including growth factors, chemokines, cytokines 
and  proteases  [20;42;104;104].  Acting  as  docking  receptor,  syndecan-1  recruits  growth 
factors  to  the  cell  surface  and  allows  them  to  interact  with  their  cognate  receptors.  In 
addition,  syndecan-bound  chemokines  can  be  presented  to  patrolling  leukocytes  on  the 
endothelial and epithelial surface and then activate their chemokine receptors [165].
Various  studies  have  shown  that  syndecan-1  critically  modulates  adhesion  and 
migration of various cell types including tumor cells  in vitro and  in vivo. Knockdown of 
syndecan-1 via siRNA in lung epithelial  cells showed decreased lung tumor formation in 
mice  [119].  Further,  leukocytes  from  syndecan-1-deficient  mice  showed  an  increased 
leukocyte-endothelial  interaction  [69].  Of  note,  full-length  knockdown  of  syndecan-1 
promotes  adhesion  of  breast  cancer  cells  to  fibronectin  [78].  Furthermore,  removal  of 
syndecan-1 increased apoptosis in myeloma cells in vitro [184]. This activity can be in part 
due  to  the  docking  receptor  function  of  syndecan-1  for  extracellular  proteins.  However, 
syndecan-1  is  also  capable  of  various  intracellular  interactions,  which  can  influence  cell 
adhesion and migration (Figure  ).  The C-terminal  C2 region of syndecan1 was found to 
contribute to the binding of postsynaptic density, discs large, zona occludens 1 (PDZ) domain 
proteins,  such  as  syntenin  and  T-lymphoma  invasion  and  metastasis-inducing  protein  1 
(Tiam1), as well as intracellular interaction with other surface proteins such as α6β4 integrin 
[73;159;174]. In this study, it was shown that a part of the V and C2 region of syndecan-1 can 
couple to α6 and β4 integrin and thereby regulate cell motility. Moreover, the V region of 
syndecan-1 has been implicated in fascin rich spikes during cell spreading [30]. In addition, 
syndecan-1 can act as regulator of αvβ3  and αvβ5  integrin activation [12;174]. Cooperation 
between α5β1 integrins and syndecan1 was also reported during focal adhesion formation and 
migration. Interestingly, the latter pathway can either enhance or suppress these processes 
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[13;78;119]. Further, activation of focal adhesion kinase (FAK) and Rho GTPase have been 
implicated in syndecan-1 mediated effects on cell migration [118;159].
1.6.3 Syndecan-4
Syndecan-4  is  mainly expressed  by epithelial  and endothelial  cells,  but  is  also  found in 
various other cell types. The syndecan-4 ectodomain can bind several ligands such as ECM 
proteins, growth factors, proteases, chemokines and cytokines. Besides capturing molecules 
via glycosaminoglycan chains, the ectodomain of syndecan-4 can cooperate with integrins to 
maintain cell adhesion and migration [43].  In vivo experiments with syndecan-4-deficient 
mice showed decreased wound healing and angiogenesis [52]. Knockout of syndecan-4 in 
murine fibroblasts impaire focal adhesion formation in an heparin-binding domain dependent 
manner  [93].  Overexpression  of  syndecan-4  in  Chinese  hamster  ovary  cells  (CHO)  was 
shown to promote focal adhesion resulting in reduced cell migration, whereas disruption of 
the V domain of syndecan-4 reduced focal adhesion formation in rat endothelial cells [81]. 
The cytoplasmic domain of syndecan-4 includes a number of signaling motifs for adapter and 
signaling  molecules  involved  in  cell  motility  (Figure  ).  In  fact,  the  unique  V region  of 
syndecan-4 has been shown to activate and recruit protein kinase C α (PKCα) by binding of 
phosphatidylinositol 4, 5-bisphosphate (PIP2) to stabilize the dimer formation [126]. PKCα 
recruitment  and  activation  were  shown  to  regulate  focal  adhesion  and  cytoskeleton 
reorganization [58].  Moreover, the C2 region interacts with PDZ binding proteins synectin 
and  calcium/calmodulin-dependent  serine  kinase  (CASK),  which  are  described  to  be 
involved in cell motility [65;82]. 
Syndecan-1 Syndecan-4
C1
V
C2
ezrin*  ezrin*  
α6β4 integrin cytoplasmic 
domain
PKCα
α-actinin
syndesmos
syntenin
Tiam1
α6β4 integrin
cytoplasmic domain
CASK
synectin
synbindin
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Figure . Interaction partners of syndecan-1 and -4 cytoplasmic subdomains.
Syndecan-1 and -4 have been shown to interact with different molecules in the cytoplasm. The C1 subdomain of 
syndecan-4 is thought to interact with proteins involved in cytoskeletal reorganization such as ezrin [167]. A 
part of the unique V and C2 subdomain of syndecan-1 and -4 were shown to couple with the intracellular  
domain of α6β4 integrin [174]. Further, syndecan-4 was demonstrated to interact with α-actinin and syndesmos 
[7;71]. Moreover, syndecan-4 is the only syndecan that contains a binding pocket for PIP2 which is a substrate  
for PKCα [167]. The C2 domain of syndecan-1 and -4 was shown to interact with PDZ binding proteins such as 
syntenin, Tiam1 and synectin and CASK.*Shown for syndecan-2, but it is speculated that ezrin binds to the C1 
region of syndecan-4, since the binding domain is similar [65;73;82;159].
1.6.3 Proteolytic processing of syndecans
Syndecans exist as membrane bound forms but also as soluble variants [127]. The proteolytic 
processing of syndecans is comprised of two consecutive events. The shedding by ADAM17 
or matrix metalloproteinases (MMPs) leads to the generation of a soluble ectodomain and a 
remaining  C-terminal  transmembrane  fragment  (tCTF).  The  tCTF  undergoes  further 
processing  by  intramembrane  proteolysis  generating  a  cytoplasmic  C-terminal  fragment 
(cCTF).
Syndecan shedding
Surface expressed syndecans can undergo limited proteolysis near to the plasma membrane 
leading to the generation of a residual tCTF and the release of the soluble ectodomain (Figure
). The release of the soluble ectodomain is called shedding. A basal shedding activity results 
in the constitutive release of soluble syndecans by cultured cells. However, shedding can also 
be  induced  by  a  number  of  extracellular  stimuli  such  as  growth-factors,  chemokines, 
heparanase, bacterial toxins as well as cellular stress [32;37;39]. The release of a soluble 
syndecan  ectodomain  is  mediated  by  proteolytic  enzymes,  which  belong  to  the 
metalloproteinase family. MMPs -7; -9; -14 as well as a disintegrins and metalloproteinases 
(ADAMs), especially ADAM17, were found to be capable of cleaving syndecans close to the 
cell surface [26;36;143]. ADAMs are transmembrane proteins that contain a cell adhesion 
and a protease domain. Various stimuli molecules including thrombin, phorbol 12-myristate 
13-acetate (PMA) or proinflammatory mediators such as tumor necrosis factor-α (TNF-α) 
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and interferon-γ (IFN-γ) stimulate ADAM17-dependent shedding of syndecan-1 and -4 in 
lung tumor epithelial A549 cells [143]. Soluble syndecan-1 and -4 can fulfil various functions 
and have  been described to  promote  inflammation,  cell  migration,  metastasis  and  tumor 
proliferation [55;149;163]. Further, soluble syndecan-1 was found to increase transepithelial 
migration of neutrophils in a murine model of acute lung injury by promoting the formation 
of  a  chemokine  gradient  [110].  Moreover,  soluble  syndecan-1  and  -4  ectodomains  were 
found in wound fluids  from acute dermal  injuries [57].  In addition,  clinical studies have 
demonstrated that  the  ectodomain of  syndecan-1 is  released  into  the blood fluid of  lung 
cancer  patients  and  high  levels  have  been  associated  with  poor  prognosis  and  outcome 
[77;96;158].
Extracellular space
Intracellular space
Membrane
Active ADAM17
C1
V
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C 1
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C 2
TM
Syndecan Soluble syndecan ectodomain
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C2
TM Transmembrane C-terminal 
fragment (tCTF)
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C2
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Figure . Syndecan shedding by ADAM17.
The ectodomains of syndecans are cleaved by activated ADAM17 near to the plasma membrane, which results 
in the release of a soluble ectodomain and a residual transmembrane C-terminal fragment (tCTF) of syndecan  
(modified from [142]).
Intramembrane proteolysis of syndecans
Following  ectodomain  cleavage,  the  membrane  associated  tCTF of  syndecans  undergoes 
intramembrane proteolytic cleavage leading to the generation of the cCTF (Figure  ).  The 
process  of  intramembrane  proteolysis is  mediated  by  the  γ-secretase-complex.  The  γ-
secretase-complex consists of four integral membrane proteins: presenilin enhacer-2 (PEN-
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2), anterior pharynx-defective-1 (APH-1), nicastrin and presenilin, which is the proteolytic 
active component of the complex [97]. The process of intramembrane proteolysis via the γ-
secretase-complex  was  described  for  syndecan-3  and  was  shown  to  decrease  membrane 
localization of the cytosolic signaling molecule CASK [157].
Extracellular space
Intracellular space
Membrane
γ-secretase complex
C1
V
C2
C1
V
C2
Syndecan cytoplasmic C-terminal 
fragtment (cCTF)
intramembrane proteolysis
C1
V
C2
TM
C1
V
C2
TM Syndecan tCTF
Figure . Intramembrane proteolysis of syndecans by γ-secretase.
The intramembrane proteolysis of syndecan is mediated by the γ-secretase-complex and results in the release of 
the cytoplasmic C-terminal fragment (cCTF) into the cytoplasm (modified from [142]).
Potentional function of syndecan cleavage fragments 
The process of shedding and intramembrane proteolysis leads to loss of syndecan. However, 
it remains unclear how the loss of syndecans affects cell functions such as cell motility  in  
vitro and  in  vivo.  Moreover,  the  analysis  of  potential  functions  of  syndecan cytoplasmic 
cleavage fragments emerging from intramembrane proteolysis is complicated by the fact that 
these fragments can undergo further proteolysis via the proteasome as it has been described 
for  the  chemokines  CX3CL1 and  CXCL16,  the  cytokine  receptor  interleukin  6  receptor 
(IL6R) or the amyloid precursor protein (APP) [31;130;155].  The question arises to what 
extend  syndecan  cleavage  fragments  affects  cell  function.  In  particular,  what  the 
consequences of the residual tCTF are on cell motility and whether the cCTF impacts the cell 
function in vitro and in vivo.
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2 Aim of the study
The aim of this study was to investigate the consequences of syndecan-1 and -4 shedding and 
intramembrane proteolysis with regard to the influence of generated cleavage fragments on 
cell motility in vitro and in vivo. Human lung epithelial adenocarcinoma (A549) cells were 
used as model since these cells express syndecan-1 and -4. Further, these cells were used in a 
xenograft  transplantation  model  of  lung  metastasis  formation  to  investigate  the  in  vivo 
relevance. The study was divided into two parts focusing on the transmembrane cleavage 
fragments  generated  by  shedding  and  the  cytoplasmic  cleavage  fragments  generated  by 
intramembrane proteolysis, respectively. 
Part  1:  Functional  analysis  of  the  transmembrane  C-terminal  fragment  (tCTF)  of 
syndecan-1 and -4 on cancer cell motility in vitro and in vivo
First, the  generation  of  the  transmembrane  cleavage  fragments  was  investigated  during 
wound closure of A549 cells. To understand the function of syndecan-1 and -4 proteolysis on 
cancer cell motility, lentiviral-shRNA mediated knockdown of syndecan-1 or -4 in A549 cells 
was performed. This allowed to analyze the impact of syndecan-1 and -4 on cell migration, 
proliferation, invasion and related signaling pathways. To address the  in vivo relevance of 
syndecan-1 and -4, a xenograft transplantation model in severe combined immunodeficiency 
(SCID)  mice  was  established.  This  model  was  then  used  to  study  the  lung  metastasis 
formation of syndecan deficient A549 cells.  To understand  the role of syndecan tCTFs as 
possible  regulators  in  cell  migration,  proliferation,  invasion,  syndecan-related  signaling 
pathways and lung metastasis formation,  syndecan deficient A549 cells were transduced to 
express syndecan tCTFs.
Part  2:  Functional  analysis  of  the  cytoplasmic  C-terminal  fragment  (cCTF)  of 
syndecan-1 on cancer cell motility in vitro and in vivo
The  second  part  addresses  the  question  whether  the  cCTF  generated  by  intramembrane 
proteolysis can still exert specific functions that may be relevant in the context of cancer cell 
motility. For this study, A549 cells were transduced with lentivirus to overexpress syndecan-1 
cCTF. These cells were then analyzed for transcriptional regulation, cell migration, invasion, 
proliferation, syndecan-related signaling pathways in vitro and lung metastasis formation in  
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vivo. To confirm the effects  of  syndecan-1 cCTF overexpression  on cellular  functions,  a 
synthetic peptide corresponding to the syndecan-1 cCTF was used to investigate the effects 
on cell migration and syndecan-related signaling pathways.
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3 Materials and Methods
3.1 Materials, chemicals and equipment
Equipment 
Cell culture bench Hera Safe KS 12 Thermo Fischer, Waltham, MA USA
Cell culture incubator C150 Binder, Tuttlingen, Ger
Centrifuge 5415R Eppendorf, Hamburg, Ger
Centrifuge 5810R Eppendorf, Hamburg, Ger
Centrifuge Avanti J-25 Beckman Coulter, Krefeld, Ger
Flowcytometer LSRFortessa BD Biosciences, Heidelberg, Ger
Fluorescence microscope DMIRB Leica, Wetzlar, Ger
Hemocytometer Brand, Wertheim, Ger
IncuCyteTM ZOOM
Live-cell imaging microscope
Essen Biosciences, Hertfordshire, UK
LAS-3000 (Western Blot) Fujifilm, Düsseldorf, Ger
LightCycler 480 Roche, Penzberg, Ger
MS2-Minishaker (Vortex) IKA® Werke GmbH & Co. KG, Staufen, Ger
NanoDrop-ND-1000 PEQLAB Biotechnologie GmbH, Erlangen, Ger
PCR-Cycler Biometra Analytik GmbH, Göttingen, Ger
Pipettes Eppendorf, Hamburg, Ger
Polyacrylamidgelelectrophoresechamber BIO-RAD, Hercules, USA
Thermomixer comfort Eppendorf, Hamburg, Ger
Ultracentrifuge L7-65 Beckman Coulter, Krefeld, Ger
96-well wound makerTM Essen Biosciences, Hertfordshire, UK
Consumables
All cell culture dishes were purchased from Sarstedt (Nürnberg, Ger).
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50ml Tubes Greiner Bio-One GmbH, Frickenhausen, Ger
Filter pipette tips Tip One Starlab, Merenschwand, CH
Glass pipettes Brand GmbH & Co KG, Wertheim, Ger
Pipette tips (1000 µL)
Heinz Herenz Medizinalbedarf, Hamburg, 
Ger
Pipette tips (100/10 µL) Sarstedt, Nürnberg, Ger
Polycarbonate ultra-centrifugation tubes BD biosciences, Heidelberg, Ger
qPCR-plates (96 wells) BIO Plastics, Landgraaf, NL
Chemicals
Basement membrane matrigel BD biosciences, Heidelberg, Ger
BSA PAA Laboratories GmbH, Linz, Austria
Chariot™ active motif Active motif, Rixensart, B
Collagen G Biochrome, Berlin, Ger
Fibronectin Biochrom, Berlin, Ger
Lipofectamin 2000 Lifetechnologies, Carlsbad, CA, US
Mitomycin medac 10 mg Medac, Hamburg, Ger
jetPEI Poly Plus Transfections, Illkirch, F
Kits
QIA Shredder (cell homogenization) Qiagen, Hilden, Ger
Chariot peptide delivery reagent Active Motif, Rixensart, Be
ECL Plus/Advanced Western Blotting Amersham, Little Chalfont, UK
LightCycler480 DNA SYBR Green I Master Roche, Penzberg, Ger
NucleoBond PC 500 
(maxi-plasmid-preparations)
Macherey-Nagel, Düren, Ger
NucleoSpin Extract II (DNA-gelextraktion) Macherey-Nagel, Düren, Ger
NucleoSpin Plasmid Macherey-Nagel, Düren, Ger
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(mini-plasmid-preparations)
RevertAid™ H Minus First 
Strand (cDNA-synthesis)
Fermentas GmbH, St. Leon-Rot, Ger
RNeasy Mini Kit (RNA-Isolation) Qiagen, Hilden, Ger
Rho activation kit Enzo Life Sciences, Antwerp, Be
Z-CompetentTM  E.  Coli  Transformation 
Buffer 
Set Zymo Research, Irvine, CA USA
Buffer and solutions
Annealing-buffer for shRNA-Oligos (x2) 200 nM potassium-acetate
60 nM HEPES
4 mM magnesium-acetate
pH 7.4
FACS buffer Dulbecco’s PBS (PAA)
0.2% BSA
LB medium 10 g bakto-trypton
5 g yeast extract
10 g NaCl
ad 1 l H2O bidest.
pH 7.0
LB agar 10 g bakto-trypton
5 g yeast-extract
10 g NaCl
15 g bakto-agar
ad 1l H2O bidest.
pH 7.0
Phospho-lysis-buffer (SDS-PAGE) 20 mM Tris, 150 mM NaCl, 5mM EDTA, 30 
mM NaF, 5 mM DTT, 1 mM PMSF, 10 mM 
pNPP, 1 mM benzamidine, 10 mM 
glycerophosphate, 1 mM Na3PO4, 1% Triton 
X-100, 1xComplete protease inhibitor
 
PBS 150 mM NaCl
120 mM KCl
10 nM Na2HPO4/KH2PO4
pH 7.4
PBST PBS
0.1% Tween 20
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Running-buffer (SDS-PAGE) 25 mM Tris/HCl
200 mM Glycin
3.5 mM SDS
pH 7.5
Stacking gel buffer (SDS-PAGE) 30.28 g Tris/HCl
2 g SDS
ad 500 ml H2O bidest.
pH 6.8
SDS-sample buffer (SDS-PAGE) 20% Glycin
4.5% SDS
125 mM Tris/HCl
a spatula tip of bromphenol blue
pH 6.8
for reducing conditions: 5% mercapto-
ethanol
Separation gel buffer (SDS-PAGE) 90.85 g Tris/HCl
2 g SDS
ad 500 ml H2O bidest.
pH 8.8
Syndecan dot blot buffer 0.15 M NaCl buffered to pH 4.5 with 50 mM 
sodium acetate
0.1% Triton X-100
Stripping-buffer (for PVDF-Membranen) 2% SDS
60.25 mM Tris/HCl
0.83% β-Mercaptoethanol
in H2O bidest.
pH 6.8
TAE (x50) 242g Tris
57.1 ml glacial acetic acid
1 mM EDTA
ad 1 l H2O bidest.
pH 7.4
TBS 20 mM Tris-HCl
150 mM NaCl
1 mM EDTA
pH 7,4
TBST TBS
0,1 % Tween-20
Transferbuffer (wet blot) 192 mM Glycin
25 mM Tris/HCl
10% Methanol
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Cell culture media
The  following  cell  culture  media,  buffers  and  supplements  were  purchased  from Sigma 
Aldrich, Steinheim, Germany: 
Accutase
Dulbecco’s modified Eagle Medium (DMEM) High Glucose (4.5 g/ml)
Dulbecco’s PBS without Ca and Mg (PBS)
Fetal Calf Serum (FCS)
Penicilin-Streptomycin (PS)
Trypsin-EDTA (TE)
Hanks balanced solution (HBSS) was purchased from Gibco (UK)
Antibodies
Table  presents primary antibodies used for this study. 
Table . Primary antibodies. 
Name Company Isotype Specifity Dilution 
FACS
Dilution 
Immunoblo
t
Immuno
cytochemistry
Syndecan-1* 
(DL-101)
Santa Cruz
Mouse 
IgG1
Human
(N-terminal)
4 µg/ml 2 µg/ml -
Syndecan-4* (5G9) Santa Cruz
Mouse 
IgG2B
Human
(N-terminal)
4 µg/ml 2 µg/ml -
Syndecan-1/-3 tCTF*
(clone 2E9)
Pascale 
Zimmerann
University 
Leuven
Mouse 
IgG2
Human
(C-terminal)
- 0.2 µg/ml 50 µg/ml
β1 integrin
(4B7R)
R&D 
systems
Mouse 
IgG1
Human
(N-terminal)
4 µg/ml - -
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α5 integrin
/CD49e (230307)
R&D 
systems
Mouse 
IgG1
Human
(N-terminal)
4 µg/ml - -
β1 integrin
active conformation
(HUTS-4)
Millipore
Mouse 
IgG2B
Human
(N-terminal)
4 µg/ml - -
β4 integrin 
(422325)
R&D 
systems
Mouse 
IgG2b
Isotype 
control,
Mouse IgG2b
4 µg/ml - -
Isotype IgG1
R&D 
systems
Mouse 
IgG1
Isotype 
control,
Mouse IgG1
4 µg/ml - -
Isotype IgG2a
R&D 
systems
Mouse 
IgG2a
Isotype 
control,
Mouse IgG2a
4 µg/ml - -
Isotype IgG2b
R&D 
systems
Mouse 
IgG2b
Isotype 
control,
Mouse IgG2b
4 µg/ml - -
Flotillin-1*
(18/flotillin)
BD 
Biosciences
Mouse 
IgG1
Human - 0.25 µg/ml -
Transferrinreceptor 1 * 
(CD71) 
(clone D7G9X)
Santa cruz
Rabbit 
IgG
Human - 0.25 µg/ml -
GAPDH*
Thermo 
Fisher 
Scientific
Mouse 
IgG1
Human - 0.33 µg/ml -
ERK1*
(clone C-16)
Santa cruz
Rabbit 
IgG
Human - 0.66 µg/ml -
ERK1/2* phosphorylation 
sites (Thr202/Tyr20)
(clone 16982)
Santa cruz
Rabbit 
IgG
Human - 0.66µg/ml -
p38*
Cell 
signalling
Rabbit 
IgG
Human - 1:800 -
p38* phosphorylation sites 
Thr180/Tyr182
(clone D3F9)
Cell 
signalling
Rabbit 
IgG
Human - 1:800 -
Akt*
(clone C67E7)
Cell 
signalling
Rabbit 
IgG
Human - 1:800 -
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Akt* phosphorylation site 
Ser473
(clone D9E)
Cell 
signalling
Rabbit 
IgG
Human - 1:800 -
FAK*
(clone C-20)
Santa cruz
Rabbit 
IgG
Human - 0.33 µg/ml -
FAK*
phosphorylation site Tyr925
(clone 101680)
Santa cruz
Rabbit 
IgG
Human - 0.33 µg/ml -
FAK*
phosphorylation site Tyr397
(clone 141-9)
Invitrogen
Rabbit 
IgG
Human - 0.1 µg/ml -
Syntenin* 
(clone 2C12)
Lifespan 
Biosciences
Mouse 
IgG1
Human - 1 µg/ml -
GIPC1*
Novus 
Biologicals
Goat 
IgG
Human - 1 µg/ml -
Paxillin
(349/paxillin)
BD 
Biosciences
Mouse 
IgG1
Human - - 10 µg/ml
*Blocking: 3% BSA in TBS-T, 1 h at RT; primary antibody: overnight incubation at 4°C
*Blocking: 3% BSA in TBS-T, 1 h at RT; primary antibody: overnight at 4°C or 1 h at RT 
incubation 
*Blocking: 3% milk powder in TBS-T, 1 h at RT; primary antibody: overnight at 4°C or 1 h 
at RT incubation
*Blocking: 3% milk powder + 1% BSA in PBS-T, 1 h at RT; primary antibody: overnight at  
4°C or 1 h at RT incubation
Table  presents secondary antibody used in this study.
Table . Secondary antibody.
Name Company Conjugate Dilution 
FACS
Dilution 
Immunoblot
Immuno
cytochemistry
Goat anti mouse 
IgG
Jackson 
Immuno 
Research 
Horseradish
peroxidas
- 0.02 µg/ml -
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Rabbit anti goat 
IgG
Jackson 
Immuno 
Research 
Horseradish
peroxidas - 0.02 µg/ml -
Goat anti rabbit 
IgG
Jackson 
Immuno 
Research
Horseradish
peroxidas - 0.02 µg/ml -
Goat anti mouse 
IgG
Jackson 
Immuno 
Research
Allophycocyanin 5 µg/ml - -
Goat anti mouse 
IgG
Invitrogen Alexa Fluor® 647 - - 1:1000
Goat anti mouse 
IgG
Invitrogen Alexa Fluor® 488 - - 1:1000
Secondary  antibodies  for  Western  blot  were  diluted  in  corresponding  primary  blocking 
buffer. The FACS antibodies were diluted in FACS buffer. Immunocytochemistry antibodies 
were diluted in PBS.
Oligonucleotides
Table  presents oligonucleotids used for quantitative PCR.
Table . Oligonucleotides used for quantitative PCR.
Name Sequence (5´3´) Bp 
length
Melting temperature
SDC-1 CTF_For AGGACGAAGGCAGCTAC 20 61.4°C
SDC-1 CTF_Rev GCCTGGTGGGGTTTCTGGTAG 20 59.4°C
SDC-4 CTF_For GAAGGATGAAGGCAGCTATGA 21 57.9°C
SDC-4 CTF_Rev TCACGCGTAGAACTATTGG 20 57.3°C
full length SDC-1 _For CCACCATGAGACCTCAACCC 20 57.3°C
full length SDC-1 _Rev GCCACTACAGCCGTATTCTCC 21 61.8°C
full length SDC-4 _For GGACCTCCTAGAAGGCCGATA 21 61.8°C
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full length SDC-4 _Rev AGGGCCGATCATGGAGTCTT 21 59.4°C
α5 integrin_For CTTACGGCTATGTCACCATCCT 22 60°C
α5 integrin_Rev CCCACCAGCAAGTCATCCAG 20 61°C
β1 integrin_For CGTAGCAAAGGAACAGCAGAG 21 59.8°C
β1 integrin_Rev ATAAGGTAGTAGAGGTCAATGGGA 24 59.3°C
GAPDH_For CGGGGCTCTCCAGAACATCATCC 23 61°C
GAPDH_Rev CCAGCCCCAGCGTCAAAGGTG 21 60°C
shRNA sequences
Table  presents shRNA target sequences integrated into pLVTHM used for human syndecan-
1 or -4 knockdown.
Table . shRNA target sequences integrated into pLVTHM.
Name Target Target sequence
scr
no target; unspecific scrambled 
DNA
CCGTCACATCAATTGCCGT
SDC-1-1061 CDS of syndecan-1 mRNA GGACTTCACCTTTGAAACC
SDC-1-3116 UTR of syndecan-1 mRNA GTGTCCGGTATTCGATACT
SDC-1-1560 UTR of syndecan-1 mRNA CCGGCCGACTGCTTTGGAC
SDC-4-271 CDS of syndecan-4 mRNA GTTGTCCATCCCTTGGTGC
SDC-4-2185 UTR of syndecan-4 mRNA GCACTATTCTAGAGAACTA
SDC-4-718 UTR of syndecan-4 mRNA GTGAGGTCAACCTAATACT
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Plasmids
Table   presents plasmids used in this thesis. Plasmid maps, restriction sites and nucleotide 
sequences are listed in the appendix.
Table . Plasmids.
Name Properties 
pLVTHM Lentiviral shRNA expression plasmid
encoding the reporter gene GFP 
pMD2 Lentiviral envelope plasmid encoding VSV-G
psPAX Lentiviral packaging plasmid encoding the HIV gag-pol gene and further 
auxiliary HIV proteins
pLVX-EF1α-IRES-mCherry  empty 
vector
Lentiviral expression vector encoding no insert and the reporter gene 
mCherry 
pLVX-EF1α-IRES-mCherry  SDC-1 
cCTF
Lentiviral expression vector encoding syndecan-1 intracellular 
cytoplasmic CTF and the reporter gene mCherry
pLVX-EF1α-IRES-mCherry  SDC-4 
cCTF
Lentiviral expression vector encoding syndecan-4 intracellular 
cytoplasmic CTF and the reporter gene mCherry
pLVX-EF1α-IRES-mCherry  SDC-1 
cCTF-HA tag
Lentiviral expression vector encoding syndecan-1 intracellular 
cytoplasmic CTF + HA (at the C2 domain) and the reporter gene mCherry
pLVX-EF1α-IRES-mCherry  SDC-1 
tCTF
Lentiviral expression vector encoding syndecan-1 transmembrane CTF 
expression and the reporter gene mCherry
pLVX-EF1α-IRES-mCherry  SDC-4 
tCTF
Lentiviral expression vector encoding syndecan-4 transmembrane CTF 
expression and the reporter gene mCherry
pLVX-EF1α-IRES-mCherry  full  length 
SDC-1
Lentiviral expression vector encoding syndecan-1and the reporter gene 
mCherry
Cell lines
The used cell lines are listed  in table 6.  Cells were maintained in standard medium, high 
glucose  DMEM-medium  supplemented  with  10%  FCS  and  penicillin  (100  U/ml)  and 
streptomycin (100 µg/ml). All cell lines were grown at 37°C in a cell incubator in a 5% 
carbon dioxide/100% humidity atmosphere.
Table . Cell lines.
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Name Description Culture Medium
A549 human alveolar basal epithelial adenocarcinoma High glucose DMEM
HEK293T Variant of HEK293 cells, stably expressing the 
large T-antigen
High glucose DMEM
Collagen G coating
3.2 Cell culture methods
3.2.1 Thawing of cells
A cryovial was warmed to 37°C and the content was immediately dissolved in pre-warmed 
standard medium. In order to remove DMSO, cells were centrifuged (300 x g for 5 min), 
resuspended in standard medium and transferred to cell culture dish.
3.2.2 Cell line propagation
Cells were cultured at 37°C and 5% CO2 under standard conditions. High glucose DMEM 
medium supplemented with 10% fetal calf serum (FCS) and 1% penicillin/streptomycin was 
used as standard medium. When 80% confluence was reached, cells were sub-cultured using 
trypsin/EDTA. After detachment, the cells were resuspended in standard medium and seeded 
(at the desired dilution) in new culture dishes.
3.2.3 Cell counting
The  number  of  viable  cells  was  counted  by  trypan  blue  dye  exclusion  using  the 
hemocytometer.  10 µl  of  cell  suspension were mixed with 10 µl  of  a  0.4% trypan blue 
solution. A quantity of 10 µl of the mixture was added to the hemocytometer. Dead cells take 
up the trypan blue dye and appear blue under the microscope; these cells were excluded from 
cell count.
3.2.4 Production and concentration of lentiviral-shRNA particles 
HEK293T cells were used as producer cell line. 2 x 106  HEK293T cells were seeded on a 
collagen G coated 10 cm culture dish and cultured for 48 h. The medium was changed at 
31
Materials and methods
least 2-3 h prior to transfection. Transfection mixture 1 and 2 were produced (quantities only 
for one 10 cm dish):
Transfection mixture 1 : Transfection mixture 2 :
5 µg pLVTHM 20 µl jetPEI
3.25 µg psPAX2 in 250 µl NaCl (150 mM)
1.75 µg pMD2
 in 250 µl NaCl-solution (150 mM)
Then, transfection mixture 2 was added to transfection mixture 1 and mixed briefly.  The 
mixture was incubated for 15-30 min at room temperature.  The transfection solution was 
added dropwise to the cells. After transfection (24 h), the medium was replaced by 10 ml of  
fresh medium. Lentiviral particle containing supernatant was collected after additional 48 h. 
The supernatant was centrifuged at 500 x g to remove cell debris and sterile filtered, using a 
0.2 µm filter. To produce larger amounts of lentivirus containing supernatant, 15 cm dishes 
were used and the amount of cells, DNA, NaCl (150 mM), jetPEI and medium was scaled up 
by factor 2.5. 
Lentiviral shRNA particles were concentrated via ultracentrifugation. Therefore 10-30 ml of 
supernatant was centrifuged in screw-top ultracentrifuge tubes in the ultracentrifuge L7-65 at 
50,000  x  g  for  2  h.  After  the  centrifugation  the  medium was  discarded  and  the  pellet 
containing  the  lentiviral-shRNA particles  was  dissolved  in  50  µl  PBS.  The concentrated 
lentivirus was aliquoted and stored at -80°C [80]. 
3.2.5 Production and concentration of lentiviral overexpressing particles 
HEK293T cells were used as producer cell line. 2 x 106  HEK293T cells were seeded on a 
collagen G coated 10 cm culture dish and cultured for 48 h. The medium was changed at 
least 2-3 prior to transfection. Transfection mixture 1 and 2 were produced (quantities only 
for one 10 cm dish and transfection conditions/DNA concentrations are listed in table 7).
Table  .  DNA and  transfection  conditions  for  the  production  of  lentiviral  overexpressing 
particles.
Name of plasmide Transfection mixture 1 Transfection mixture 2
pLVX-EF1α-IRES-mCherry  empty 10 µg plasmide 20 µl jetPEI
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vector 8 µg psPAX2
3 µg pMD2 in 250 µl NaCl (150 mM)
pLVX-EF1α-IRES-mCherry  SDC-1 
cCTF
10 µg plasmide
8 µg psPAX2
3 µg pMD2
20 µl jetPEI
in 250 µl NaCl (150 mM)
pLVX-EF1α-IRES-mCherry  SDC-4 
cCTF
10 µg plasmide
8 µg psPAX2
3 µg pMD2
20 µl jetPEI
in 250 µl NaCl (150 mM)
pLVX-EF1α-IRES-mCherry  SDC-1 
cCTF-HA tag
10 µg plasmide
8 µg psPAX2
3 µg pMD2
20 µl jetPEI
In 250 µl NaCl (150mM)
pLVX-EF1α-IRES-mCherry  SDC-1 
tCTF
10 µg plasmide
6.5 µg psPAX2
3.5 µg pMD2
42 µl Lipofectamin 2000
In 158 µl DMEM without P/S and 
FCS
pLVX-EF1α-IRES-mCherry  SDC-4 
tCTF
10 µg plasmide
8 µg psPAX2
3.5 µg pMD2
42 µl Lipofectamin 2000
In 158 µl DMEM without P/S and 
FCS
pLVX-EF1α-IRES-mCherry  full 
length SDC-1
10 µg plasmide
8 µg psPAX2
3 µg pMD2
42 µl Lipofectamin 2000
In 158 µl DMEM without P/S and 
FCS
The  transfection,  production  and  lentivirus  particle  concentration  were  carried  out  as 
described in chapter 3.2.4.
3.2.6 Transduction of target cells
The  cells  were  generally  transduced  with  concentrated  lentiviral  particles.  Second 
transduction  with  lentiviral  overexpressing  particles  was  carried  out  4-5  days  post-
transduction with lentiviral-shRNA particles. Before transduction, cells were seeded in six-
well  plates,  at  2.5 x 105  cells  in  2 ml  standard medium per  well.  10 µl  of  concentrated 
lentivirus  or  2  ml  of  unconcetrated  lentivirus  were  added.  To increase  transduction  rate, 
polybrene  was  added  to  the  medium at  a  final  concentration  of  4  µg/ml.  After  24  h  of 
transduction,  the  medium  was  replaced.  The  transduction  efficiency  was  analyzed  by 
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GFP/mCherry  reporter  gene  expression  72  h  after  transduction  using  a  fluorescence 
microscope o the Incucyte ZOOM (GFP: 488 nm emission; mCherry: 588 nm emission).
3.2.7 Production of synthetic syndecan cCTF peptides
The  production  of  syndecan  cCTF  peptides  was  carried  out  by  ThermoScientific  (Ulm, 
Germany).  Syndecan-1 cCTF amino acid sequence was (YR MKK KDE GSY SLE EPK 
QAN  GGA YQK  PTK  QEE FYA).  A scramble  syndecan-1  cCTF  with  the  amino  acid 
sequence (ED KKK MRY E QKT PKQ YAG GNA QKP EEL SYS G AYFE) was used as 
control.  Successful  production  and  purity  of  synthetic  peptides  were  verified  by quality 
control  certificates  (see  appendix).  Lyophilized  synthetic  peptides  were  reconstituted  in 
sterile water at a concentration of 0.1, 1.0 and 10 µM.
3.2.8 Synthetic syndecan cCTF peptide delivery 
Peptide delivery was carried out using the Chariot™ peptide carrier reagent according to the 
manufacturer’s  recommendations.  For  peptide  delivery  in  cells,  synthetic  peptides  were 
diluted in PBS and mixed with an equal volume of 1/25 diluted Chariot transfection reagent 
in sterile water. The mixture was incubated at room temperature for 30 min to allow complex 
formation. Cells grown in 96-well plates were overlaid by 20 µl mixture and 80 µl of serum-
free medium was added. Cells grown in 6-well plates were overlaid with 200 µl mixture and 
1.5 ml serum-free medium was added.
3.3 Protein biochemistry methods
3.3.1 Sodium dodecyl sulfate - polyacrylamide gel electrophoresis (SDS-PAGE)
SDS-PAGE  allows  the  separation  of  proteins  according  to  their  molecular  mass  in  a 
denaturing discontinuous polyacrylamdide gel electrophoresis (PAGE) system developed by 
Laemmli (1970) [105]. Proteins were separated on self-made 10 or 15% (1.5 mm gel) mini 
SDS-PAGE gels (Table , volumes to cast two gels) or precast 4 to 20% gradient gels using 
the MINI PROTEAN gel electrophoresis chamber.
Table . Composition of separating and stacking gels
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Separating gel 10% Separating gel 15% Stacking gel 5%
Rothiphorese®
Gel 30 (37,5:1) 3.3 ml 5 ml 0.85 ml
1.5 M Tris Buffer pH 8.8
(seperating gel buffer) 2.5 ml 2.5 ml -
0.5 M Tris Buffer pH 8.8
(stacking gel buffer) - - 1.25 ml
10% SDS 100 µl 100 µl 50 µl
MilliQ H20 3.97 ml 2.3 ml 2.8 ml
10% APS 100 µl 100 µl 50 µl
TEMED 10 µl 10 µl 5 µl
The size of the protein bands was determined by applying 5 µl  PageRulerTM Prestained 
Protein Ladder per line on each SDS-PAGE. Separation was done at constant 120 V for 80 
min at room temperature.
3.3.2 Western blotting
After  protein  separation  via  SDS-PAGE,  proteins  were  electrophoretically  transferred  to 
polyvinylidene difluoride (PVDF) membranes by wet blotting (Mini Trans-Blot, BioRad) at 
constant  85 V for  120 min.  The membranes  were  blocked with  suitable  blocking buffer 
(listed in table 1).  The primary antibody against the protein of interest  was added to the 
membrane at the concentration and incubation condition listed in table 1. Membranes were 
washed three times for 5-10 min each with PBST or TBST and incubated with the secondary 
antibody listed in table 1 for 1 h at room temperature. The secondary antibodies conjugated 
with horseradish peroxidase (HRP) were diluted in corresponding blocking buffer listed in 
table 1. After washing three times with PBST or TBST, the ECL Plus HRP substrate solution 
was added to the membranes. The HRP signals were analysed using the LAS-3000-scanner. 
3.3.3 Western blotting for syndecan-1 cCTF-HA 
Samples  were  subjected  to  SDS-PAGE  under  reducing  conditions  using  4%-20%  Mini-
Protean® TGX TM Gel (Biorad).  Proteins were transferred onto PVDF based membranes 
using the Trans-Blot®Turbo™ transfer system. HA-tagged syndecan-1 cCTF was detected via 
HA-antibody (Table  ). Bound antibodies were visualized by incubation with corresponding 
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peroxidase-coupled  secondary  antibodies  (Table  )  and  subsequent  chemiluminescence 
reaction. Equal loading and transfer of proteins to the membrane was verified by detection of 
GAPDH.
3.3.4 Syndecan-1 tCTF protein analysis after scratch induction 
Wild  type  A549  cells  were  cultured  in  six-well  plates  in  the  presence  of  serum to  full 
confluence. A defined scratch was introduced using a 1000 µl pipette tip. After 24 h, cells 
were  cooled  on  ice  and  lysed  in  200  µl  lysis  buffer  containing  1% Trition  X-100  and 
Complete protease inhibitor (Roche). Cell homogenates were centrifuged at 16,000 x g for 
10 min yielding a pellet of cell debris. The 150 µl of the supernatant was supplemented with 
1x SDS sample buffer and boiled for 5 min at 95°C. 40 µl of cellular lysates was subjected to 
SDS-PAGE (15% separating gel) followed by Western blotting (wet bot) using an antibody 
against syndecan-1 tCTF (Table  ). Equal loading and transfer of proteins to the membrane 
was verified by detection of GAPDH.
3.3.5 Phosphorylation analysis of ERK, p38, Akt, Src and FAK
A549 cells (3.0 x 106 cells per well) were cultured in the absence of serum for 24 h, cooled 
on  ice  and lysed  in  300 µl  phosphor-lysis-buffer.  Cell  homogenates  were  centrifuged at 
16,000  x  g  for  10  min  yielding  a  pellet  of  cell  debris.  250  µl  of  the  supernatant  was 
supplemented with 1x SDS sample buffer and boiled for 5 min at 95°C. 40 µl of cell lysates 
were  subjected  to SDS-PAGE  followed  by  Western  blotting  using  antibodies  against 
phosphorylated and non-phosphorylated forms of ERK, p38, Akt and FAK. Antibodies were 
used according to table 1.
3.3.6 Rho GTPase activation assay
A549 cells (3.0 x 106 cells per well) were cultured in the absence of serum for 24 h and 
subsequently cell lysates (500 µg total protein) were analyzed for content of total and active 
Rho  using  a  commercial  kit  (Enzo  Life  Sciences,  Plymouth,  USA)  according  to  the 
manufacturer’s recommendations. As positive control, cell lysates were treated with GTPγS, 
leading to Rho GTPase activation.
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3.3.7 Cytosol-membrane fractions 
A549 cells (3.0 x 106 cells per well) were cultured in six-well plates in the presence of serum. 
Cells were washed twice with ice-cold PBS and removed from the cell culture dish in 500 µl  
5 mM HEPES containing Complete protease inhibitor (Roche) by gentle scraping with a cell 
scraper and lysed by passaging 15 times through a 27 gauge needle on ice. Cell homogenates 
were centrifuged for 15 min at 200 x g to remove nuclei. The resulting supernatant was added 
to 50 µl 1.4 mM NaCl and centrifuged at 16.000 x g for 60 min yielding a pellet of plasma 
membrane containing membrane fraction. The supernatant representing the cytosolic fraction 
was  concentrated.  The  membrane  and  cytosolic  fractions  were  subject  to  SDS-PAGE 
followed by Western blot using antibodies against ERK, flotillin-1, transferrin receptor 1 and 
syndecan-1 tCTF (2E9) antibody. Antibodies were used according to table 1.
3.3.8 Dot blotting for soluble syndecan-1 and -4 after scratch induction
Wild type A549 cells were cultured in six-wells to full confluence in the presence of serum. A 
defined scratch was introduced using a 1000 µl pipette tip. One ml of serum free medium 
was added. After 48 h, the supernatant was collected and centrifuged for 10 min at 16.000 x 
g. Conditioned media were diluted in syndecan dot blot buffer, and applied to cationic PVDF 
based membrane (Hybond-N, Amersham) under vacuum in a dot blot apparatus (Amersham 
Biosciences).  By acidifying the samples in syndecan dot blot buffer,  only highly anionic 
molecules in the conditioned media, such as proteoglycans, were retained by the cationic 
membrane. The membranes were washed twice with syndecan dot blot buffer, blocked for 1 
h with PBS supplemented with 0.5% bovine serum albumin, 3% nonfat dry milk, and 0.1% 
Tween  20  (all  from  Sigma).  Human  syndecan-1  and  -4  were  detected  by  incubating 
membranes overnight at 4°C with syndecan-1 or -4 antibody, respectively (Table ) followed 
by incubation  with  secondary antibody conjugated  with  HRP (Table  ).  After  addition  of 
chemiluminescence substrate (ECL Plus, Amersham Biosciences), signals were recorded and 
quantified  using  a  luminescent  image  analyzer  LAS3000  and  Multi  Gauge  3.0  software 
(Fujifilm, Tokyo, Japan).
3.3.9 Surface staining for fluorescence activated cell sorting (FACS)
Flow  cytometric  analysis  was  used  to  determine  cellular  surface  proteins.  Cells  were 
harvested (detachment of cell with accutase), counted and resuspended in standard medium at 
a concentration of 1 x 106 cells/ml. 200 µl (2 x 105 cells) were transferred into a FACS-tube 
containing 100 µl  of  4% PFA to fix  the cells  and to  inactivate  lentiviral  particles.  After 
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centrifugation at 300 x g for 5 min, the supernatant was discarded, washed once with 1 ml 
ice-cold FACS buffer and again centrifugated at 300 x g for 5 min. Cells were resuspended in 
50 µl of primary antibody solution (against target protein, table 1). Samples were incubated 
on ice for 30-45 min, than washed twice with 1 ml ice-cold FACS buffer and centrifuged at 
300 x g for 5 min. Subsequently, 50 µl secondary antibody solution (Table  ) was added and 
resuspended. The suspension was incubated in the dark on ice for 30-45 min, then washed 
twice with 1 ml ice-cold FACS buffer and centrifuged at 300 g for 5 min. Finally, cells were 
resuspended in 100 µl ice-cold PBS and were stored at 4°C or analyzed immediately.
3.3.10 Immunocytochemistry 
Immunocytochemistry was carried out in cooperation with Ph.D. Nicole Schwarz (RWTH 
Aachen University hospital,  Institute for Molecular and Cellular Anatomy). For syndecan-1 
tCTF immunofluorescence staining,  double transduced A549 cells  were grown onto glass 
coverslips and fixed by incubation in 4% paraformaldehyde for 20 min at room temperature. 
The cells were permeabilized with 0.1% Triton X-100 in PBS, incubated with the mAb SDC-
1 tCTF antibody (50 µg/ml, table 1) for 1 h at RT, followed by Alexa 657–conjugated goat 
anti-mouse (Table 2) for 1 h at RT. Slides were analyzed by fluorescence microscopy using 
an ApoTome.2 (Zeiss, Goettingen, Germany) with a Plan-Apochromat 63x/1.4 Oil objective 
(Zeiss)  using AxioVision LE software (Zeiss).  For  paxillin  immunofluorescence staining, 
syndecan-1 cCTF or empty vector expressing cells were grown onto glass coverslips and 
fixed  with  4% paraformaldehyde  for  20  min  at  room temperature.  The fixed  cells  were 
probed with the paxillin antibody (Table 1) followed by AlexaFluor®488 FITC (Table 2) 
secondary antibody.  Length of focal adhesions was quantified using the measure option in 
ImageJ 1.49s software. Three independent experiments were performed of each condition 
and at least 70 focal adhesions were measured.
3.3.11  Trypsin  digestion  of  syndecan  cCTFs  and  Matrix-Assisted  Laser 
Desorption/Ionization-Mass-spectrometrie- (MALDI MS)
The MALDI-TOF/TOF analysis was performed in cooperation with Ph.D. Vera Jankowski 
(RWTH Aachen University Hospital,  Institute of Molecular Cardiovascular Research).  Cell 
lysats  of  transduced  A549  cells  were  subjected  to  15%  SDS-PAGE  under  reducing 
conditions.  Staining of the proteins was carried out using Coomassie Brilliant Blue G 250. 
Polypeptide bands of interest were cut out manually and plugs were washed/equilibrated with 
ammonium bicarbonate  in  acetonitrile.  Afterwards  the  plugs  were  digested  with  0.05  µg 
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trypsin.  The resulting peptides  were desalted utilizing the  ZipTip™ (Millipore,  Billerica, 
MA, USA) technology and eluted with 80% acetonitril directly onto the MALDI target plate 
using a-cyano-4-hydroxycinnamic acid as matrix.  The subsequent mass spectrometric (MS) 
analyses  were carried out  using a  MALDI-time of  flight/time of flight  (TOF/TOF) mass 
spectrometer ( Ultraflex III;  Bruker-Daltonic, Germany). Calibrated and annotated spectra 
were subjected to a database search (Swiss-Prot, Zürich, Switzerland) utilizing Bruker’s Bio- 
Tools  3.2  and the  Mascot  2.3  search  engine  (Matrix  Science  Inc,  Boston (MA),  US) to 
compare the experimental MS as well as MS/MS data set and the calculated peptide mass-
signal for each entry in the sequence database and empirically determined factors to assign a 
statistical  weight  to  each  individual  peptide  match.  Quantification  of  the  mass-signal 
intensities of syndecan-1 cCTFs were compared to the mass-signal intensities of diinosine 
pentaphosphat used as internal standard.
3.4 Molecular biology methods
3.4.1 Construction of pLVTHM-shRNA plasmids
Short hairpin RNA (shRNA) targeting human syndecan-1 or syndecan-4 was inserted into the 
lentiviral expression vector pLVTHM using MluI and ClaI as established and described by 
Martin  Heß [80].  The targeting sequences  are  listed  in  table  4.  To form the  shRNA, all 
sequences  were  separated  by  a  non-complementary  spacer  (ttcaagaga)  from  their 
corresponding reverse complement sequence. All sequences were verified by sequencing by 
MWG Biotech  (Ebersberg,  Germany).  Plasmid maps,  restriction  enzymes  and nucleotide 
sequences are listed in the appendix.
3.4.2 Construction of pLVX-IRES-mCherry-overexpression plasmids
The human cDNAs encoding the Kozak and the signal peptide sequence followed by the 
transmembrane C-terminal  fragments  (tCTFs) of  human syndecan-1 (amino acid position 
253-310) or syndecan-4 (amino acid position 144-198), respectively,  were synthesized by 
MWG  Biotech  (Ebersberg,  Germany)  and  inserted  into  the  lentiviral  expression  vector 
pLVX-IRES-mCherry (Clontech,  Mountain  View, CA, USA) using EcoR1 and SpeI.  For 
construction of the syndecan cCTFs, synthetic human cDNAs encoding the Kozak sequence 
directly followed by the cytoplasmic C-terminal fragment (consisting of the C1, V and C2 
domain) of syndecan-1 (amino acid position 276-310), syndecan-4 (amino acid position 171-
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198) or the syndecan-1 cCTF HA tag variant (HA tag, amino acid sequence YPYDVPDYA, 
at  the  C-terminus  of  C2  domain)  respectively,  were  synthesized  by  MWG  Biotech 
(Ebersberg,  Germany)  and  inserted  into  the  lentiviral  expression  vector  pLVX-IRES-
mCherry (Clontech, Mountain View, CA, USA) using NotI and SpeI. For overexpression of 
full  length syndecan-1,  the human cDNAs encoding the Kozak and the complete  coding 
sequence  of  the  full  length  syndecan-1  was  synthesized  by  MWG  Biotech  (Ebersberg, 
Germany) and inserted into the lentiviral expression vector pLVX-IRES-mCherry (Clontech, 
Mountain View, CA, USA) using EcoRI and NotI. All sequences were verified by sequencing 
by MWG Biotech. Construction of syndecan cCTFs and syndecan-4 tCTF pLVX plasmids 
were  carried  out  by  Sarah  Weidenfeld  [177].  Plasmid  maps,  restriction  enzymes  and 
nucleotide sequences are listed in the appendix.
3.4.3 Transformation of bacteria
Chemical competent DH5α E.coli bacteria (Z-Compentent™ E.Coli Transformation Buffer 
Set) were thawed on ice. After thawing, 5 µl of ligation product or 200 ng of plasmid were 
added to 100 µl chemical competent DH5α cells. The mixture was incubated on ice for 15 
min. The transformed bacteria were plated out on prewarmed (room temperature) LB-agar 
plates containing 50 μg/ml carbenicillin and incubated for 24 h at 37°C. 
3.4.4  Preparation of  starter culture  and DNA plasmid purification (mini  and 
maxiprep)
A 4 ml LB broth containing 50 µg/ml carbenicillin  was inoculated with a  single colony 
picked from a freshly streaked LB-agar plate bacterial culture. The inoculated LB-broth was 
cultured for 16 h at 37°C and 300 x g. After 16 h, 2 ml of bacterial suspension was used for 
miniprep  plasmid  purification  and  was  carried  out  with  the  NucleoSpin  Plasmid  kit 
(Macherey-Nagel) according to manufacturer’s instructions. The remaining 2 ml were used to 
inoculated 250 ml LB broth containing 50 µg/ml carbenicillin for large scale DNA plasmid 
purification. Maxiprep DNA plasmid purification was carried out with the NucleoBond PC 
500 kit (Macherey-Nagel) according to manufacturer’s instructions.
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3.4.5 RNA isolation from cells and cDNA synthesis
Target cells for RNA isolation were harvested, counted and resuspended in standard medium 
at  a  concentration  of  1  x 106  cells/ml  cell  suspension were  transferred  into  a  tube,  then 
washed with 1 ml  ice-cold  PBS and centrifuged at  300 x  g  for  5  min.  Supernatant  was 
discarded  and  cells  were  resuspended  in  lysis  buffer  (supplied  by  QIA  shredder  kit). 
Suspension was stored at  -80°C until  homogenization using a  QIA Shredder (Qiagen)  to 
allow RNA extraction.  RNA extraction  was performed using  RNeasy  Mini  Kit (Qiagen). 
Equal amounts of total RNA from each sample were reversely transcribed into cDNA after 
DNase  digestion  using  RevertAid  First  Strand  cDNA  Synthesis  kit (Fermentas). 
Homogenization  of  cells,  RNA extraction  as  well  as  cDNA synthesis  were  carried  out 
according to manufacturer’s instructions.
3.4.6 Quantification of DNA and RNA concentration 
Concentration  of  DNA or  RNA was quantified  using  the  NanoDrop-ND-1000 (PEQLAB 
Biotechnologie).
3.4.7 Quantitative PCR
The mRNA expression level were analysed by quantitative PCR using the  LightCycler480 
(Roche) and Sybr Green I Master-Mix (Roch). Relative standard curves for target genes and 
the  reference  gene  (GAPDH)  were  constructed  from  a  serial  dilution  of  pooled  cDNA 
products of all samples. Data were obtained as target/reference gene ratio calculated from the 
LightCycler®480 software (Roche) and used for statistical analysis. 
The master mix was prepared as follows (recipe for 1 reaction): 
5.5 µl Sybr Green I Master-Mix
1.92 µl H20
0.88 µl MgCl2
0.55 µl forward primer* (Table )
0.55 µl reverse primer* (Table )
*final concentration: 6.25 qmol/µl
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Samples and standards were run in duplicates on 96-well plates. 9 µl of the final master mix 
and 1 µl of diluted cDNA samples (Table ) were added to each well. Quantitative PCR was 
performed in the LightCycler 480 (Roch). The quantitative PCR cycles, conditions, annealing 
temperature and the cycler conditions are listed in table 10 and 11.
Table . cDNA dilution factor.
Target gene cDNA dilution factor
SDC-1 CTF 10
SDC-4 CTF 10
Full length SDC-1 10
Full length SDC-4 10
α5 integrin 20
β1 integrin 10
GAPDH 10/20
Table . Quantitative PCR cycler conditions.
Cycles Conditions
Denaturation 95°C – 10 s
Annealing X °C – 10 s
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Amplification 74°C – 15 s
X = depending on target gene (Table )
Table . Annealing temperatures and number of cycles for the quantitative PCR.
Target gene Annealing-Temperature Number of cycles
SDC-1 CTF 54°C 45
SDC-4 CTF 55°C 45
Full length SDC-1 58°C 45
Full length SDC-4 58°C 45
α5 integrin 60°C 45
β1 integrin 60°C 45
GAPDH 66°C 35
3.4.8 GeneChip® hybridization
Genexpression  analysis  was  carried  out  in  cooperation  with  Ph.D.  Holger  Jahr  (RWTH 
Aachen University Hospital, Department of Orthopaedic Surgery) and the evaluation was 
performed by Ph.D. Bernd Denecke  (RWTH Aachen University Hospital, Interdisciplinary 
Center for Clinical Research).
Gene  expression  was  analyzed  using  the  GeneChip®  Human  Transcriptome  Arrays  2.0 
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(Affymetrix, Santa Clara, CA, USA). Total RNA was isolated using RNeasy Kit (Qiagen) and 
the  quantified  (Nanodrop 8000 (Thermo Scientific,  Waltham,  MA, USA)).  Subsequently, 
RNA quality was assessed using RNA 6000 Nano Assay with the 2100 Bioanalyzer (Agilent, 
Santa Clara, CA, USA) to ensure that the samples had a RNA integrity number (RIN) of at 
least  9.  Samples  were prepared and hybridized  to  the  GeneChip® Human Transcriptome 
Arrays 2.0 according to the GeneChip® WT Plus Reagent Kit user manual (P/N 703174 Rev. 
2; Affymetrix). Briefly, for each sample, 250 ng of total RNA was reverse-transcribed into 
cDNA using a random hexamer oligonucleotide tagged with a T7 promoter  sequence and 
stored at -20°C until further use. After second strand synthesis, double-stranded cDNA was 
used as a template for amplification with T7 RNA polymerase to obtain antisense cRNA. 
Random hexamers and dNTPs spiked with dUTPs were then used to reverse-transcribe the 
cRNA into single-stranded sense strand cDNA. The cDNA was then fragmented by uracil 
DNA glycosylase and apurinic/apyrimidic endonuclease 1. Fragment size was checked by 
using the 2100 Bioanalyzer (fragment size between 50 and 200 bp). Fragmented sense cDNA 
was biotin-endlabelled  with Terminal Deoxynucleotidyl Transferase (TdT) and only stored 
overnight  prior  to  array  hybridization.  Samples  were  hybridized  to  GeneChip® Human 
Transcriptome Arrays  2.0 at  45 °C for 16 h with 60 rpms.  Hybridized arrays  were then 
washed and stained on a  Fluidics  Station 450 (program: FS450 0001) and scanned on a 
GeneChip® Scanner 3000 7G (both Affymetrix).
Geneexpression analysis of syndecan-1 or -4 knockdown A549 cells versus scramble control 
cells:
Raw image data were analyzed with  Affymetrix® Expression Console™ Software, and gene 
expression  intensities  were  normalized  and  summarized  with  robust  multiarray  average 
(RMA) algorithm [92]. Statistical tests for differential expression and for identification of 
differentially  expressed  genes  was  performed  using  Affymetrix® Transcriptome  Analysis  
Console (TAC) Software, which computes and summarizes a traditional unpaired One-Way 
(single factor) ANOVA for each pair of condition groups. Transcripts that were expressed 
differently more than 1.5 fold with a  raw ANOVA p-value lower than 0.05 between the 
analyzed sample groups were addressed as regulated.
Genexpression analysis of syndecan-1 cCTF overexpressing A549 cells versus empty vector 
control cells:
To assess differential expression, CEL files were normalized by robust multiarray average 
(RMA [92]) to facilitate comparisons across arrays using the AltAnalyze 2.0.9 software suite 
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(Gladstone Institutes, San Francisco, CA, USA) [54].  Default analysis options were used, 
which  included analysis  of  gene  expression  via a  rawp,  which  is  a  one-way analysis  of 
variance (ANOVA) p-value calculated for each pairwise comparison, and the log fold, which 
is the log2 fold calculated by geometric subtraction of the control from experimental group 
for each pairwise comparison. Transcripts with a log2 fold change of 1.3 or more and a raw p-
value of less than 0.05 between the syndecan-1 cCTF and the empty vector control groups 
were considered as being differentially expressed. 
3.5 Functional assays
3.5.1 Wound closure assay (scratch assay)
For live-cell analysis of scratch-induced wound closure, 1.5 x 104 cells per well were seeded 
in collagen G (40 µg/ml) or fibronectin (6 µg/ml) (Biochrom AG, Germany) coated 96-well 
plates near confluence and allowed to grow overnight in standard medium. At confluence, 
cells  were  pretreated  2  h  with  mitomycin  (10  µg/ml)  (Medac,  Germany)  to  block  cell 
proliferation and washed with standard media. Subsequently, a defined scratch (wound width 
between 642-767 µm) was performed in each well  using the certified Essen Biosciences 
automated 96-wound-makerTM (Essen Biosciences, Hertfordshire, UK) for 96-well plates. The 
medium was removed and 100 µl standard medium was added to the wells. The closure of 
the wounded area was monitored using the IncuCyte ZOOM system by taking images of each 
well every 2 h over a period of 24 h. The reduction of wound width was determined over 
time  using  the  IncuCyte  ZOOM  microscope  software  2014A.  Data  were  expressed  as 
percentage of wound closure after 24 h.
3.5.2 Invasion assay
The invasion assay was performed as described for the wound closure assay. After scratch 
induction, the medium was removed, and 40 µl matrix basement membrane matrigel (BD 
Biosciences) was added to each well. The invasion of cells into the wound field was recorded 
using the IncuCyte ZOOM system over a period of 28 h. The number of invaded cells in the 
wound area  was  determined using  the  IncuCyte  ZOOM microscope  software  2014A and 
calculated as percentage of cells present after scratch induction. 
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3.5.3 Proliferation assay
For live-cell analysis of proliferation, 5 x 103  cells in 100 µl/well were seeded in 96-well 
plates. Cell proliferation was monitored using the automated  IncuCyte ZOOM microscope 
(Essen Biosciences, Hertfordshire, UK) by taking images of each well every 2 h for a period 
of 48 h. The calculation of confluence was performed with the IncuCyte ZOOM microscope 
software  2014A.  Results  were  expressed  as  fold  increase  in  confluence  after  48  h  in 
comparison to 0 h.
3.5.4 Adhesion assay
The  adhesion  assay  was  carried  out  in  48-well  plates.  Wells  were  coated  with  125  µl 
fibronectin  (12  µg/ml)  or  collagen  G (40 µg/ml)  for  1  h  at  room temperature  or  37°C. 
Subsequently, the coated wells and uncoated controls were blocked with 200 µl 0.5% BSA 
(diluted  in  HBSS)  for  15  min  at  room temperature  and then  washed twice  with  HBSS. 
Transduced A549 cells were resuspended in HBSS and 100 µl (1 x 105 cells) cell suspension 
were added to the coated wells, sedimented for 30 s at 300 x g and incubated for 15 min at 
37°C. Subsequently,  the wells were washed several times and the fluorescence signals of 
adherent cells were analyzed using the IncuCyte ZOOM microscope.
3.6 Animal experiments 
3.6.1 Lung tumor metastasis 
A549 cells were studied for metastasis formation in severe combined immune deficient mice 
(NOD-SCID Il2rgnull, NSG) that were maintained under specific-pathogen-free conditions in 
the central animal facility of the University Hospital RWTH Aachen. All animal experiments 
were approved by local authorities in compliance with the German animal protection law 
(AZ 84-02.04.2013.A198). A549 cells were harvested, singularized, washed and resuspended 
in PBS. Subsequently, a uniform single cell suspension containing 3 x 106 cells in 100 µl of 
PBS was injected intravenously into the lateral tail vein of 6-8 week-old SCID mice. After 35 
days, lungs were prepared, fixed by intratracheal instillation of  Roti-Fix® (Roth, Germany), 
embedded in paraffin and cut in 3 µm slices.  Hematoxylin-eosin staining was performed 
using standard protocols. Images were taken with a Zeiss microscope (AxioLab.A, Carl Zeiss 
MicroImaging  GmbH,  Germany)  at  40-fold  magnification.  For  mounting  whole  lung 
overviews  the  Keyence  BZ-9000  software  BZ2Viewer Merge was  used.  The  number  of 
formed lung tumors was determined by double blinded scoring of formed tumor colonies 
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using a ranking from 1 (no colony), 2 (<50 colonies), 3 (<100 colonies), 4 (<150 colonies), 5  
(<200 colonies),  6 (<250 colonies), to 7 (>250 colonies).  For measurement of metastasis 
diameters,  images of 100-fold magnification were used and the mean tumor volume was 
calculated by the following equation: tumor volume = length x (width)2/2 [141]. Lung tumor 
area was measured using imageJ software 1.48v (Rasband, NIH, Bethesda, Maryland, US) 
and denoted as percentage of whole lung tissue area.
3.7 Statistical analysis
Quantitative  data  are  shown as  mean and SD calculated from at  least  three  independent 
experiments or cell isolates. Animal numbers are given in the figure legends. Percentage data 
were arc sin-transformed. Homoscedasticity was checked by the Bartlett test and analyzed 
using parametric student´s t-test.  If there was no homoscedasticity the data was analyzed 
using  nonparametric  Mann-Whitney  U  test.  Statistical  analyses  were  performed  using 
PRISM5.0 (GraphPad Software,  La Jollla,  CA).  All  p-values  were corrected for  multiple 
comparisons  using  false  discovery rate  (FDR) control  and differences  were  indicated  by 
asterisks or hashes. To test for difference to a single hypothetical value (e.g. 100 or 1.0) the 
one-sample t-test was used and differences were indicated by asterisks.
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4 Results
4.1  Functional  analysis  of  the  transmembrane  C-terminal  fragment  (tCTF)  of 
syndecan1 and 4 on cancer cell motility in vitro and in vivo
Syndecans are well known to undergo proteolytic shedding at the cell surface. While much of 
the previous work focused on the function of the shed N-terminal soluble ectodomain, little is 
known about the functional role of the tCTF. The aim of the first part of this thesis was to 
investigate the generation of  the transmembrane C-terminal fragment (tCTF) arising from 
syndecan-1 and -4 shedding during cell migration and to then study its functional implication 
in the migratory response in vitro and in vivo. As cellular model A549 cells were chosen. In a 
previous study, Pruessmeyer et  al.,  (2010) showed that ADAM17 mediates inflammation-
induced shedding of syndecan-1 and -4 by these cells [143]. The A549 cells express high 
levels  of  syndecan-1  and still  considerable  levels  of  syndecan-4,  whereas  syndecan-3  or 
syndecan-2 are more rare [1;18].
4.1.1 Wound closure of A549 cells is associated with syndecan1 and 4 cleavage and the 
generation of syndecan-1 tCTF
Shedding of syndecan can be enhanced by cell stimulation [32;37;39]. In the present study it 
was  investigated  whether  enhanced  generation  of  syndecan  cleavage  fragments  can  be 
observed during cell migration in vitro. For these analyses an  in vitro wound closure assay 
was  performed,  which  allows  the  investigation  of  cell  migration  into  a  wounded  area. 
Wounds were introduced by defined scratching of a confluent A459 cell layer. Analysis of the 
serum  free  media  after  scratch  induction  revealed  that  wounding  is  associated  with  an 
increased release of soluble syndecan-1 and -4 ectodomain (Figure  A and B). This correlated 
with an accumulation of syndecan-1 tCTFs, which could be detected with the 2E9 antibody 
against the C-terminus of syndecan-1 (Figure  C). The generation of the equivalent syndecan-
4 fragment could not be investigated as no specific antibodies are available. Accumulation of 
both, the soluble shed syndecan-1 and -4 as well as the syndecan-1 tCTF was abolished by 
metalloproteinase inhibition using TAPI-1. This increased accumulation after wounding was 
not associated with an increased mRNA expression of full length syndecan-1 and syndecan-4 
(Figure   D and E).  To confirm that  the syndecan-1 tCTF is  further  processed by the  γ-
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secretase complex, inhibitor experiments were carried out in wild type A549 cells. As shown 
in  figure  9,  γ-secretase  inhibition  by  DAPT treatment  led  to  increased  accumulation  of 
syndecan-1 tCTF. These findings suggest that ADAM17 activation is relevant for the release 
of  soluble  syndecan-1  and  -4  during  the  wound  closure  response.  The  transmembrane 
cleavage  fragment  of  syndecan-1  then  undergoes  further  proteolytic  cleavage  by  by  γ-
secretase.
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Figure .  Association of syndecan-1 or -4 shedding and syndecan-1 tCTF accumulation after 
wound closure in A549 cells.
A-C) A confluent monolayer of A549 cells was either wounded by a defined scratch or left untreated. The cells  
were incubated for 24 h with the metalloproteinase inhibitor TAPI-1 (10 µM) or DMSO (0.1%) as control. 
Subsequently, the supernatants were analyzed for the presence of soluble SDC-1 or SDC-4 by dot blotting using 
an antibody against the ectodomain of SDC-1 (A) or SDC-4 (B). Cell lysates were subjected to Western blotting 
using an antibody against SDC-1 tCTF (C). Signals were quantified by densitometry and expressed in relation  
to the DMSO treated control. The expression of full length SDC-1 (D) or SDC-4 (E) mRNA was controlled by  
quantitative PCR. F) Wild type A549 cells were treated with the γ-secretase inhibitor DAPT (5 µM) or DMSO 
(vehicle, 0.1%) for 16 h and cell lysates were subjected to Western blotting. The SDC-1 tCTF was quantified by 
densitometry expressed in relation to GAPDH expression. Data are presented as means + SD calculated from 
three independent experiments and representative blots are shown. Statistically significant differences compared 
to the control without scratch induction are indicated by asterisks (p<0.05).
4.1.2 shRNA mediated knockdown of syndecan-1 or -4 
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The upregulation of syndecan-1 and -4 shedding in wounded A549 cells raised the question 
whether syndecan-1 or -4 itself or probably also their tCTF can modulate the wound healing 
response.  To investigate  and confirm the  role  of  endogenous  syndecan-1  and -4  for  cell 
migration  in  a  first  set  of  experiments,  transcriptional  knockdown  experiments  were 
performed. By lentiviral transduction, short hairpin RNA (shRNA) was expressed in A549 
cells  for targeting the coding sequence (CDS) of syndecan-1 (mRNA target:  1016) or -4 
(mRNA target: 271). The transduced cells were then compared with control cells expressing a 
scramble shRNA sequence.  Downregulation of syndecan-1 or -4 on the transduced A549 
cells was confirmed by flow cytometry (Figure  A-D). Expression of syndecan-1 shRNA had 
no effect on syndecan-4 surface expression and vice versa (Figure  A and B). Two additional 
shRNA sequences targeting the untranslated region (UTR) were used to confirm efficient 
knockdown of  syndecan-1 (mRNA target:  1560 and 3116) or  syndecan-4 (mRNA target: 
2185  and  718)  without  changing  the  surface  expression  of  syndecan-4  or  syndecan-1, 
respectively  (Figure   C  and  D).  Furthermore,  microarray  results  showed  no  change  of 
syndecan-2  or  -3  mRNA expression  during  shRNA mediated  syndecan-1  (mRNA target: 
1016) or -4 (mRNA target: 271) knockdown (Figure   G and H). This excludes a possible 
compensation of syndecan-1 or syndecan-4 loss by syndecan-1, -2 -3 or -4 upregulation.
4.1.3 Syndecan-1 and -4 promote cell proliferation, migration and invasion of A549 cells
Following  shRNA mediated  silencing  of  syndecan-1  or  -4  expression,  A549  cells  were 
investigated for their migratory response in the wound closure assay. First, it was important 
to confirm that the wound healing response of A549 cells was predominantly due to cell 
migration. To exclude possible effects of cell proliferation on the wound closure response, 
control  experiments  were  performed  with  the  cytostatic  drug  mitomycin.  As  expected, 
mitomycin only had a slight effect on the wound closure of a wounded A549 wild type cell 
layer (Figure  A) and therefore the wound healing response was predominantly dependent on 
cell migration, but not on cell proliferation. In contrast, mitomycin suppressed the density 
increase of cultured A549 cells for 48 h, which was due to an arrest in cell proliferation 
(Figure  B). Therefore, in the subsequent experiments, cell migration and proliferation were 
assessed as wound closure and changes in density, respectively.
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Figure . shRNA mediated knockdown of syndecan-1 or syndecan-4 in A549 cells.
A-H) A549 cells were transduced with lentivirus  encoding scramble (scr),  SDC-1 or  SDC-4 shRNA. A-F) 
Efficiency of downregulation was controlled by flow cytometry (A-D) and quantitative PCR (E and F). Data 
represent means + SD of three independent experiments and statistically significant differences were indicated 
by asterisks (p<0.05). G and H) Changes in expression on mRNA levels for SDC-1, -2, -3 and -4 are illustrated 
for SDC-1-1061(G) or SDC-4-271 (H) shRNA expressing cells in comparison to scr cells. Shown are the log2 
fold change (FC) values with the mean + SD of three independent array experiments. Bars to the left indicate 
that a given gene is down-regulated, while bars to the right depict up-regulation of a gene. (*): significantly 
changed with an ANOVA raw p-value of 5x10-5.
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Figure . Effect of mitomycin on proliferation and wound closure.
A) Wild type A549 cells were grown to confluency, pretreated with 30 µM mitomycin for 2 h, washed twice and 
wounded by a defined scratch. Wound closure was monitored for 24 h and quantified using the IncuCyte ZOOM 
system. Wild type A549 cells were pretreated with or without 30 µM mitomycin for 2 h, washed twice and  
assayed for proliferation over 48 h by measuring changes in density using the IncuCyte ZOOM software (B). 
Data  represent  means  + SD of  three  independent  experiments  and statistically significant  differences were 
indicated by asterisks (p<0.05).
Knockdown of syndecan-1 or syndecan-4 in A549 cells significantly decreased proliferation, 
which was verified with two additional shRNA sequences (Figure   A and B). Interestingly, 
syndecan-1 knockdown showed a significant decrease in proliferation compared to syndecan-
4.  Scratch-induced  wound  closure  on  collagen  G  was  decreased  after  syndecan-1  or 
syndecan-4  knockdown  (Figure   C).  These  results  were  again  confirmed  with  the  two 
additional shRNA sequences causing decreased wound closure on collagen G (Figure   D). 
The wound closure response was also analyzed for its dependency on other extracellular 
matrix components. Syndecan-1 or syndecan-4 knockdown also decreased cell migration on 
different concentrations of fibronectin (Figure   E).  In addition,  syndecan-1 or syndecan-4 
knockdown reduced invasion of  A549 cells  into  matrigel  (Figure   F  and G).  These  data 
indicate  that  syndecan-1  and  syndecan-4  are  required  for  lung  epithelial  cancer  cell 
proliferation, migration, and invasion.
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Figure . Syndecan-1 and -4 promote cell proliferation, migration and invasion.
A-G) A549 cells were transduced with lentivirus encoding scr or different shRNA sequences targeting SDC-1 or 
SDC-4. A and B) Transduced cells were assayed for changes in density over 48 h of culture using the IncuCyte 
ZOOM software. C and D) SDC-1 or 4 deficient cells were grown to confluency on coated collagen G (D) or 
fibronectin  (E)  and  wounded  by  a  defined  scratch.  Transduced  cells  were  wounded  by  scratching  and 
subsequently covered with matrigel to analyze cell invasion from the wound edges into the matrigel within the 
wounded area (F). Exemplary images of three independent invasion experiments are shown (G). Wound closure 
or invasion were monitored from 0 h after scratch induction to 24 h or 28 h, respectively and quantified using 
the  IncuCyte  ZOOM software.  Quantitative  data  were  calculated  as  means  +  SD from three  independent  
experiments.  Statistically  significant  differences  compared  to  scr  control  are  indicated  by  asterisks,  and  
statistically significant differences compared to SDC-1 are indicated by hashes (p<0.05).
4.1.4 Syndecan-1 and -4 regulate p38, Akt, Rho GTPase activation and FAK signaling 
pathways
53
Results
The previous experiments demonstrated that syndecan-1 and syndecan-4 leads to decreased 
cell proliferation, migration and invasion. This raises the question, which signaling pathways 
would  mediate  syndecan-dependent  proliferative  and  migratory  processes.  Inhibition 
experiments were performed to investigate distinct signaling pathways for their involvement 
in A549 cell proliferation and wound healing. Both processes were considerably reduced by 
the  metalloproteinase  inhibitor  TAPI-1,  the  MEK 1/2  inhibitor U0126,  the  p38  inhibitor 
SB203580  and  the  Rho  kinase  inhibitor  Y27632 (Figure  ). The  inhibition  experiments 
indicated that  ERK, p38 kinase,  Akt  and Rho GTPase activation play important  roles  in 
proliferation  and  migration  of  A549  cells.  The  present  study  indicates  that  these  may 
represent signal transduction pathways by which syndecan-1 and syndecan-4 or its cleavage 
fragments could influence cell proliferation and migration. 
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Figure . Inhibition of cell proliferation and migration by inhibitors.
A,  B)  A549  cells  were  treated  with  DMSO  (vehicle,  0.1%),  TAPI-1 (10  µM),  SB203580  (10  µM,  p38 
Inhibitor), U0162 (10  µM,  MEK1/2  inhibitor)  or  Y27632 (10  µM,  ROCK inhibitor)  and  investigated  for 
changes in density over a period of 48 h in culture (A) or wound closure on collagen G after scratch induction  
over 24 h (B) using the IncuCyte ZOOM Imaging system.  Data represent means  + SD  of three independent 
experiments. Statistically significant differences are indicated by asterisks (p<0.05).
Therefore,  the  influence  of  syndecan-1  or  -4  depletion  on  signal  transduction  and 
phosphorylation of ERK, p38 kinase, Akt and Rho GTPase activation was analyzed in A549 
cells. Since cell migration depends on polarity, protusion and adhesion, the focal adhesion 
(FAK), which is a critical player in these events, was also analyzed for its phosphorylation 
status. In A549 cells, syndecan-1 or -4 knockdown had no effect on phosphorylation of ERK 
(Figure  A), whereas phosphorylation of p38 and Akt was significantly decreased (Figure  B 
and C). Also Rho GTPase activation was decreased by syndecan-1 or -4 depletion (Figure  
D). FAK was hyperphosphorylated at  tyrosine 397 and tyrosine 925 in syndecan-1 or -4 
deficient A549 cells  compared to the control (Figure   E and F). These data indicate that 
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syndecan-1  and  -4  influence  several  signal  transduction  pathways  that  modulate  cell 
migration  and  proliferation  of  A549  cells.  Since  all  different  shRNA sequences  against 
syndecan-1  or  4,  respectively,  showed  the  same  degree  of  syndecan  downregulation, 
suppression of cell migration and influence on signaling pathways,  the syndecan-1 shRNA 
sequence  1016  and  syndecan-4  shRNA sequence  271  were  chosen  and  used  only  as 
representative sequences for further experiments.
4.1.5  Syndecan-1,  but  not  syndecan-4  promotes  lung  metastasis  formation  in 
SCID mice
To  test  the  in  vivo relevance  of  syndecan-1  and  syndecan-4  for  epithelial  tumor  cell 
proliferation and migration,  syndecan-1 or -4 deficient  A549 cells  were investigated in  a 
xenograft lung metastasis formation model in SCID mice. When these cells were injected 
intravenously  into  the  tail  vein  of  SCID  mice,  lung  tumors  developed  as  observed  by 
histologic analysis. Syndecan-1 deficiency in A549 cells resulted in a considerably reduced 
number  and  volume  of  lung  tumors  compared  to  scramble  shRNA control  cells  still 
expressing syndecan1 (Figure  ).  In contrast,  syndecan-4 knockdown showed no effect on 
number and volume of formed lung tumors compared to scramble control. These experiments 
indicate  that  syndecan-1  is  more  relevant  for  lung  metastasis  formation  in  vivo than 
syndecan-4.  This  may  reflect  the  different  expression  level  of  the  syndecans  which  is 
generally higher for syndecan-1 in the A549 cells used in this study. Since this indicates that 
more  pronounced  effects  may  be  found  in  A549  cells  for  syndecan-1,  the  following 
experiments focused on syndecan-1.
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Figure . Syndecan-1 or -4 knockdown influences intracellular signaling pathways.
A-F) Cell lysates of A549 cells transduced to express scr or the different shRNAs against SDC-1 or SDC-4 were 
analyzed for phosphorylation or activation status of ERK (A), p38 (B) and Akt (C), Rho GTPase (D) and FAK 
at  sites  Tyr397  (E)  and  Tyr925  (F)  by  Western  blotting.  Signals  were  quantified  by  densitometry  as 
phosphorylated or activated versus total forms and calculated in relation to the control  cells expressing scr 
shRNA. Data represent means  + SD  of three independent experiments and representative Western blots are 
shown (A-F). Statistically significant differences are indicated by asterisks (p<0.05).
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Figure  .  Lung  metastasis  formation  of  A549  cells  in  SCID  mice  requires  the  presence  of 
syndecan1 but not syndecan-4.
A-C) A549 cells were transduced with scr, SDC-1 or SDC-4 shRNA. Transduced A549 cells were injected into 
the tail vein of SCID mice (n=5 per group). After 35 days animals were sacrificed and the lungs were analyzed  
for the number (A) and volume (B) of lung tumors. C) Representative histological images are shown. Three-
micrometer  sections of  formalin-fixed and  paraffin-embedded whole lungs were stained  with hematoxylin-
eosin. All data were calculated as means ± SD. Statistically significant differences compared to scr control are 
indicated by asterisks,  and  statistically significant  differences compared  to  SDC-1 are indicated by hashes  
(p<0.05).
4.1.6 Syndecan-1 tCTF expression in syndecan-1 deficient A549 cells
As shown in figure 9, wounding of A549 cells leads to the generation of a syndecan-1 tCTF. 
To  answer  the  question  whether  the  tCTF  generated  by  shedding  can  influence  cell 
proliferation  and  migration,  the  syndecan-1  tCTF  was  expressed  in  A549  cells  either 
expressing or lacking endogenous syndecan-1. For these experiments the tCTF was fused to 
the  C-terminus  of  the  syndecan-1  signal  peptide  to  achieve  membrane  expression.  The 
presence  of  endogenous  and  expressed  syndecan-1  tCTF  was  detected  using  the  2E9 
antibody (Table 1). Since the 2E9 antibody can detect both, syndecan-1 and syndecan-3 tCTF 
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[116;157],  knockdown  for  syndecan1  in  A549  cells  was  performed  confirming  that  the 
Western Blot signal is indicative for the presence of syndecan-1 tCTF (Figure  A). There was 
also no influence of the shRNA against syndecan-1 on other syndecans (-2, -3, and -4) as 
shown in figure 10 G. This finding shows that the obtained signal represents the syndecan-1 
tCTF. The expression of syndecan-1 tCTF within a physiologically relevant range was also 
confirmed by Western blotting (Figure  B) and quantitative PCR detecting both, endogenous 
syndecan-1 and the expressed tCTF (Figure  C).
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Figure . Syndecan-1 tCTF expression in syndecan-1 deficient A549 cells. 
A-C) A549 cells were transduced with lentivirus encoding scr or SDC-1 shRNA. Expression of SDC-1 tCTF or 
empty vector was carried out by second transduction of A549 cells expressing scr shRNA or SDC-1 shRNA. 
Endogenous tCTF expression in A549 cells (scr and SDC-1) receiving empty vector (A) and expression of the 
SDC-1 tCTF (B) was analyzed by Western blotting with an antibody against the tCTF (2E9). Note different  
expression levels of endogenous and expressed SDC-1 tCTF in relation of GAPDH expression in A and B. C) 
Efficiency of expression was further controlled by quantitative PCR with primers annealing to the C-terminus of 
SDC-1  for detection of both endogenous  SDC-1  and expressed tCTF mRNAs.  All data were calculated as 
means +  SD from three  independent  experiments  and  representative  Western blots  are  shown.  Statistically 
significant  differences  compared  to  shRNA_SDC-1  +  empty  vector,  shRNA_scramble  +  empty vector,  or 
shRNA_scramble + SDC-1 tCTF are indicated by hashes, asterisks or crosses, respectively (p<0.05). 
To  investigate  the  membrane-expression  of  the  generated  tCTF-construct,  cytosol  and 
membrane  preparation  as  well  as  immunocytochemistry  were  performed.  To  control  for 
purity of the cytosolic and membrane fraction, ERK was used as cytosolic marker, whereas 
transferrin receptor 1 and flotillin-1 were used as membrane markers. As expected, the tCTF 
was expressed in the membrane but not in the cytosolic fraction since the tCTF was cloned 
directly behind the signal  peptide of  syndecan-1 (Figure   A).  Immunocytochemistry was 
carried out in cooperation with Ph.D. Nicole Schwarz (RWTH Aachen University hospital, 
Institute for Molecular and Cellular Anatomy). The 2E9 antibody or isotype control was used 
to confirm plasma membrane localization of syndecan-1 tCTF. The double transduced A549 
cells expressed GFP and mCherry as reporter gene for either shRNA or syndecan-1 tCTF 
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expression. This was used to distinguish between single and double transduced A549 cells. 
As shown in figure 17 B, no signal was detected in double transduced A549 cells using the 
isotype control antibody, whereas the 2E9 antibody detected syndecan-1 tCTF within the ER, 
the secretory pathway as well as the plasma membrane. Further, it was confirmed that A549 
cells lacking endogenous syndecan-1 again do not react with the 2E9 antibody and become 
immunoreactive only when syndecan-1 tCTF is expressed. These experiments indicate that 
the  tCTF is  expressed  in  the  same compartments  as  the  endogenous  syndecan-1  and  is 
localized at the plasma membrane.
The previous experiments demonstrated that expressed syndecan-1 tCTF is localized at the 
plasma membrane. This led to next question whether the expressed syndecan-1 tCTF is also 
processed  by  the  γ-secreatase.  The  involvement  of  γ-secreatase  in  the  cleavage  of 
endogenous syndecan-1 is indicated by the inhibition experiment with DAPT (Figure   F). 
When A549 cells expressing the tCTF instead of endogenous syndecan-1 were treated with 
the γ-secretase inhibitor DAPT the Western Blot signal for the tCTF clearly increased. This 
finding suggests that also the expressed tCTF is further cleaved by γ-secretase within the cell 
membrane (Figure ).
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Figure . Plasma membrane localization of overexpressed syndecan-1 tCTF. 
A-B) A549 cells were transduced with lentivirus encoding GFP and SDC-1 shRNA. Expression of SDC-1 tCTF 
was carried out by second transduction of A549 cells with lentivirus  encoding mCherry and  SDC-1  tCTF. 
Cytosol and membrane fractions were subjected to Western blotting and assessed for SDC-1 tCTF, transferrin 
receptor 1, flotillin-1 and ERK expression (A). Double transduced A549 cells were fixed, permeabilized and 
stained with isotype control (upper panel) or SDC-1 tCTF antibody (lower panel). GFP (green) and mCherry  
(red) signal were used as transduction controls and double transduced cells expressing the SDC-1 tCTF showed 
a pink signal. Exemplary images of three independent experiments are shown (B).
60
Results
0
2
4
6
8
DAPT
DMSO +
-
-
+
SDC
-1-
tCTF
A
*
SDC-1 tCTF
GAPDH
shRNA_SDC-1 + SDC-1 tCTF
Figure . Accumulation of expressed syndecan-1 tCTF in the presence of a γ-secretase inhibitor.
A549 cells were transduced with lentivirus encoding SDC-1 shRNA.  Expression of  SDC-1 tCTF was carried 
out by lentivirus encoding SDC-1 tCTF. SDC-1 deficient A549 cells expressing SDC-1 tCTF were treated with 
γ-secretase inhibitor  DAPT (5 µM) or DMSO (vehicle,  0.1%) for  16 h and cell  lysates  were subjected to 
Western blotting. The SDC-1 tCTF was quantified by densitometry expressed in relation to GAPDH expression.  
All data were calculated as means + SD from three independent experiments and representative Western blots 
are shown. Statistically significant difference compared to DMSO control is indicated by asterisks (p<0.05).
4.1.7 Syndecan-1 tCTF regulates p38, Akt, Rho GTPase activation and FAK signaling 
pathways
Next, it was investigated whether the syndecan-1 tCTF expression contributes to syndecan-1 
dependent signaling pathways (for comparison see figure 14). For this purpose, syndecan-1 
tCTF was expressed in  A549 cells  expressing shRNA against  syndecan-1 or scramble as 
control.  Expression of the tCTF in A549 control cells expressing endogenous syndecan-1 
(expressing scramble shRNA) did not show significant effects on ERK, p38, Akt and FAK 
Tyr397 phosphorylation, but a significant reduction of FAK Tyr925 phosphorylation (Figure  
A-F). More pronounced and significant effects were observed when the tCTF was expressed 
in syndecan-1 deficient cells. ERK phosphorylation was significantly reduced. Especially, the 
responses  suppressed  by  syndecan-1  knockdown,  including  p38,  Akt  and  Rho  GTPase 
activation,  were  restored  by  expression  of  the  tCTF  (Figure   B-D).  Vice  versa,  FAK 
phosphorylation on  tyrosine 397 and 925, which  was enhanced by syndecan-1 knockdown 
was  reduced  by  tCTF  expression  (Figure   E-F).  These  findings  demonstrate  that  the 
transmembrane  cleavage  fragment  of  syndecan-1  is  sufficient  to  restore  and  promote 
signaling pathways involved in cell migration and proliferation of A549 cells.
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Figure . Restoration of intracellular signaling by expression of syndecan-1 tCTF in A549 cells  
lacking endogenous syndecan-1.
A549 cells  were transduced with scr or SDC-1 shRNA. Subsequently,  a second transduction was 
carried  out with virus for expression of SDC-1 tCTF or empty vector control virus.  Cell lysates of double 
transduced A549 cells were analyzed for phosphorylation or activation status of ERK (A), p38 (B), Akt (C),  
Rho GTPase (D), and FAK at sites Tyr397 (E) and Tyr925 (F) by Western blotting. Signals were quantified by  
densitometry as phosphorylated or activated versus total forms and calculated in relation to the appropriate 
control cells. All data were calculated as means + SD from three independent experiments and representative 
Western blots are shown. Statistically significant differences compared to shRNA_scramble + empty vector and 
other relevant differences are indicated by asterisks or hashes with horizontal bars, respectively (p<0.05).
4.1.8 Syndecan-1 tCTF restores cell proliferation, migration and invasion of A549 cells 
lacking endogenous syndecan-1 
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As shown above, syndecan-1 tCTF was sufficient to restore signaling pathways in syndecan-
1 deficient cells. Next, it was questioned whether the tCTF was also sufficient to influence or 
to restore cellular functions such cell  proliferation,  migration and invasion in  A549 cells 
expressing or lacking endogenous syndecan-1. In A549 cells treated with scramble shRNA 
and still expressing endogenous syndecan-1, expression of the syndecan-1 tCTF did neither 
affect  cell  proliferation,  wound  closure  on  collagen  G  or  fibronectin,  nor  invasion  into 
matrigel (Figure  A-E). In contrast, in cells with shRNA-mediated knockdown of syndecan-1, 
expression of the syndecan-1 tCTF slightly enhanced cell proliferation and clearly restored 
wound closure on collagen G and fibronectin as well as invasion into matrigel (Figure  A-E). 
These data indicate that the transmembrane cleavage fragment of syndecan-1 is sufficient to 
promote A549 cell proliferation, migration and invasion.
4.1.9 Syndecan-1 tCTF upregulates integrin surface and gene expression 
Since migration on collagen and fibronectin as well  as invasion into extracellular  matrix 
involves  the  integrins  α5 and  β1,  it  was  further  investigated  whether  syndecan-1  tCTF 
expression influences  the surface and mRNA expression level of these integrins.  Surface 
expression of α5 and β1 integrins (total protein and active conformation) was increased when 
syndecan-1 tCTF was expressed in A549 cells lacking endogenous syndecan-1 (Figure  A-F). 
Interestingly, the gene expression of α5  was increased, whereas β1  was unaffected (Figure  G 
and H). These experiments indicate that the upregulation of integrins by enhancing cell matrix 
interaction could contribute to the observed promigratory effects of syndecan-1 tCTF.
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Figure  .  Restoration  of  cell  proliferation,  migration  and  invasion  by  syndecan-1  tCTF 
expression in syndecan-1 deficient A549 cells.
A-E) A549 cells were transduced with lentivirus encoding scr or SDC-1 shRNA. Expression of SDC-1 tCTF 
was carried out by second transduction of A549 cells expressing scr shRNA or SDC-1 shRNA with lentivirus  
encoding SDC-1 tCTF. Double transduced A549 cells were analyzed for changes in density over 48 h (A).  
Double transduced A549 cells were grown to confluency on collagen G (B) or fibronectin (C) coated wells and 
wounded by a defined scratch. Wound closure was monitored for 24 h and quantified using the IncuCyte ZOOM 
software. Transduced cells were covered with matrigel after scratch induction and monitored as described above 
to analyze cell invasion (D). Exemplary images of three independent invasion experiments are shown (E). All  
data were calculated as means + SD from three independent experiments. Statistically significant differences 
compared to  shRNA_scramble + empty vector  and  other  relevant  differences  are  indicated by asterisks  or 
hashes with horizontal bars, respectively (p<0.05).
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Figure . Syndecan-1 tCTF upregulates expression of α5 and β1 integrins.
A-H) A549 cells were transduced with lentivirus encoding SDC-1 shRNA. Subsequently, a second transduction 
was carried out with virus for expression of SDC-1 tCTF, or with empty vector control virus. A-F) Double  
transduced A549 cells expressing SDC-1 tCTF or empty vector were investigated for α5 integrin (A and B), β1 
integrin (C and D) or active β1 integrin (E and F) surface expression. G-H) Gene expression of α5 and β1 was 
controlled by quantitative PCR. Data represent means + SD of three independent experiments (A, C, E, G, H) 
and representative  histograms  (B,  D  and  F)  are  shown.  Statistically  significant  differences  compared  to 
shRNA_SDC-1+empty vector control are indicated by asterisks (p<0.05).
4.1.10 Syndecan-1 tCTF mediated cell migration is dependent on β1 integrin
Binding to collagen and fibronectin is mediated by  the β1 integrin subunit [83].  To further 
investigate the involvement of β1 integrin in the promigratory effect of the syndecan-1 tCTF, 
inhibition  experiments  with  a  blocking  β1 integrin  antibody  or  an  isotype  control  were 
performed. For these experiments collagen was used as substrate. As shown in figure 22 A 
and B, inhibition of β1 integrin suppressed cell migration of the syndecan-1 tCTF expressing 
cells.  In  contrast,  no  such  inhibition  was  observed  in  cells  treated  with  isotype  control 
antibody or/and  cells  lacking  the  syndecan-1  tCTF.  These  findings  demonstrate  that  the 
promigratory effect of the transmembrane cleavage fragment of syndecan-1 is dependent on 
β1 integrin.
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Figure . Syndecan-1 tCTF mediated cell migration is blocked by β1 integrin inhibition.
A, B)  Double-transduced A549 cells were grown to confluency on collagen G coated wells, wounded by a 
defined scratch and treated with antibodies against β1 integrin (clone 4B7R) (20 µg/ml), isotype (clone 11711) 
(20 µg/ml) as control or left untreated. Wound closure was monitored for 24 h and quantified using the IncuCyte 
ZOOM software  (A).  Exemplary images  of  three  independent  blocking  experiments  are  shown (B).  Data 
represent  means  +  SD of  three  independent  experiments.  Statistically  significant  differences  compared  to 
shRNA_SDC-1  +  empty  vector  and  other  relevant  differences  are  indicated  by  asterisks  or  hashes  with 
horizontal bars, respectively (p<0.05).
4.1.11 Syndecan-1 and its tCTF promote lung metastasis formation in SCID mice
As shown in figure 8, syndecan-1 deficiency resulted in a considerably reduced number and 
volume of lung tumors compared to scramble shRNA control cells expressing syndecan-1. To 
test the in vivo relevance of syndecan-1 tCTF, it was further investigated whether the tCTF of 
syndecan-1 is sufficient for critical functions of syndecan-1 in lung metastasis formation in 
A549  cells  in  SCID  mice.  Lung  tumor  formation  of  A549  cells  lacking  endogenous 
syndecan-1 was restored by expression of the syndecan-1 tCTF (Figure  ).  Therefore,  the 
transmembrane syndecan-1 fragment generated by proteolytic shedding is sufficient to fulfil 
the functions of syndecan-1 in lung tumor metastasis and formation.
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Figure . Expression of syndecan-1 tCTF restores lung metastasis formation of A549 cells lacking 
endogenous syndecan-1 in SCID mice.
A-C) A549 cells were transduced with lentivirus encoding scr or SDC-1 shRNA followed by a second 
transduction with virus for expression of SDC-1 tCTF or empty control vector. Double transduced 
A549 cells were injected into the tail  vein of mice (n=6 per group). After 35 days animals were  
sacrificed  and  the  lungs  were  analyzed  for  the  number  (A)  and  volume  (B)  of  lung  tumors. 
Representative histologic images are shown (C).  Sections (3 µm) of formalin-fixed and paraffin-
embedded whole lungs were stained with hematoxylin-eosin. All data were calculated as means ± SD 
and statistically significant differences are indicated by asterisks (p<0.05).
4.1.12  Syndecan-4  tCTF  restores  cell  migration,  syndecan-1  dependent  signaling 
pathways and modulates integrin expression
As shown in figure 9, wounding of A549 cells does not only result in syndecan-1 cleavage 
and tCTF generation but also in the shedding of syndecan-4 and the equivalent syndecan-4 
tCTF, which could fulfil similar functions as the syndecan-1 tCTF. To address the question 
whether the promigratory function and integrin regulation is limited to syndecan-1 tCTF, 
syndecan-4 tCTF was expressed in A549 cells lacking syndecan-1. Expression was controlled 
by quantitative PCR detecting mRNA for both endogenous syndecan-4 and the expressed 
tCTF of syndecan-4 (Figure  A). Syndecan-1 tCTF expression had no influence on syndecan-
4 tCTF expression. Syndecan-4 tCTF promoted wound closure of syndecan-1 deficient A549 
cells  as  efficient  as  syndecan-1  tCTF  (Figure   B).  These  findings  demonstrate  that  the 
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syndecan-4 tCTF is able to compensate syndecan-1 dependent cell migration comparable to 
the effect seen after syndecan-1 tCTF expression.
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Figure . Expression of syndecan-4 tCTF restores the cell migration defect of A549 cells lacking 
syndecan-1.
A,  B)  A549  cells  were  transduced  with  lentivirus  encoding  SDC-1  shRNA.  Subsequently,  a  second  viral  
transduction was carried out for expression of SDC-1 tCTF, SDC-4 tCTF or with empty vector control virus. 
Efficiency of expression was controlled by qPCR with primers annealing to the C-terminus of SDC-4 allowing 
to detect both endogenous SDC-4 and expressed tCTF mRNAs (A). Double transduced A549 cells were grown 
to confluency on collagen G coated wells and wounded by a defined scratch. Wound closure was monitored for 
24 h and quantified using the IncuCyte ZOOM software (B). All data were calculated as means + SD from three  
independent experiments. Statistically significant differences compared to shRNA_SDC-1 + empty vector are  
indicated by asterisks (p<0.05).
Next, it was investigated whether the expression of syndecan-4 tCTF expression could also 
restore syndecan-1 dependent signaling pathways as shown for syndecan-1 tCTF in figure 
19.  Expression  of  the  syndecan-4  tCTF  in  A549  control  cells  expressing  endogenous 
syndecan-1 (expressing scramble shRNA) did not show significant effects on ERK, p38, Akt 
and  FAK  phosphorylation  on  tyrosine  925  but  a  significant  reduction  of  FAK 
phosphorylation  on  tyrosine  397 (Figure   A-E).  Again,  more  pronounced and significant 
effects were observed when the syndecan-4 tCTF was expressed in syndecan-1 deficient cells 
(expressing  shRNA against  syndecan-1).  ERK phosphorylation  was  significantly reduced 
(Figure   A).  Moreover,  those  responses  that  were  suppressed  by syndecan-1  knockdown 
including p38, and Akt phosphorylation were restored by expression of the syndecan-4 tCTF 
(Figure  B and C). A similar restoration has been observed when the syndecan-1 tCTF was 
expressed  in  syndecan-1  deficient  cells  (Figure  ).  Further,  syndecan-4  tCTF  was  also 
comparable  to  syndecan-1  tCTF  in  its  ability  to  inhibit  FAK  Tyr397  and  Tyr925 
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phosphorylation (Figure  D and E). These data suggest that both syndecan-1 and syndecan-4 
tCTF share functional properties to promote signaling towards cell migration.
Since the previous experiments demonstrated that the promigratory effect of the syndecan-1 
tCTF is associated with the upregulation of β1 and α5 integrins, it was questioned whether the 
expression of syndecan-4 tCTF may also lead to integrin upregulation. The integrins α5 and 
β1 were both increased on surface expression level when syndecan-4 tCTF was expressed in 
A549 cells lacking endogenous syndecan-1, comparable to the effect seen after syndecan-1 
tCTF expression (Figure   A-F, for comparison see  Figure  ). The gene expression of  α5  was 
increased,  whereas β1  was unaffected (Figure   G-H).  These data  indicate  that  syndecan-4 
tCTF upregulates α5 and β1 integrin expression as efficient as syndecan-1 tCTF.
4.1.13  The  cCTFs  of  syndecan-1  or  syndecan-4  cannot  compensate  endogenous 
syndecan-1 deficiency 
Further processing of syndecan tCTF by intramembrane proteolysis results in the generation 
of the cCTF [142]. To answer the question whether membrane insertion of the syndecan-1 
and -4 tCTF is essential for mediating the promigratory function, expression of syndecan-1 or 
-4  cytoplasmic  C-terminal  fragments  (cCTF)  lacking  the  transmembrane  domain  were 
performed.  Expression  of  syndecan-1  or  -4  cCTF  in  A549  cells  after  knockdown  of 
endogenous syndecan-1 was verified by quantitative PCR (Figure  A and B). An HA tagged 
variant of syndecan-1 cCTF was chosen to demonstrate the protein expression (Figure  A). 
When the non-tagged cCTFs were studied in the wound closure assay in A549 cells lacking 
endogenous syndecan-1 no effect on the wound closure response was observed (Figure  D). 
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Figure  .  Restoration  of  intracellular  signaling  by  syndecan-4  tCTF  expression  in 
syndecan1 deficient A549 cells.
A-E) A549 cells were transduced with a scr or SDC-1 shRNA vector. Subsequently, a second transduction was 
carried out with an empty vector control virus or with virus for expression of SDC-1 tCTF, SDC-4 tCTF or  
empty vector as control.  Cell lysates of double transduced A549 cells were analyzed for phosphorylation or 
activation status of  ERK1/2 (A),  p38 (B),  AKT (C),  FAK at  sites  Tyr397 (D) and Tyr925 (E) by Western 
blotting.  Signals  were  quantified  by  densitometry  as  phosphorylated  or  activated  versus  total  forms  and 
calculated  in  relation  to  the  appropriate  control  cells.  Data  represent  means  +  SD of  three  independent 
experiments  and  representative  Western  blots  are  shown. Statistically  significant  differences  compared  to 
shRNA_scramble  +  empty  vector  or  other  relevant  differences  are  indicated  by  asterisks  or  hashes  with  
horizontal bars, respectively (p<0.05).
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Figure . Expression of syndecan-4 tCTF upregulates integrin surface and gene expression.
A-H)  A549  cells  were  transduced  with  lentivirus  encoding  scr  or  SDC-1 shRNA.  Subsequently,  a  second 
transduction was carried out with virus for expression of SDC-4 tCTF or with empty vector control virus. (A-F) 
Double transduced A549 cells were investigated for α5 integrin (A and B), β1 integrin (C and D) or active β1 
integrin (E and F) surface expression. Data represent means + SD of three independent experiments (A, C, E, F, 
G and H) and representative histograms (B, D and F) are shown. Statistically significant differences compared 
to shRNA_SDC-1+empty vector are indicated by asterisks (p<0.05).
Since  syndecan-1 and -4 tCTFs were both  capable of inducing integrin upregulation,  the 
syndecan cCTF expressing cells were analyzed for α5 and β1  surface expression. Expression 
of either syndecan-1 or syndecan-4 showed no changes of surface expressed integrins (Figure
). These data suggest that removal of the transmembrane domain, which can occur via γ-
secretase-mediated cleavage, abrogates the promigratory activity and integrin regulation of 
the tCTFs. 
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Figure  .  Expression  of  syndecan-1  or  syndecan-4  cCTFs  cannot  compensate  endogenous 
syndecan-1 deficiency.
A-B) A549 cells were transduced with a SDC-1 shRNA vector. Subsequently, a second transduction was carried 
out with virus for  expression of SDC-1 or SDC-4 cCTF or with empty vector  control  virus.  Efficiency of 
expression was controlled by quantitative PCR with primers annealing to the C-terminus of SDC-1 or SDC-4 
allowing  to  detect  both  endogenous  and  overexpressed  cCTF  mRNAs. C)  SDC-1  deficient  A549  cells 
expressing SDC-1 cCTF-HA were harvested and cell lysates were subjected to Western blotting. The SDC-1 
cCTF-HA was quantified by densitometry expressed in  relation to  GAPDH expression. Double transduced 
A549 cells were grown to confluency on collagen G coated wells and wounded by a defined scratch. Wound 
closure was monitored for 24 h and quantified using the IncuCyte ZOOM software. All data were calculated as 
means  +  SD  from  three  independent  experiments.  Statistically  significant  differences  compared  to 
shRNA_SDC-1 + empty vector are indicated by asterisks (p<0.05).
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Figure . Expression of syndecan-1 or -4 cCTF lacking the transmembrane domain does not 
affect integrin surface expression.
A-F) A549 cells were transduced with lentivirus encoding SDC-1 shRNA. Subsequently, a second transduction 
was carried out with virus for overexpression of SDC-1 cCTF, SDC-4 cCTF or with empty vector as control.  
Double transduced A549 cells were investigated for α5-integrin (A and B), β1 integrin (C and D) or active β1 
integrin (E and F) surface expression. Data represent means + SD of three independent experiments (A, C and 
E) and representative histograms (B, D and F) are shown. No statistically significant differences were detected.
4.1.14 Expression of  full  length syndecan-1  restores cell  migration,  proliferation and 
upregulates surface expression of β1 integrin
Finally,  it  was asked whether expression of full  length syndecan-1 would yield a similar 
effect on cell migration and regulation of integrins as seen for the syndecan-1 tCTF. For this 
experiment A549 cells  expressing shRNA against the UTR region (mRNA target: 3116) of 
syndecan-1 were used. This allowed the expression of full length syndecan-1 by a plasmid 
with  the  minimal  sequence  for  expression,  which  was not  affected  by the  used  shRNA. 
Downregulation and reconstitution of full length syndecan-1 surface expression was verified 
by flow cytometry (Figure  A and B). Surface expression of syndecan-4 was neither affected 
by syndecan-1 knockdown via the shRNA against the UTR mRNA nor by expression of full 
length syndecan-1 (Figure  C and D). As expected, reconstitution of full length syndecan-1 
lead  to  full  recovery of  the  proliferative  and the  migratory response (Figure   E  and F). 
Further, reconstitution of full length syndecan-1 induced upregulation of integrin α5, β1 total 
and active conformation surface expression (Figure  A-F). These data show that expression of 
either  the full  length syndecan-1 or its  transmembrane cleavage fragment  is  sufficient  to 
restore the migratory response in the absence of endogenous syndecan-1.
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Figure . Expression of full length syndecan-1 restores cell proliferation and migration.
A-F)  A549  cells  were  transduced  with  shRNA directed  against  the  SDC-1  untranslated  region  (UTR),  to 
downregulate endogenous SDC-1 expression, or with scr as control. Subsequently, a second transduction was 
carried out with lentivirus encoding full length SDC-1 or with empty vector.  A-D) Double transduced A549 
cells were investigated for surface expression of SDC-1 (A and B) or SDC-4 (C and D). Transduced A549 cells 
were assayed for proliferation over 48 h by measuring fold change in density using the IncuCyte ZOOM system 
(E). Cells were grown to confluency on collagen G and wounded by a defined scratch. Wound closure was  
monitored from 0 h after scratch induction to 24 h and quantified using the IncuCyte ZOOM system (F). Data 
represent means  + SD of three independent experiments (A, C, E,) and representative histograms (B, D) are 
shown. Statistically significant differences compared to shRNA_scr or other relevant differences are indicated 
by asterisks and hashes, respectively (p<0.05).
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Figure  . Expression  of  full  length  syndecan-1  upregulates  surface  expression  of  α5 and  β1 
integrin.
A-F) A549 cells were transduced with lentivirus encoding shRNA directed against  the SDC-1 untranslated 
region (UTR), to downregulate endogenous SDC-1 expression, or with scr as control. Subsequently, a second  
transduction  was  carried  out  with  lentivirus  encoding  full  length  SDC-1  or  with  empty  vector. Double 
transduced A549 cells were investigated for α5 integrin (A and B), β1 integrin (C and D) or active β1 integrin (E 
and  F)  surface  expression. Data  represent  means  +  SD of  three  independent  experiments (A,  C,  E)  and 
representative histograms (B, D, F) are shown. Statistically significant differences compared to shRNA_SDC-1-
3116+empty vector are indicated by asterisks (p<0.05).
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4.2  Functional  analysis  of  the  cytoplasmic  C-terminal  fragment  (cCTF)  of 
syndecan1 on cancer cell motility in vitro and in vivo
In the first part, it was shown that the presence of syndecan-1 tCTF is sufficient to mediate 
syndecan-dependent functions in cell proliferation, migration, invasion and lung metastasis 
formation.  However,  the  syndecan-1 cCTF was  not  sufficient  to  restore  the  functions  in 
syndecan-1 deficient cells. Yet, this fragment could still fulfil regulatory functions in A549 
cells expressing endogenous syndecan-1. Therefore, the aim of this part of the thesis was to 
investigate  the  influence  of  the  syndecan-1  cCTF  on  cellular  functions  including  cell 
proliferation, migration, and invasion in the settings described in the first part. 
4.2.1 Syndecan-1 cCTF is present in A549 cells and does not affect gene transcription
Following ectodomain cleavage the  membrane associated tCTF of  syndecan-1 undergoes 
intramembrane  proteolysis  leading  to  the  generation  of  a  syndecan-1  cCTF  [142]. To 
demonstrate the presence of endogenous syndecan-1 cCTF in A549 cells, the cell lysate of 
A549 cells  was subjected to  SDS-PAGE and the protein band with the expected size of 
syndecan-1 cCTF was analyzed by tryptic digestion and MALDI-TOF/TOF. The MALDI-
TOF/TOF  analysis  was  performed  in  cooperation  with  Ph.D.  Vera  Jankowski  (RWTH 
Aachen  University  Hospital,  Institute  of  Molecular  Cardiovascular  Research).  The 
characteristic MALDI-TOF/TOF mass-fingerprint spectrum indicates a mass signal with the 
expected molecular weight of 785 m/z (Figure  A). This signal was due to syndecan-1 cCTF 
as verified by MALDI-TOF/TOF fragment MS/MS mass-spectra revealing the ultimate N-
terminal sequence QEEFYA of the cCTF (Figure  B). Moreover, this fragment accumulated 
after inhibition of the proteasome with bortezomib and this accumulation was prevented by 
the γ-secretase inhibitor DAPT . Next, a lentiviral vector was used to overexpress human 
syndecan-1 cCTF in wild type A549 cells. Overexpression was controlled by quantitative 
PCR (Figure   C), and the increased presence of protein with the expected molecular mass 
was confirmed and quantified by mass spectrometry (Figure  D).
It is well known for other substrates of γ-secretase such as Notch, which the release of their 
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C-terminal intracellular domains into the cytoplasm, induce transcriptional responses [102]. 
Therefore, it was examined whether overexpression of syndecan-1 cCTF would result in the 
alteration of the overall transcriptional expression profile in A549 cells. The transcriptional 
analysis was carried out in cooperation with Ph.D. Holger Jahr and Ph.D. Bernd Denecke 
(RWTH  Aachen  University  Hospital, Department  of  Orthopaedic  Surgery  and 
Interdisciplinary Center for Clinical Research). However, no significant gene induction or 
repression above a 2.5fold level was observed, suggesting that the cCTF by itself does not 
function to generally control transcription (Figure   E). It was therefore speculated that the 
overexpressed cCTF could rather act as a non-transcriptional regulator.
4.2.1  Syndecan-1 cCTF blocks syndecan-1 dependent lung tumor cell  migration and 
invasion
Since  syndecan-1  regulates  epithelial  tumor  cell  migration  and  proliferation,  it  was 
questioned whether these functions are influenced by the accumulation of syndecan-1 cCTF. 
This was studied in proliferation, wound closure and invasion assays. Overexpression of the 
cCTF did not affect proliferation of A549 cells compared to controls (Figure  A). In contrast, 
scratch-induced cell migration on collagen G or fibronectin was significantly reduced upon 
overexpression  of  syndecan-1  cCTF  (Figure   B  and  C).  In  addition,  syndecan-1  cCTF 
overexpression also reduced invasion  of  A549 cells  into the  wounded area  covered with 
matrigel  directly after  scratch  induction  (Figure   D and E).  These  data  indicate  that  the 
cytoplasmic CTF of syndecan-1 blocks migration as well  as invasion of cells  expressing 
endogenous syndecan-1.
4.2.2 Syndecan-1 cCTF promotes adhesive events and related signaling pathways
The observation that the cCTF influences cell migration led to the question whether it would 
also affect adhesive events which are important during cell  movement.  First,  adhesion to 
collagen G and fibronectin were studied. Interestingly,  adhesion to collagen G as well as 
adhesion  to  fibronectin  was  increased  when  the  cCTF was  overexpressed  in  A549  cells 
expressing endogenous syndecan-1 (Figure  A-C).
77
Results
D
relative mass intensity (AU)
molecular weight (m/z)
relative mass intensity (AU)
molecular weight (m/z)
A B
E
significance level (-log10 raw p
-value)
mean expression difference 
(log2_fold change SDC-1 cCTF vs empty vector)
F
10 -4
10-2
100
rel. intensity/ int. standard (AU)
*
10
SDC
-1  CTF mRNA
-1
010
101
*
empty vector SDC-1 cCTF
0
1
2
Bortezomib - + +
DAPT - - +
control + - -
rel. intensity/ int. standard (AU)
*
#
C
Figure . Overexpression of syndecan-1 cCTF does not affect gene transcription.
A,  B)  Lysates  of  A549  cells  were  subjected  to  SDS-PAGE.  The  protein  band  with  the  expected  size  of 
syndecan-1 cCTF was digested with trypsin and analyzed by MALDI-TOF/TOF. A)  Characteristic  MALDI-
TOF/TOF mass-fingerprint-spectrum: The arrows indicate characteristic mass-signals of peptides corresponding 
to the tryptic  digested syndecan-1 cCTF with a molecular  mass of  785 Da.  B) Verification of  amino acid 
sequences of the 785 Da peptide by mass spectrometry. C) A549 cells were incubated for 16 h in the presence or 
absence of the proteasome inhibitor bortezomib (5 µM) or γ-secretase inhibitor DAPT (5 µM) an investigated 
for the presence of endogenous syndecan-1 cCTF by MALDI-TOF/TOF. Quantified mass-signal intensities of 
the 785 Da peptide were compared to the mass-signals intensities of diinosine pentaphosphate, which was used 
as internal standard. D-F) A549 cells were transduced with lentivirus encoding empty vector or SDC-1 cCTF. 
D) Efficiency of overexpression was controlled by quantitative PCR with primers annealing to the C-terminus 
of SDC-1 allowing to detect both endogenous SDC-1 and overexpressed cCTF mRNAs expressed in relation to 
GAPDH mRNA. E)  Mass-signal intensities of SDC-1 cCTF expressing cells or empty vector control were 
analyzed by quantitative MALDI-TOF/TOF. F) A549 cells transduced with SDC-1 cCTF or empty control virus 
were subjected to microarray gene expression analysis. Results are shown as volcano plot in which each tested  
gene is indicated as a dot. The x-axis represents the log2 
value of fold change in gene expression between the 
two groups and the y-axis indicates the negative log10 raw 
p-value for this difference. Areas top left and top right 
represent the genes which are up-/down-regulated more or equal to log2 1.3 with a p-value lower than 0.05. Data 
are shown as representative plots and means + SD calculated from three independent experiments. Statistically 
significant differences compared to the respective control or other relevant differences are indicated by asterisks 
and hashes, respectively (p< 0.05).
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Figure . Overexpression of syndecan-1 cCTF blocks cell migration and invasion.
A-E) A549 cells were transduced with lentivirus encoding empty vector or SDC-1 cCTF. Transduced A549 cells 
were analyzed for proliferation measured as change in density over 48 h (A). Cells were grown to confluence on 
collagen G (B) or fibronectin (C) coated wells and wounded by a defined scratch. Wound closure was monitored 
continuously for 24 h and quantified as percent wound closure in relation to full wound closure using the  
IncuCyte ZOOM. D-E) Transduced cells were wounded by scratching and subsequently covered with matrigel 
to  analyze  cell  invasion  from the  wound edges  into  the  matrigel  within  the  wounded  area.  Results  were  
expressed as percent of invaded cells in relation to the empty vector control (D). Exemplary images of three  
independent  invasion  experiments  are  shown  (E).  All  data  were  calculated  as  means  +  SD  from  three 
independent  experiments.  Statistically  significant  differences  compared  to  empty  vector  are  indicated  by 
asterisks (p<0.05)
Since  adhesion  to  ECM  components  such  as  collagen  G  or  fibronectin  is  mediated  by 
integrins and since syndecan-1 tCTF was shown to influence integrin surface expression, it 
was  investigated  next,  whether  the  syndecan-1  cCTF  also  modulates  the  basal  surface 
expression levels of α5,  β1 (total  and active conformation)  and β4  integrins.  However,  no 
changes in their surface expression level were observed (Figure ).
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Figure . Syndecan-1 cCTF overexpression increases adhesion to collagen G and fibronectin.
A-C) A549 cells were transduced to express SDC-1 cCTF or empty vector. Transduced cells were investigated 
for adhesion to collagen G (A) or fibronectin (B). Cells were seeded on coated wells, sedimented and incubated  
for  15  min.  After  washing,  the  number  of  adherent  cells  was  determined  using  the  Incucyte  ZOOM and  
expressed in relation to the number of seeded cells. Images of a representative cell adhesion experiment to 
fibronectin and collagen G are shown (C). Statistically significant differences compared to corresponding empty 
vector control are indicated by asterisks (p<0.05).
After it  had become clear that  the basal  integrin surface expression is  not modulated by 
syndecan -1 cCTF expression, it was studied if syndecan-1 cCTF expression would affect the 
formation  of  focal  adhesion  contacts,  which  could  explain  the  observed  effects  on  cell 
adhesion. Syndecan-1 cCTF expressing cells were subjected to immunocytochemistry and 
analyzed for  recruitment  of  the  adapter  protein  paxillin  as  a  crucial  component  of  focal 
adhesions (Figure ). Immunocytochemistry was carried out in cooperation with Ph.D. Nicole 
Schwarz (RWTH Aachen University hospital, Institute for Molecular and Cellular Anatomy). 
The intracellular assembly of focal adhesions was quantified as length of paxillin positive 
structures  at  the  contact  zone  of  two  adjacent  cells.  The  focal  adhesion  length  was 
significantly increased upon overexpression of the cCTF as shown in figure 35 A and B.
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Figure . SDC-1 cCTF overexpression does not modulate integrin surface expression.
A-H) A549 cells were transduced with empty vector or SDC-1 cCTF expression vector. Transduced A549 cells 
were investigated for α5-integrin (A and B), β1-integrin (C and D), active β1-integrin (E and F) and β4-integrin 
surface expression (G and H) by flow cytometry. Data were quantified as relative changes of the fluorescence 
signal compared to the empty vector control and represent means + SD of three independent experiments (A, C, 
E and  G).  Representative  histograms are  shown (B,  D,  F,  H).  No statistically significant  differences  were  
detected.
Next, it was investigated whether syndecan-1 cCTF overexpression also affected signaling 
pathways that have been implicated in syndecan-1 dependent adhesion. As shown in figure 
14, syndecan-1 regulates phosphorylation of ERK, p38, Akt and FAK as well as Rho GTPase 
activation. In contrast, overexpression of syndecan-1 cCTF had no effect on phosphorylation 
of ERK, p38, Akt, and FAK tyrosine 925 (Figure   A-D). However, Src phosphorylation on 
tyrosine 416 and FAK phosphorylation on tyrosine 397 were significantly increased (Figure  
E and F) compared to the control. Also Rho GTPase activation was increased by syndecan-1 
cCTF overexpression (Figure   G). These data indicate that syndecan-1 cCTF increases the 
basal activation level of signal transduction pathways, which are related to focal adhesion 
formation and cell migration. This disturbance may lead to the suppression of syndecan-1 
mediated cell migration.
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Figure . Syndecan-1 cCTF overexpression increases paxillin recruitment to focal adhesion. 
A,  B)  A549  cells  were  transduced  with  an  empty  vector  or  a  SDC-1  cCTF  expression  vector. 
Transduced  cells  were  grown  on  collagen  G,  fixed,  permeabilized  and  stained  with  an  paxillin 
antibody (green signal). Expression of mCherry (expression vectors, red signal) was visualized as 
transduction  control.  The  lengths  of  the  focal  adhesion  structures  were  determined  via  the 
visualization of recruited paxillin (A). Focal adhesions are shown as representative images (B). Data 
shown  in  A represent  means  +  SD  of  three  independent  experiments.  Statistically  significant 
differences compared to corresponding empty vector control are indicated by asterisks (p<0.05).
4.2.3 Syndecan-1 cCTF suppresses lung metastasis formation in SCID mice
To investigate the  in vivo relevance of the observed antimigratory activity of syndecan-1 
cCTF,  the  xenograft  lung  metastasis  formation  model  in  SCID mice  was  performed.  As 
described in figure 15, tumor formation is suppressed when cells lack endogenous syndecan-
1. It was now tested whether inhibition of cell migration by syndecan-1 cCTF would yield a  
comparable effect. Lung tumor formation of A549 cells transduced to express syndecan-1 
cCTF  showed  significantly  reduced  lung  tumor  areas  compared  to  cells  that  had  been 
transduced with an empty vector (Figure  ). Hence, the cytoplasmic C-terminal fragment of 
syndecan-1 can be regarded as an antagonist blocking the functions of syndecan-1 in lung 
metastasis formation.
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Figure . Syndecan-1 cCTF overexpression upregulates activation of Src, FAKTyr397 and Rho, but 
not of ERK, p38, Akt or FAKTyr925.
A-G) Cell lysates of A549 cells transduced with lentivirus encoding empty or SDC-1 cCTF expression vector 
were analyzed for phosphorylation or basal expression status of ERK (A), p38 (B), Akt (C), FAK site Tyr925 
(D), Src (E), FAK site Tyr397 (E) and Rho GTPase (F) activation by Western blotting. Signals were quantified  
by densitometry as phosphorylated versus total forms and calculated in relation to the control empty vector. 
Data  are  shown as  means  +  SD  of  three  independent  experiments  and with  representative  Western  blots. 
Statistically  significant  differences  compared  to  the  corresponding  empty  vector  control are  indicated  by 
asterisks (p<0.05).
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Figure . Overexpressed syndecan-1 cCTF suppresses lung metastasis formation of A549 cells in 
SCID mice.
A, B) A549 cells were transduced with empty vector or SDC-1 cCTF expression vector. Transduced  A549 cells 
were injected into the tail vein of SCID mice (n=6 per group). After 35 days, animals were sacrificed and the  
lungs were analyzed for lung tumor formation. Lung tumor area was calculated as percentage of total lung 
tissue  area  (A).  Sections  (3  µm) of  formalin-fixed  and  paraffin-embedded whole  lungs  were  stained  with 
hematoxylin-eosin. Representative histologic images are shown (B). All data were calculated as means ± SD 
and statistically significant differences are indicated by asterisks (p<0.05).
4.2.4  A synthetic syndecan-1 cCTF peptide blocks cell migration and regulates Src and FAK 
activation
Cell migration is blocked by overexpression of syndecan-1 cCTF in A549 cells. To confirm 
this finding by an alternative approach, the influence of synthetic syndecan-1 cCTF peptides 
on cell migration was  investigated. To deliver the peptides into the cells Chariot® peptide 
delivery reagent  was chosen as  a  carrier.  Uptake of  β-galactosidase was used  as  control 
peptide and successful delivery was visualized by the hydrolysis of X-gal leading to blue 
spotted cells (data not shown). Additionally, no carrier reagent was added, to study effects of 
the syndecan peptides originating from their potential extracellular binding to the cells. A549 
cells were incubated with synthetic peptides corresponding to the wild type or a scrambled 
sequence of syndecan-1 cCTF in the presence or absence of carrier  reagent allowing the 
uptake of the peptides (Figure  A). In the absence of the carrier reagent both peptides showed 
no influence on cell migration and proliferation (Figure  B) indicating that the peptides do not 
act as extracellular stimuli or inhibitors for A549 cells. In contrast, in the presence of carrier 
reagent the syndecan-1 cCTF peptide (1 and 10 µM) significantly decreased cell migration, 
while the scramble control peptide had no effect (Figure  C). The proliferative response was 
not affected by any of the peptides. Furthermore, treated A549 cells showed no changes in 
morphology compared to controls (Figure ).
Finally, it was investigated whether the uptake of the syndecan-1 cCTF peptide would also 
affect migratory signals such as Src and FAK activation. In the absence of the carrier reagent 
both peptides did not show an effect on the phosphorylation of both kinases (Figure  A and B) 
compared to the PBS treated control. In contrast, in the presence of the carrier reagent the 
syndecan-1 cCTF peptide significantly increased phosphorylation of Src and phosphorylation 
of FAK on tyrosine 397 compared to the controls receiving the scrambled peptide (Figure  A 
and B).  This  finding  confirms  that  the  cCTF  counterregulates  tumor  cell  migration  and 
dysregulates signaling pathways related to cell migration. 
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Figure . A synthetic syndecan-1 cCTF peptide blocks cell migration.
A) Schematic representation of the human SDC-1 cCTF peptide and the scrambled control peptide. B, C) A549  
cells were treated with SDC-1 cCTF peptide or the scrambled peptide without (B) or with (C) carrier reagent  
(Chariot delivery reagent). A549 cells were grown to confluency on collagen G coated wells and wounded by a 
defined scratch. After wounding, cells were treated with SDC-1 cCTF peptide or scrambled peptide (0.1 µM, 1 
µM or 10 µM) and investigated for wound closure over 24 h (left). In parallel, cells were seeded at a lower 
density and proliferation was quantified as change in density (right) over a period of 24 h using the IncuCyte 
ZOOM  Imaging  system.  All  data  were  expressed  as  means  +  SD  and  statistically  significant  differences  
compared to corresponding scramble peptide treatment are indicated by asterisks (p<0.05).
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Figure . The synthetic SDC-1 cCTF peptide does not affect cell morphology.
A549 cells were treated with 1 or 10 µM SDC-1 cCTF peptide or the scrambled peptide with carrier reagent  
(Chariot delivery reagent) and analyzed for morphological changes over a period of 48 h using the IncuCyte  
ZOOM Imaging system.
peptide carriere in PBS+H20
scrambled SDC-1 cCTF peptide
SDC-1 cCTF peptide 
A B
0
2
4
6
pFAK
397
/FAK
FAK
pFAK397
*
0
1
2
3
pSrc/Src
pSrc416
Src
*
peptide carrier +          - - +         + peptide carrier +          - - +        +
Figure . The synthetic SDC-1 cCTF peptide regulates Src and FAK397.
A, B) A549 cells were treated with 10 µM SDC-1 cCTF or 10 µM scramble SDC-1 cCTF with carrier reagent  
for 2 h. Cell lysates of treated A549 cells were analysed for phosphorylation of Src at Tyr416 (A) and FAK at 
Tyr397 (B) by Western blotting. Signals were quantified by densitometry as phosphorylated versus total forms 
and calculated in relation to the control cells. All data were expressed as means + SD of three independent 
experiments  and  representative  Western  blots  are  show.  Statistically  significant  differences  compared  to 
corresponding scramble syndecan-1 cCTF treatment are indicated by asterisks (p<0.05).
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5 Discussion
Syndecan-1  and  -4  are  heparan  sulfate  proteoglycans  expressed  on  the  cell  surface  of 
endothelial and epithelial cells. By influencing cell motility and cell proliferation syndecan-1 
and -4 are involved in different pathophysiological processes such as wound closure, tumor 
development, and metastasis [106].
The general importance of syndecan-1 and -4 for the wound closure response was shown in 
this  Ph.D.  study  by  knockdown  of  syndecan-1  or  -4,  which  critically  affected  cell 
proliferation, migration during wound closure and signaling pathways  in vitro.  The results 
are  listed  in  detail in table  12  and  discussed  in  the  following.  In  an  in  vivo xenograft 
transplantation  model  in  mice,  loss  of  syndecan-1,  but  not  syndecan-4,  reduced  lung 
metastasis  formation.  These  in  vitro  and  in  vivo  results  consistently  demonstrate  a 
promigratory activity of syndecan-1. 
Syndecans undergo proteolytic cleavage by metalloproteinases (e.g ADAM17) at the 
extracellular site close to the plasma membrane, which releases a soluble ectodomain. This 
process is  called shedding.  The residual  transmembrane C-terminal  fragment  (tCTF) is  a 
substrate for further intramembrane proteolysis by the γ-secretase. This results in the release 
of the cytoplasmic C-terminal fragment (cCTF) into the cytoplasm [142]. The present Ph.D. 
thesis demonstrates that the proteolytic processing of syndecan-1 and -4 is enhanced during 
the  wound  closure  response  of  A549  cells  leading  to  an  increased  release  of  soluble 
syndecans and the accumulation of  their  tCTFs.  This  raised the question to  what  extend 
syndecan cleavage fragments affect cell motility in vitro and in vivo. Notably, all defects of 
syndecan-1 deficiency described above were overcome by expression of syndecan-1 or -4 
tCTF, but not by the cCTFs lacking the transmembrane domain as summarized in table 12. In 
addition, the tCTFs mediate the upregulation of integrins α5 and β1. Finally, reconstitution of 
the syndecan-1 tCTF in syndecan-1-depleted cells is sufficient to fulfil syndecan-1 related 
functions in lung metastasis formation  in vivo. In contrast to the tCTF of both syndecans, 
their cCTF showed no promigratory activity. In cells expressing endogenous syndecan-1 the 
overexpression  of  the  syndecan-1  cCTF  rather  antagonized  syndecan-1  mediated  cell 
migration and invasion in vitro and in vivo. Basal activation of Src, FAK and Rho GTPase 
was enhanced by the cCTF and associated with a more tight adhesion and recruitment of 
paxillin to focal adhesions suggesting that the cCTF dysregulates adhesive events required 
for  syndecan-1  mediated  cell  migration  (Table  ).  On  the  basis  of  these  experiments,  a 
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synthetic  syndecan-1  cCTF  peptide  inhibitor  was  developed  that  suppressed  syndecan-1 
mediated tumor cell migration and the related signaling pathways in vitro.
Table . Summary and results of the present study. 
SDC: syndecan, tCTF: transmembrane C-terminal fragment, cCTF: cytoplasmic C-terminal fragment; symbole 
description: no change compared to control (=); not analyzed (n.a.); upregulation, increase compared to control  
; decrease compared to control .
Downregulation of tCTF expression in 
SDC-1 deficient cells
SDC-1 cCTF 
overexpression in 
syndecan-1 expressing 
cells
SDC-1 SDC-4
α5 integrin
mRNA
surface expression
β1 integrin
mRNA
surface expression
β4 integrin
surface expression
=
n.a.
=
=
n.a.
=
n.a.
=
=
n.a.
=

=

n.a.
n.a.
=
n.a.
=
=
activation of signaling proteins
FAK
Src
Rho GTPase
ERK
p38
Akt

n.a.

=



n.a.

=



n.a.







=
=
=
paxillin recruitment n.a. n.a. n.a. 
functional properties
cell proliferation
cell migration 
cell invasion 
cell adhesion 



n.a.



n.a.



n.a.
=



The generation of syndecan cleavage fragments 
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The present thesis showes that the wound closure response of A549 cells is associated with 
an increased cleavage of syndecan-1 and -4. This was evidenced by the enhanced release of 
the soluble syndecan-1 and -4 ectodomain as well as by the accumulation of the syndecan-1 
tCTF within the cell membranes. The increased release and accumulation of the syndecan 
cleavage fragments was not associated with an increase in gene expression suggesting that 
regulation of gene expression does not play a critical role. The generation of the tCTF could 
be  blocked  by  a  metalloproteinase  inhibitor  indicating  that  the  enhanced  release  and 
accumulation of the tCTF is mediated by proteolytic shedding. Moreover, the tCTF generated 
during wound closure was found to accumulate in the presence of γ-secretase suggesting that 
it undergoes further intramembrane proteolysis via the γ-secretase.
A previous study from our laboratory showed that most of the syndecan shedding in A549 
cells  is  mediated by ADAM17 [143].  Shedding of syndecans can occur  in  a constitutive 
manner, but can also be induced by various stimuli including cytokines, pathogens or danger 
associated molecular pattern molecules [143]. In the present thesis, soluble syndecan-1 and 
-4 was increased upon wounding of A549 cells, which was blocked upon metalloproteinase 
inhibition. The exact mechanism of this activation remains to be determined, but cellular 
stress  and the release of  danger  associated mediators  could be involved in  the enhanced 
activity of ADAM17 as it has been reported for the shedding of other substrates including 
IL6R and L-selectin [31;176]. Different studies indicate a role of the cleaved syndecan-1 
ectodomain  in  proliferation  and  cell  migration  [21;53;57;144].  Ramani  et  al.,  (2012) 
demonstrated that the shed syndecan-1 ectodomain mediates the inflammatory response by 
facilitating the formation of a chemokine gradient which enhanced transepithelial migration 
of  neutrophils  in  a  murine  model  of  acute  lung  injury  [144].  Further,  shed  syndecan 
ectodomain can also be measured as biomarker in patients with certain cancers including 
lung cancer in which high levels of shed syndecan-1 correlates with poor outcome of the 
patient [96]. Furthermore, soluble syndecan-1 ectodomain was found in serum of patients 
with colorectal  cancer and multiple myeloma [145;175].  Moreover,  Elenius et  al.,  (2004) 
showed that overexpression of syndecan-1 in mice lead to a high concentration of soluble 
syndecan-1 ectodomain upon wounding and this correlates with delayed wound healing [53]. 
In  a  study  by  Stepp  et  al.,  (2002),  proliferation  of  keratinocytes  at  wound  edges  was 
markedly reduced in mice overexpressing the syndecan-1 ectodomain. Thus, positive as well 
as negative influences of syndecan-1 ectodomains on cell migration and proliferation have 
been reported, which may be explained by the complex pathological situation of the used 
models. However, as demonstrated in the present thesis, wounding of A549 cells does not 
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only lead to the ectodomain release, but also to the accumulation of the syndecan-1 tCTF. 
Therefore,  it  is  important  to  consider  biological  activities of the cell  associated cleavage 
fragment and not only different activity of the ectodomain. Following ectodomain shedding, 
syndecan-1 and -4 in human kidney cells as well as syndecan-3 in murine fibroblasts  were 
shown to undergo further intramembrane proteolysis, which is sensitive to inhibition of the γ-
secretase complex [157]. The involvement of the γ-secretase in syndecan-1 processing during 
the  wound  healing  response  is  confirmed  by the  present  work  showing  that  γ-secretase 
inhibition in the lung cancer cell line A549 increased the basal level of syndecan-1 tCTF. 
Moreover,  mass  spectrometry  analysis  showed  reduced  accumulation  of  the  syndecan-1 
cCTF  after  γ-secretase  inhibition. Thus,  upon  syndecan  shedding,  the  residual  tCTF 
undergoes  γ-secretase-dependent  degradation  leading  to  the  generation  of  a  small 
cytoplasmic C-terminal fragment. The role of syndecan-1 and -4, their tCTFs and cCTFs will 
be discussed in the three following chapters. 
Role of syndecan-1 and -4 in proliferation and cell motility
In the present study, syndecan-1 deficient A549 cells showed decreased proliferation in vitro 
and reduced tumor volume in the lung metastasis model in vivo. This observation is in line 
with previous observations made in other cell types in vitro and in vivo. In a study of Li et al. 
(2014)  overexpression  of  microRNA-143  which  targets  syndecan-1  in  melanoma  cells 
showed  decreased  cell  growth  [111].  Further,  Celie  et  al.,  (2012)  demonstrated  that 
knockdown of syndecan-1 in human tubular epithelial cells reduced cell proliferation [29]. In 
addition, treatment of bladder cancer in mice with siRNA targeting syndecan-1 decreased 
tumor growth. Moreover, in a study of Matsumoto et al., 2013, siRNA mediated knockdown 
of  syndecan-1  in  murine  lewis  lung  carcinoma  (LLC)  cells  reduced  micrometastasis 
formation  in  vivo  [119].  In  contrast  to  the  present  thesis,  knockout  of  syndecan-1  was 
reported to promote cell proliferation of murine vascular smooth muscle cells  in vitro [34]. 
This may be explained by a possible compensation of other syndecans expressed in smooth 
muscle cells. 
Syndecans  belong  to  the  heparan  sulfate  proteogylcans  and  regulate  proliferation  by 
promoting  the  activity  of  growth  factors.  It  is  thought  that  the  main  function  of  their 
ectodomain is to bind growth factors via their covalently bound heparan sulfate GAG chains 
[126].  Reduced  proliferation  of  syndecan-1  and  -4  cells  A549  cells  may  result  from  a 
reduction of potential binding sites for growth factors after syndecan-1 or -4 knockdown. In 
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contrast to syndecan-1 knockdown, syndecan-4 knockdown showed a slight decrease in cell 
proliferation in vitro but no influence in vivo. This could be explained by the finding that the 
expression of syndecan-4 in A549 cells is much lower in comparison to syndecan-1 (present 
thesis,  figure  10  and [19]).  For,  A549 cells,  it is  possible  that  syndecan-4  deficiency is 
compensated  by  high  levels  of  syndecan-1.  Conversely,  knockdown  of  syndecan-1  is 
probably not compensated by syndecan-4 since the expression level of the latter syndecan is 
already low. In fact, the breast cancer cell line MDA-MB-231 expresses more syndecan-4 
compared to syndecan-1 and lentiviral knockdown of syndecan-4, but not syndecan-1, led to 
their decreased proliferation (unpublished data).
Besides from cell proliferation, syndecans are also involved in cell motility [42]. Different 
experimental setups exist  to investigate cell migration  in vitro.  Wound closure assays are 
often used for adherent cells [30;40;115;161]. In this assay wound closure depends on the 
ability of a cell to migrate into the wound area. However, proliferative effects can modulate 
the outcome of wound closure assays. To overcome this problem, pretreatment of cells with 
an antiproliferative drug such as mitomycin is often used in wound closure assays [107;131]. 
In the present  thesis,  the wound closure assay was used to  show that  downregulation of 
syndecan-1 or  -4 is  involved in  cell  migration.  These  observations  are  well  in  line with 
previous reports. Longley et al., (1999) reported that CHO cells transfected with syndecan-4 
antisense RNA showed an impaired wound closure, which indicated impaired cell migration 
[115]. In a study of Charni., et al (2009), the shRNA-mediated knockdown of syndecan-1 and 
-4 decreased chemokine-induced migration of hepatoma cells in an chemotaxis assay in vitro  
[33]. Regarding the role of syndecan1 in cell migration, Hassan et al., (2013) showed that the 
siRNA mediated knockdown of syndecan-1 in breast cancer cells reduced cell migration in  
vitro  [78]. Further, deletion of a specific motif of the syndecan-1 ectodomain in LLC cells 
decreased  cell  migration  [119].  The  in  vitro studies  of  the  present  thesis  indicated  that 
syndecan-1 and -4 may be involved in metastasis formation in vivo. Also in previous in vivo 
studies, syndecan-1 deficient keratinocytes showed a decreased migratory ability in a wound 
closure assay in vivo [161]. Moreover, syndecan-1 depletion in LLC cells led to reduced lung 
metastasis formation in mice [119]. This is in line with the in vivo results of the present thesis 
showing that syndecan-1 promotes lung metastasis formation of A549 lung epithelial cancer 
cells.  Thus,  several  cancer  cell  types  seem to require  syndecan-1  for  cell  migration  and 
metastasis formation. 
Besides from acting as positive regulator in cell migration, syndecans have been described as 
negative  regulators  of  cell  migration.  For  example,  knockout  of  syndecan-1  in  murine 
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fibroblasts  increased  the  cell  migration  speed  in  vitro  [160].  Moreover,  silencing  of 
syndecan-1 enhances squanoma cell migration and miRNA targeting of syndecan-1 enhances 
breast cancer cell motility [86;94]. Vice versa, overexpression of syndecan-1 in mesenchymal 
tumor cells reduced cell migration and adhesion [189]. In another study, overexpression of 
syndecan-4 in CHO cells resulted in increased focal adhesion formation and decreased cell 
migration  [115].  As summarized  above,  different  reports  show that  syndecans  can  either 
promote  or  suppress  cell  migration.  This  may be  explained by the  various  experimental 
differences  of  each  study.  This  includes  different  molecular  approaches  using  shRNA, 
knockout or overexpression of syndecans. In addition, syndecans may have varying effects 
on migration and proliferation depending on the type of cells used. Moreover, the expression 
patterns of syndecan-1 and -4 differ in several cell types, which may affect their relative 
contribution towards cell migration and probably also lead to different compensatory effects 
between syndecan-1 or syndecan-4 [167]. Finally,  different models of migration, reflecting 
different pathological situations, have been used (e.g. use of different extracellular matrix 
coating procedures, pretreatment with mitomycin,  in vivo  wound closure asays or growth 
factor induced cell motility).
Syndecans  have  been  shown to  regulate  signaling  pathways  controlling  cell  motility.  In 
previous studies, knockdown or overexpression of syndecan-1 or -4 were shown to modulate 
p38, Akt, Rho GTPase and FAK [10;86;109;119;181]. Again, the effects appear to be cell 
type  dependent.  For  example,  overexpression  of  syndecan-1  was  found  to  enhance  p38 
phosphorylation in myocardial cells  in vivo and knockdown of syndecan-1 was reported to 
enhance cell migration of breast cancer cells via Rho GTPase activation [86;109]. In a study 
by Hassan et al., (2013) siRNA mediated knockdown of syndecan-1 in breast cancer cells 
enhanced cell migration, adhesion and increased phosphorylation of FAK at tyrosin 925 [78]. 
Further,  deletion of a specific motif of the syndecan-1 ectodomain in LLC cells decreased 
interaction with α5 integrin as well as adhesion to fibronectin via increased phosphorylation 
of tyrosin 925 and paxillin activation [119]. With regard to syndecan-4, murine fibroblasts 
lacking  syndecan-4  displayed  a  higher  phosphorylation  of  p38  [150].  Moreover,  murine 
kidney  cells  of  syndecan-4  knockout  mice  showed  increased  RhoA activation  [113]. In 
addition,  deletion  of  syndecan-4  in  murine  endothelial  cells  resulted  in  decreased  Akt 
activation in vitro and in vivo. In the present Ph.D. study using A549 cells, phosphorylation 
of p38 and Akt as well as activation of Rho GTPase were clearly reduced in the absence of 
syndecan-1 or -4. These results correlate with the observation that these cells show reduced 
migration when syndecan-1 or -4 were lacking. Especially the activation of Rho GTPase is 
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known to be critical for cell migration by controlling polarity, protrusion and adhesion [129]. 
In addition, phosphorylation of FAK at tyrosines 397 and 925 was enhanced by syndecan-1 
knockdown. The phosphorylation at tyrosine 397 is initially associated with an activation of 
FAK whereas  an  additional  phosphorylation  at  tyrosine  925  by Src  kinase  leads  to  the 
exclusion of FAK from cell contacts [75;121;121]. These findings point towards an inhibition 
of FAK activity in A549 cells with syndecan-1 or -4 knockdown. Since focal adhesions are 
important for cell movement, the exclusion of FAK may constitute an additional mechanism 
by which syndecan-1 or -4 knockdown could reduce cell  migration.  A possible signaling 
mechanism after loss of syndecan is shown in figure 41.
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Figure . Potentional signaling pathways after loss of syndecan.
Syndecan  knockdown  led  to  decreased  Rho  activation  and  to  enhanced  phosphorlation  of  FAK.  The 
downstream signaling proteins p38 and Akt showed decreased phosphorylation, which in turn could decrease  
cell motility. Black: normal signaling pathways and cell motility; red: inhibition of signaling pathways and cell  
motility.
Role of syndecan-1 and -4 tCTF in cell motility
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The findings of the present Ph.D. study showed that the expression of syndecan-1 tCTF in 
syndecan-1  deficient  cells  increased  the  proliferation  in  vitro  and  in  vivo.  In  addition, 
syndecan-1  tCTF  influenced  signaling  pathways  involved  in  syndecan-1  mediated  cell 
migration  as  well  as  integrin  surface  expression.  Similar  observations  were  made  when 
syndecan-4 tCTF was expressed in syndecan-1 deficient cells. Therefore, the syndecan-1 and 
-4 tCTF by itself can take over cellular functions in the absence of the endogenous syndecan-
1.  Such  an  activity  was  not  observed  for  syndecan-1  cCTF  suggesting  that  the 
transmembrane region of the tCTF is required for the promigratory activity.
Different studies indicate a crucial role for the transmembrane domain of syndecans in cell 
motility. In a study of Altemeier et al., (2012), the syndecan-1 knockdown in murine lung 
epithelial cells increased cell speed and focal adhesion assembly, which was slowed down by 
reconstitution  of  full  length  syndecan-1  lacking  the  cytoplasmic  domain.  In  addition, 
mutation  of  the  syndecan1  transmembrane  domain  showed  decreased  cell  spreading  in 
lymphoblast-like  cells  [120].  With  regard  to  syndecan-4,  overexpression  of  the  whole 
molecule in rat embryonic fibroblasts decreased cell migration, whereas overexpression of 
syndecan-4  variant  with  mutated  transmembrane  domain  increased  cell  migration  [40]. 
Further,  mutation  within  the  syndecan-4  transmembrane  domain  affected  syndecan-4 
oligomerization,  which  had  profound  consequences  on  cell  adhesion  and  focal  adhesion 
formation in rat embryonic fibroblasts [38]. These observations demonstrate a regulatory role 
of the transmembrane domain by either enhancing or decreasing cell motility depending on 
the molecular approach and cell specific syndecan expression profile. In this Ph.D. study, it 
seems that the transmembrane domain is probably required for localizing the tCTF at the site 
of action, but it has not been further analysed whether oligomerization of the tCTF occurs 
and whether this is relevant for its activity.
Syndecans  are  described  to  cooperate  with  different  integrins  to  regulate  cell  motility 
[124;174].  In  a  study  of  Beauvais  et  al.,  (2009),  an  extracellular  peptide  inhibitor  was 
developed  to  inhibit  the  interaction  between  syndecan-1  and  αVβ3 or  αVβ5  integrin.  This 
inhibition blocks cell adhesion  in vitro and  tumor growth  in vivo [12]. Further, syndecan-1 
was demonstrated to be necessary for α2β1  integrin-mediated interaction with collagen [94]. 
Moreover, syndecan-1 was found to form a complex with MMP9 and α5β1 integrin in murine 
lung epithelial  cells  and this complex is  involved in cell  migration [119].  In addition,  β1 
integrin was demonstrated to colocalize with syndecan-1 in murine keratinocytes [161]. In 
regard to syndecan-4, it was shown that a trimolecular complex consist of thymocyte antigen 
1  (Thy-1)  α5β1 and  syndecan-4  [101]. Further,  β1 integrin  was  found  to  colocalize  with 
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syndecan-4 in human keratinocytes. Furthermore, syndecan-4 was reported to cooperate with 
α5β1  integrin to promote focal adhesion assembly on fibronectin [11].  In the present Ph.D. 
study, the expression of tCTFs or the full length syndecan-1, but not the cCTFs lacking the 
transmembrane domain in syndecan1 deficient cells, upregulated the expression of α5 and β1 
integrins (Figure ). Moreover, the promigratory effect of the syndecan-1 tCTF was inhibited 
by blocking β1 antibodies  suggesting that  β1  integrin critically mediates  the promigratory 
effect. Again, as seen in the migration assays, membrane localization of syndecan-1 and -4 
tCTF is essential for regulatory mechanisms towards integrin regulation. It can therefore be 
speculated that the transmembrane domain serves as interaction site to stabilize or enhance 
integrin expression. The role of the transmembrane domain regarding integrin upregulation is 
not fully understood and needs to be further investigation. 
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Figure . Integrin α5 and β1 expression are upregulated by plasma membrane localized syndecan 
in syndecan-1 defiecent cells.
The expression of the full length syndecan or its tCTF, but not the cCTF in syndecan-1 deficient cells, induces  
an upregulation of integrin α5 and β1 integrin at the cell surface. Green: upregulation, red : no change.
The intracellular domain of syndecans carries a number of signaling motifs for adapter and 
signaling molecules  involved in cell  motility.  For  example,  the C2 domain of syndecans 
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carries  a  conserved  PDZ  motif  for  adapter  and  signaling  molecules  such  as  syntenin, 
synectin,  syndesmose, and  Tiam1  domain  [7;66;73;159].  In  addition,  a  recent  report 
demonstrated that a part of the V and C2 region of syndecan-1 and syndecan-4 can couple to 
the α6 and β4 integrin intracellular domain [174]. These pathways have been linked to the 
activation of p38, Akt, Rho GTPase and FAK, which could then influence cell migration and 
focal  adhesion  formation  [119;126;137;167].  In  this  thesis,  the  expression  of  the 
transmembrane bound CTFs in syndecan1 deficient cells was sufficient to maintain a normal 
activation  status  of  p38,  Akt,  Rho  GTPase  and  FAK  indicating  that  crucial  signaling 
pathways towards cell proliferation and migration can be restored by the tCTFs (Figure  ). 
Further, expression of the tCTFs in syndecan-1 deficient cells decreased the phosphorylation 
of FAK at tyrosine 925. As mentioned above, this phosphorylation site leads to the exclusion 
of FAK from cell contacts. This could lead to a reduced stationary phase in cell movement 
and  promote  an  increased  assembly  and  disassembly  of  focal  adhesions  by  the  tCTFs. 
Another  possibility  is  that  expression  of  the  tCTF  restores  the  interaction  site  for  PDZ 
binding  proteins  or  the  cytoplasmic  domain  of  integrins  to  maintain  signal  transduction 
towards cell motility (Figure ). However, it is not yet clear how the transmembrane domain 
influences the different signaling motifs within the intracellular domain of syndecan-1 and -4. 
As mentioned above, the transmembrane domain could be involved inducing clustering of 
receptors to syndecans and bringing their cytoplasmic domain into closer proximity.  Future 
studies should elucidate the transmembrane domain in more detail. 
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Figure . Potentional signaling pathways after syndecan tCTF expression.
Expression of the tCTF in syndecan-1 deficient cells maintained a normal activation status of Rho, FAK, p38 
and Akt indicating that crucial signaling pathways towards cell proliferation and migration can be restored by 
the  tCTF.  As  shown in  yellow,  the  reconstituted  signaling  pathway could  also  be  influenced  by potential  
signaling molecules such as PDZ binding proteins, or by direct interaction with the cytoplasmic domain of 
integrins.  Red:  inhibition  of  signaling  pathway and  cell  motility;  black:  no  change;  green:  restoration  of 
signaling pathways and cell motility; yellow: potential signaling pathways.
As shown in  the  present  Ph.D.  thesis,  proteolytic  shedding generates  N-terminal  and C-
terminal syndecan-1 and -4 fragments that both contribute to cell migration. On the one hand, 
several studies have shown that the soluble ectodomain promotes cell migration by capturing 
chemokines creating a chemotactic gradient and by activation of integrins [13;96]. On the 
other hand, the present thesis demonstrates that the transmembrane C-terminal fragment also 
promotes cell migration. Therefore, loss of syndecan-1 expression as a result of enhanced 
shedding  would  not  directly  lead  to  inhibition  of  cell  migration,  because  the  generated 
soluble ectodomain and also the tCTF would still fulfil critical functions for cell migration. It  
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is not excluded that proteolytic shedding even constitutes an important step in syndecan-1 
mediated cell migration. Only at a later stage, when soluble syndecan-1 has disappeared in 
the intercellular fluid and when the tCTF has been degraded by the γ-secretase, it can be 
expected that migration will be inhibited. This could then help to turn off regenerative or 
possibly also malignant processes.
The role of syndecan-1 cCTF in cell motility 
There is a clear difference between the cCTF and the tCTFs with regard to their involvement 
in cell motility and proliferation. The presented findings showed that the syndecan-1 cCTF is 
present in A549 cells and that overexpression of the syndecan-1 cCTF blocks cell migration, 
invasion  and increased  adhesive  events  in  vitro.  This  inhibitory effect  on  cell  migration 
becomes apparent only when endogenous syndecan-1 is expressed. This effect is not seen in 
cells lacking syndecan-1. Further, lung metastasis formation was reduced upon syndecan-1 
cCTF overexpression in A549 cells in vivo. A synthetic peptide corresponding to the cCTF of 
syndecan1  can  be  used  to  suppress  lung  epithelial  tumor  cell  migration  and  disturb 
promigratory signals.  In contrast, syndecan-1 cCTF overxpression as well as cCTF peptide 
treatment in vitro showed no effect on cell proliferation in vitro and in vivo.
Several  surface  proteins  with  a  single  transmembrane  domain  undergo  intramembrane 
proteolysis  upon  their  proteolytic  shedding  at  the  cell  surface.  The  analysis  of  potential 
functions  of  cytoplasmic  cleavage  fragments  arising  from  intramembrane  proteolysis  is 
complicated  by  the  fact  that  these  fragments  can  undergo  further  proteolysis  via  the 
proteasome as it has been described for the chemokines CX3CL1 and CXCL16, the cytokine 
receptor IL6R or the amyloid precursor protein APP [31;130;156]. In fact, also the syndecan-
1 cCTF can undergo ubiquitin dependent degradation via the proteasome [142]. However, 
this does not exclude the possibility that the cCTF itself can fulfil a function within the cell.  
Such a potential function may become more relevant under conditions of reduced proteasome 
activity, which occurs upon treatment with drugs blocking the proteasome in cancer therapy 
such as bortezomib [35] or genetic proteasomal disorders [35;95].  A proteasome-regulated 
function  of  the intracellular  cleavage fragment  is  well  known for  Notch  [132].  Notch  is 
sequentially  cleaved  by  ADAMs  and  the  γ-secretase  complex  [48].  This  leads  to  the 
intracellular release of a C-terminal fragment into the cytoplasm, which is a critical step for 
its  nuclear  transport  and  transcriptional  activity  during  development  and  hematopoiesis. 
Intramembrane proteolysis by γ-secretase was also found to contribute to the transcriptional 
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regulation induced by CD44 and the MHC class II chaperone CD74 [14;138]. Compared to 
the cCTF of Notch,  CD44 and MHCII,  the C-terminus of syndecan-1 cCTF is  relatively 
small  and it  does  not  contain motifs  that  suggest  a  transcriptional  activity.  Nevertheless, 
following its overexpression syndecan-1 was found to translocate into the nucleus in human 
fibrosarcoma cells and this was dependent on a portion of the cytoplasmic C1 domain with 
the amino acid sequence RMKKK [189]. By this mechanism syndecan-1 was proposed to 
upregulate proadhesive and promigratory genes. However, in the present thesis there is no 
evidence  that  such  a  possible  mechanism is  used  by the  syndecan-1  cCTF.  In  fact,  the 
transcriptional  analysis  did  not  indicate  significant  changes  on  transcriptional  level  upon 
syndecan-1 cCTF overexpression. Therefore, the suppressive effect of the syndecan-1 cCTF 
on cell migration seems to involve posttranslational rather than transcriptional mechanisms. 
Of  note,  the  proteasomal  inhibitor  bortezomib,  which  is  used  in  the  clinic  to  prevent 
transcription factor  activation in  multiple  myeloma cells,  causes  the accumulation of  the 
syndecan-1 cCTF in cancer cells. Such a process would reduce cancer cell migration and 
could be beneficial for the treatment. In the present thesis, syndecan-1 cCTF overexpression 
showed no effect on proliferation in A549 cells.  However, a study by Zong et al.,  (2011) 
indicates  a  regulatory  role  of  the  cCTF  on  proliferation.  The  authors  showed  that 
overexpression  of  syndecan-1  C1  domain  fused  to  GFP  decreased  proliferation  in 
mesenchymal tumor cells. Again, these contradictory findings may be due to the fact that 
different cell types with different expression levels of syndecans have been used. 
In  contrast  to  proliferation,  cell  migration  and  invasion  were  clearly  decreased  by  the 
overexpression of syndecan-1 cCTF. This was associated with an increased adhesion of cells 
overexpressing syndecan-1 cCTF. This finding is in line with previous reports indicating that 
the cytoplasmic domain of  syndecan-1 is  involved in  events  related  to  cell  motility.  For 
example,  overexpression of full  length syndecan-1 with mutations in the V region of the 
cytoplasmic  domain  led  to  altered  cell  spreading  and  fascin-actin  bundling  of  monkey 
fibroblast-like cells [30]. Moreover, the cytoskeletal organization was shown to be disturbed 
by overexpression of full length syndecan-1 cytoplasmic domain truncation mutants in rat 
Schwann  cells  [28].  In  addition,  decreased  wound  closure  was  demonstrated  during  the 
overexpression  of  the  C1  domain  of  syndecan-1  in  human  fibrosacroma  cells  [189]. 
Interestingly, the latter effect was explained by a decreased adhesion whereas in the present 
thesis increased adhesion and increased focal adhesion formation were observed as discussed 
below. 
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It has been mentioned above that the cytoplasmic proportion of syndecan-1 can interact with 
various binding proteins.  The highly conserved C2 region of syndecan-1 contains a PDZ 
binding motif  and interacts  with PDZ binding proteins  [73;159].  Moreover,  the cCTF of 
syndecan-1 was found to interact with the intracellular domain of β4 integrin and to thereby 
regulate cell adhesion. This was mediated by the C2 domain plus part of the adjacent variable 
region of syndecan-1. In this thesis, overexpression of the syndecan-1 cCTF had no direct 
effect on the PDZ binding protein syntenin or basal integrin surface expression. Yet, adhesion 
and related processes  such as  paxillin  recruitment  to  focal  adhesions  increased when the 
cCTF was overexpressed. In fact,  syndecan-1 is well  known to modulate focal adhesions 
formation [13;78;119;129] and has been reported to promote paxillin exchange within the 
focal  adhesion  [4].  Moreover,  basal  activation  of  signaling  proteins  implicated  in  cell 
adhesion, such as FAK phosphorylation at tyrosine 397 as well as Rho GTPase activation, 
were found to be enhanced by the cCTF. And indeed, activation of focal adhesion kinase and 
Rho  GTPase  have  been  implicated  in  syndecan-1  mediated  effects  on  cell  migration 
[118;159].  Of  note,  FAK  phosphorylation  at  tyrosine  925  which  would  normally  drive 
exclusion of the kinase from focal adhesions, was not affected by the cCTF [75;121]. In 
addition, the cCTF also enhanced basal Src phosphorylation at tyrosine 416 which has been 
reported  to  be  syndecan-1  dependent  [34].  All  these  syndecan-1  mediated  responses  are 
known  to  regulate  tumor  cell  migration  [59;125;129;164;171].  The  syndecan-1  cCTF 
critically  influences  proadhesive  signaling  events,  which  are  syndecan-1  dependent  and 
implicated in tumor cell migration.
The observed upregulation of constitutive signaling by FAK and Src may directly cause more 
mature focal adhesion contacts and may finally lead to stronger adhesion. As the formation 
and resolution of focal adhesions is a critical step in cell migration, this dysregulation of cell 
adhesion by the cCTF may then result in the defect in cell migration. Such a dysregulation 
could arise from an intracellular interaction of the cCTF with signaling proteins that normally 
bind to intact syndecan-1 such as PDZ binding proteins or integrin (Figure  ) [73;159;174]. 
Since syndecan1 cCTF only exerts its inhibitory function on cell migration when endogenous 
syndecan1  is  present,  it  may  be  possible  that  the  cCTF  competes  with  the  full  length 
syndecan1 for intracellular interaction partners and thereby reduces signaling of syndecan-1 
(Figure ). Further, the syndecan-1 C-terminal fragment was found to be a binding partner of 
FAK [154]. Therefore, it  is possible that syndecan-1 cCTF overexpression disturbes FAK 
function (Figure ). Another possibility is that the expression of additional syndecan-1 cCTF 
modulates  intracellular  dimerisation  and  complex  formation  of  membrane  spanning 
100
Discussion
syndecan-1  by either  antagonising  or  providing  additional  interaction  sites  by the  cCTF 
(Figure  ). However,  the exact  mechanism of the single regions of  the cCTF is  not  fully 
understood regarding focal adhesion formation. Future studies should elucidate the region 
and binding partners of the cCTF, which are involved and promote these adhesive events. 
Syndecan-1 plays critical  roles in tumor development and has been proposed as target in 
myeloma  therapy [185].  As  a  pharmacological  approach,  an  inhibitory  antibody  against 
syndecan1 has been developed and successfully used to block melanoma growth and ovarian 
carcinoma in vitro [134]. Inhibitory peptides may represent an alternative approach as shown 
for a peptide termed synstatin which competitively displaces the integrin and  insulin-like 
growth factor 1 receptor (IGF1R) from the extracellular domain of syndecan-1 and thereby 
inhibits tumorigenesis and angiogenesis in vitro [146]. In addition, a peptide of the V domain 
of syndecan-1 fused to a cell permeable TAT peptide that could therefore be delivered into 
the target cells was shown to decrease cell migration in murine myoblast  cells [30]. The 
present Ph.D. thesis shows that a peptide corresponding to the natural syndecan-1 cCTF can 
be  deliverd  into  the  A549  cells  by  a  carrier  reagent.  The  peptide  delivery  blocks  cell 
migration  and  induces  basal  activation  of  Src  and FAK in  A549 cells.  This  was  clearly 
dependent on the presence of the carrier indicating that the peptide exerts its function in the 
cytoplasm. Further,  syndecan-1 cCTF peptide treatment  had no effect  on proliferation or 
morphology suggesting that the peptide does not induce obvious side effects. Therefore, the 
pharmacological data obtained with the peptide inhibitor correspond well to the data of the 
genetic experiment in which the cCTF was overexpressed. It is therefore well possible that 
the underlining inhibitory mechanisms are the same and that the syndecan-1 cCTF peptide 
affects interaction partners as discussed for syndecan-1 cCTF overexpression (Figure ). 
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Figure . Potentional model of syndecan-1 cCTF mediated inhibition of cell migration.
Overexpression of syndecan-1 cCTF or syndecan-1 cCTF peptide treatment increases the activation of FAK. 
Src, Rho GTPase and paxillin are recruited to focal adhesions. This results in increased focal adhesion and 
decreases the cell migration and invasion. A possible explanation could be that syndecan1 cCTF competes with 
the  full  length  syndecan-1  for  intracellular  interaction  partners  (1.).  Other  possibilities  are  that  either  the  
dimerization of full length syndecan-1 is blocked by the cCTF (2.) or the interaction of PDZ binding proteins or 
the intracellular domain of integrins is blocked by the cCTF (3.) Further, FAK function is alterte by syndecan-1  
cCTF to maintain focal adhesion assembly and disassembly (4.).
These  results  indicate  that it  may be  possible  to  target  selected  functions  of  syndecan-1 
mediated by different domains. These peptide inhibitors against the cytoplasmic portion of 
syndecan-1  may  serve  to  selectively  target  the  intracellular  promigratory  activity  of 
syndecan-1, without affecting its extracellular function. In the future, side effects of these 
approaches on wound healing and inflammatory responses need to be studied in detail.
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6 Outlook
Syndecans  undergo  proteolytic  cleavage  by  e.g.  the  metalloproteinase  ADAM17  at  the 
extracellular  site.  The  residual  tCTF is  further  processed  by the  γ-secretase  [142].  With 
respect to the generation of the tCTF and cCTF of syndecans, there are some aspects that 
deserve  further  investigation.  In  particular,  the  exact  mechanism of  ADAM17  mediated 
shedding  and  intramembrane  proteolysis  by  the  γ-secreatse  towards  cell  motility  is  not 
completely understood. One approach to address this still  open issue is the generation of 
cleavage  resistant  mutants  of  syndecan.  This  would  allow  to  study  how  abrogates  of 
syndecan cleavage would affect cell motility in detail. Further, these mutants could be used to 
study the involvement of other proteases in syndecan shedding as these proteases potentially 
still  process the mutated syndecan variant.  However,  the generation of shedding resistant 
substrates  may  not  be  straightforward.  While  the  generation  of  other  shedding  resistant 
substrates such as CX3CL1 for ADAM17 failed, it has been reported that syndecan-1 and -4 
ectodomain mutation led to decreased ectodomain shedding mediated by MMPs and a TIMP-
3  sensitive  metalloproteinase  [6;57;117].  Further,  γ-secreatse  cleavage  resistant  syndecan 
mutants are not described so far.  At least,  for Notch and  human epidermal growth factor 
receptor 4 (HER4) cleavage resistant mutants are described [84;173]. Yet, such mutants have 
to be carefully characterized for residual shedding as it is generally thought that ADAM17 as 
well  as  the  γ-secretase do  not  recognize  a  specific  sequence  motif  but  rather  multiple 
structural determinants distant from the cleavage site [8;15]. Such cleaving resistant mutants 
could then be expressed in A549 cells lacking endogenous syndecan-1 to study the impact on 
cell migration, invasion, adhesion and signaling events.
Syndecans are known to interact with integrins, but the exact mechanism regarding signaling 
pathways and cell surface regulation of integrins appears quite complex [124;148]. In the 
present  Ph.D.  thesis,  syndecan  tCTFs  and  full  length  syndecan-1,  but  not  the  cCTFs 
expression in syndecan1 deficient cells, was able to induce α5 and β1 surface expression. This 
pathway seems to play a role in syndecan-mediated cell migration. It seems likely that the 
plasma membrane insertion via the transmembrane domain of syndecans is required for this 
upregulation. It would be interesting to investigate whether a mutation of the transmembrane 
domain abrogates the induction of α5 and β1  integrins and abolishes the promigratory effect. 
For  this  purpose  various  mutations  could  be  introduced  including  complete  amino  acid 
exchange by alanine repeat, which was shown to decrease cell spreading in a previous study 
[120]. In addition, the syndecan-1 and 4 transmembrane domains could be replaced by the 
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transmembrane domain of other syndecans. For example, replacement of the transmembrane 
domain  of  syndecan-2  by  syndecan-4  failed  to  mediate  syndecan-2  dependent  cellular 
functions such as cell migration of rat embryonic fibroblast in vitro [103].
The results of the present thesis support the current view that syndecans play an important 
role in cancer cell motility and that each syndecan domain exhibits different functions. With 
respect  to the inhibitory function of the overexpressed syndecan-1 cCTF and syndecan-1 
cCTF peptide, there are some aspects that need further investigation. To clarify whether the 
C1, V or C2 region is involved in the antagonistic activity of the syndecan-1 cCTF, the single 
regions  of  the  cytoplasmic  domain  should  be  mutated  and  analysed  in  wound  closure 
response,  promigratory signaling events and paxillin recruitment. Furthermore,  interaction 
partners  of  the  cCTF should  be  analysed.  For  example,  Tiam1 and FAK were  found to 
interact  with  the  cCTF.  Follow-up  projects  could  study  such  possible  interactions  by 
performing e.g. immunoprecipitation, pull-down, and fluorescence resonance energy transfer 
(FRET) experiments [154;159].
The present thesis indicates that the C-terminus of syndecan-1 may represent a novel target to 
suppress  cancer  cell  motility.  This  view  is  also  supported  by  different  in  vitro  studies 
[30;174].  To further analyse the  in  vivo relevance,  it  will  be necessary to  administer  the 
syndecan-1 cCTF peptide to mice. However, this  approach is limited by the fact that the 
peptide  per se will not be delivered into the cancer cells in mice.  As reported for the two 
other  syndecan  peptids,  the  syndecan-1  cCTF  peptide  variant  could  be  fused  to  a  cell 
permeable  TAT peptide.  In  fact,  TAT fusion  peptides  against  cancer  cells  were  already 
generated and showed promising in vitro and in vivo results [112;114;135]. Another approach 
could  be  the  development  of  small  cell  permeable  molecular  compounds  against  the 
cytoplasmic portion of syndecan-1 to block the promigratory activity. This approach may be 
difficult  by the fact that the C-terminus of syndecans is  relatively small.  However,  small 
molecular inhibitors against the PDZ domain of the  PRKCA-binding protein (PICK1) are 
described [166].  These  inhibitors  could  be  used  as  a  basis  to  develop syndecan specific 
inhibitors targeting the PDZ domain as well as the unique variable domain of syndecans.
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7 Summary
Syndecan-1 and -4 are cell surface heparan sulphate proteoglycans that  are predominantly 
found on endothelial and epithelial cells. The core protein consists of an ectodomain carrying 
heparan  sulphate  and  chondroitin  sulphate  rich  glycosaminoglycan  chains,  a  single 
transmembrane  domain  and  a  short  cytoplasmic  domain. Surface  expressed  syndecans 
undergo limited  proteolysis  by a  disintegrin  and metalloproteinase  (ADAM) 17 near  the 
plasma  membrane  leading  to  the  generation  of  a  residual  transmembrane  C-terminal 
fragment (tCTF) and the release of the soluble ectodomain. This process is termed shedding. 
Following ectodomain cleavage the tCTF undergoes intramembrane proteolysis by  the  γ-
secretase-complex, leading to the generation of a cytoplasmic CTF (cCTF). Syndecan-1 and 
-4  play regulatory roles in wound healing,  inflammation and tumor development  and are 
released as soluble variants, into the serum of cancer patients and the bronchoalveolar fluid 
of inflamed lungs. While much of the previous work focused on the function of the shed 
ectodomains, little is known about the functional role of the tCTFs, which were investigated 
in the present study.  The production of these fragments was enhanced during the wound 
closure response of A549 cells associated with increased release of soluble syndecan1 and -4 
and accumulation of syndecan-1 tCTF. Lentiviral transduction of A549 lung epithelial cancer 
cells with shRNA against syndecan-1 or syndecan-4 resulted in loss of syndecan-1 or -4, 
which  critically  reduced  cell  proliferation  and  migration  during  wound  closure  in  vitro. 
Syndecan depletion also led to decreased activation of signaling pathways related to  cell 
motility such as the small GTPase Rho, Akt, p38, whereas the FAK was hyperphosphorylated 
at  tyrosines  397 and 925. In an  in  vivo xenograft  transplantation model  in mice,  loss of 
syndecan-1, but not syndecan-4, reduced lung metastasis formation. These defects due to loss 
of syndecan-1 were overcome by expression of syndecan-1 or -4 tCTF but not by the cCTFs 
lacking the transmembrane domain. Further,  the expression of tCTFs but not the cCTFs in 
syndecan-1 deficient cells upregulated the expression of α5 and β1 integrins and blocking of 
β1 integrin inhibited the promigratory effect of the syndecan-1 tCTF. In contrast, lentiviral 
overexpression of the syndecan-1 cCTF in A549 cells inhibited cell migration and invasion 
in vitro and in vivo. This effect was only seen in cells expressing endogenous syndecan-1 but 
not in syndecan-1 deficient cells,  indicating that the cCTF may function by antagonizing 
activities of endogenous syndecan-1. Transcriptional analysis showed no changes during the 
expression of the syndecan-1 cCTF. Basal activation of Src, 
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FAK and Rho GTPase was enhanced by the cCTF and associated with a tighter adhesion and 
recruitment of paxillin to focal adhesions suggesting that the cCTF dysregulates adhesive 
events required for syndecan-1 mediated cell migration. On the basis of these experiments, a 
synthetic  syndecan-1  cCTF  peptide  inhibitor  was  developed  that  suppressed  syndecan-1 
mediated tumor cell migration and the related signaling pathways  in vitro.  Taken together, 
this study demonstrates the importance of syndecan-1 and -4 cleavage fragments in cancer 
cell motility in vitro and in vivo. The cleavage fragments can act either as agonist in the case 
of the tCTFs or as antagonist in the case of cCTF. It is  therefore proposed that therapeutic 
strategies aiming at blocking cell motility by inhibition of syndecan-1 or -4 should target 
both extracellular as well as intracellular activities of the molecule. The peptide presented in 
this thesis could serve to develop such intracellular inhibitor of syndecan-1.
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8 Zusammenfassung
Syndekan-1 und -4 gehören zur Klasse der Heparansulfat-Proteoglykane und werden primär 
auf Endothel- und Epithelzellen exprimiert. Die Syndekane beinhalten ein Kern-Struktur, an 
die eine oder mehrere Heparansulfat-Glykosaminoglykan (GAG) Ketten angeheftet sind, eine 
transmembrane Domäne und eine kleine zytoplasmatische Domäne. Die auch als Shedding 
bekannte  proteolytische  Spaltung  der  Syndekane  durch  die  Metalloproteinase  ADAM17, 
führt  zur Freisetzung der löslichen Ektodomäne der Syndekane.  Das in  der Zellmembran 
verbleibende transmembrane C-terminale Fragment (tCTF) wird nachfolgend durch den  γ-
Sekretase-Komplex  prozessiert,  wodurch  ein  lösliches,  cytoplasmatisches  CTFs  (cCTF) 
entsteht. Syndekan-1 und -4 sind an der Regulation von Wundheilung, Tumorentstehung und 
Metastasierung  beteiligt.  Die  lösliche  Ektodomäne  von  Syndekan-1  und  -4  konnte  im 
Blutserum  von  Krebspatienten  sowie  in  der  bronchoalveolären  Lavage  während 
Entzündungsprozessen  in  der  Lunge  nachgewiesen  werden.  Bisherige  Studien  waren 
hauptsächlich  auf  den  Einfluss  der  lösliche  Ektodomäne  ausgerichtet,  wohingegen  die 
Funktion  der  verbleibenden  C-terminale  Spaltfragmente  wenig  bekannt  ist.  In  der 
vorliegenden  Arbeit  wurden  die  tCTFs  von  Syndekan-1  und  -4  sowie  das  cCTF  von 
Syndekan-1  auf  ihren  funktionellen  Einfluss  auf  die  Zellmotilität  von  epithelialen 
Lungentumorzellen  in  vitro und  in  vivo untersucht.  Bei  kultivierten  epithelialen 
Lungentumorzellen der  Linie  A549 zeigte  sich,  im Verlauf  der  experimentell  Induzierten 
Wundschlussreaktion  in  vitro eine  erhöhte  Freisetzung  der  löslichen  Ektodomäne  von 
Syndekan1 und -4 sowie eine Akkumulation des tCTFs von Syndekan-1.  Die lentivirale-
shRNA vermittelte  Herabregulation  von  endogenen  Syndekan-1  oder  -4  in  A549  Zellen 
zeigte eine verminderte Zellmigration und Zellinvasion. Des Weiteren wurden Signalwege, 
die eine Rolle bei der Zellmotilität spielen untersucht. Die Aktivierung der Rho GTPase, Akt 
und p38 waren durch die Herabregulation von Syndekan-1 oder -4 reduziert. Im Gegensatz 
dazu, konnte eine vermehrte Phosphorylierung von Tyrosin 397 und 925 der FAK detektiert 
werden. Syndekan-1-defiziente Zellen zeigten in einem murinen Xenotransplantationmodell 
eine reduzierte Ausbildung von Lungenmetastasen,  während Syndekan-4-defiziente Zellen 
keine  Veränderung  im  Vergleich  zur  Kontrolle  aufwiesen.  Der  Verlust  von  endogenem 
Syndekan-1  und  die  damit  verbundenen  Effekte  wurden  mittels  lentiviral-vermittelte 
Expression des Syndekan-1 oder Syndekan-4 tCTFs wieder aufgehoben, wobei die lentiviral-
vermittelte  Überexpression  der  cCTFs  keinen  Einfluss  auf  die  Zellmigration  hatte.  Die 
Syndekan1 oder -4 tCTF exprimierenden Zellen zeigten ferner eine erhöhte Expression von 
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α5 und  β1 Integrin  wobei  die  Syndekan  cCTFs  Expression  keine  Induktion  der 
Integrinexpression  auf  der  Zelloberfläche  zeigte.  Im  Gegensatz  dazu  führte  die 
Überexpression des Syndekan-1 cCTFs in A549 Zellen in vitro und in vivo zur verminderten 
Zellmigration  und Zellinvasion.  Die Überexpression  des  Syndekan-1 cCTF zeigte  keinen 
Einfluss  auf  Transkriptionsebene  jedoch  konnte  eine  Zunahme  der  Aktivierung  von 
Signalmolekülen  wie  Src,  focal  adhesion  kinase  (FAK)  und  Rho  GTPasen  beobachtet 
werden, die in Verbindung mit einer erhöhten Adhäsion stehen. Die ebenfalls beobachtete 
Rekrutierung von Paxillin zu fokalen Adhäsionen sowie die erhöhte Adhäsion legen nahe, 
dass  die  Dysregulation  der  Adhäsionsprozesse  durch  die  Überexpression  des  Syndekan-1 
cCTF in Zellen mit endogenem Syndekan-1 zu einer verminderten Zellmotilität führt. Des 
Weiteren  zeigten  Syndekan-1  cCTF  überexprimierende  A549  Zellen  eine  verminderte 
Metastasen-Ausbildung.  Auf  Grundlage  der  in  vitro und  in  vivo Experimente  wurde  ein 
synthetisches  Syndekan-1  Peptid  entwickelt,  welches  die  Zellmigration  und  die  damit 
verbundene Signalwege in A549 Zellen, die endogenes Syndekan-1 exprimieren, hemmte. 
Diese Arbeit zeigt, dass Syndekan-1 und -4 Spaltfragmente regulatorisch auf die Zellmotilität 
wirken können. Das tCTF wirkt agonistisch wohingegen das cCTF als Antagonist fungiert. 
Darauf basierend sollten für die Tumortherapie Strategien entwickelt werden, um nicht nur 
die  extrazelluläre  sondern  auch  die  cytoplasmatische  Aktivität  von  Syndekan-1  und  -4 
blockieren. Als ein Ansatz hierfür könnte das in der Arbeit vorgestellte Peptid sein. 
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10 Appendix
10.1 Abbreviations
ADAM a disintegrin and metalloproteinase
Amp ampicillin
ANOVA analysis of variances
APP  amyloid precursor protein 
APC allophycocyanin
APH-1 anterior pharynx-defective-1
BSA bovine serum albumin
°C degrees Celsius
CCL [C C motif] ligand
cCTF cytoplasmic C-terminal fragment
C1 membrane proximal region
C2 c-terminal region
CAM cell adhesion molecules
CASK calcium/calmodulin-dependent serine kinase
CCL18 [C C motif] ligand 18 
cDNA complementary DNA
CHO Chinese hamster ovary cells
COPD chronic obstructive pulmonary disease
CTF c-terminal fragment
CXCL [C X C motif] ligand
Da Dalton
DMEM Dulbecco´s modified Eagle´s medium
DMSO dimethyl sulfoxid
DNA deoxyribonucleic acid
ECM extracellular matrix
EGF epithelial growth factor
E-selectin endothelial-selectin
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ERK extracellular-signal regulated kinase
et al. et alii
FACS fluorescence activated cell sorter
FAK focal adhesion kinase
FAT focal adhesion targeting sequence
FCS fetal calf serum
FDR fold discovery rate
FERM 4.1 protein, ezrin-radixin-moesin
FGF fibroblast growth factor
g g-force
GAG glycosaminoglycan
GFP green fluorescent protein
GPCR G-protein coupled receptor
GPI glycosylphosphatidylinosito
h hour
HA human influenza hemagglutinin
HER human epithelial growth factor receptor
HRP horseradish peroxidase
HSPG heparansulfate proteoglycan
IFN-γ interferon-γ 
Ig immunoglobulin
IGF1R insulin-like growth factor 1 receptor
IL6R Interleukin 6 receptor 
kDa kilo dalton
L-selectin leukocyte-selectin
LD leucine-rich domains (LD)
LLC lewis lung carcinoma
mAb monoclonal antibody
MALDI Matrix-assisted laser desorption/ionization
MAPK mitogen-activated protein kinase
MCP-1 monocyte chemoattractant protein-1
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mCherry fruit fluorescence protein developed by Dr. Rogen Tsiens lab
min minute
ml millilitre
mM millimolar
MMP matrix metalloproteinase
mRNA messenger RNA
nm nanometer
p probability
PAGE polyacrylamide gel electrophoresis
P-selectin platelet-selectin
P/S penicillin/streptomycin
PCR polymerase chain reaction
PDZ postsynaptic density, discs large, zona occludens 1
PEN-2 presenilin enhancer-2
PFA paraformaldehyde
PI3-K phosphatidylinositol-3-kinase 
PIP2 phosphatidylinositol 4,5-bisphosphate 
PKCα protein kinase c α
PMA phorbol 12-myristate 13-acetate
PVDF polyvinylidene difluoride
qPCR quantitative real-time polymerase chain reaction
RNA ribonucleic acid
RMA robust multiarray average 
RIN RNA integrity number
rpm rounds per minte
SCID severe combined immunodeficiency
SD standard deviation 
SDC syndecan
TAC transcriptome analysis console
TAT transactivator protein
tCTF transmembrane C-terminal fragment 
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shRNA shorthairpin RNA
TGF transforming growth factor
Tiam1 T-lymphoma invasion and metastasis-inducing protein 1
TNF-α tumor necrosis factor alpha
TOF time of flight
Tyr tyrosin
V variable 
Amino acids 
A alanine (Ala) G glycine (Gly) M methionine (Met) S serine (Ser)
C cysteine (Cys) H histidine (His) N asparagine (Asn) T threonine (Thr)
D aspartic acid (Asp) I isoleucine (Ile) P proline (Pro) V valine (Val)
E glutamic acid (Glu) K lysine (Lys) Q glutamine (Gln) W tryptophane (Trp)
F phenylalanine (Phe) L leucine (Leu) R arginine (Arg) Y tyrosine (Tyr)
10.2 List of figures
10.3 List of tables
10.4 Plasmid maps and nucleotide sequences
Figure . Plasmid map of psPAX2, source from addgene.com
Addgene number: 12260.
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Figure . Plasmid map of pMD2.G, source from addgene.com.
Addgene number: 12259.
Figure . Plasmid map of pLVTHM, source from addgene.com.
Addgene number: 12247.MluI and ClaI were used to insert shRNA sequences (annealed oligonucleotides) [80].
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Figure . Plasmid map of pLVX-EF1a-IRES-mCherry empty vector
Figure . Plasmid map of pLVX-EF1a-IRES-mCherry SDC-1 tCTF.
SpeI and EcoRI were used to insert the SDC-1 tCTF sequence.
Figure . Plasmid map of pLVX-EF1a-IRES-mCherry SDC-4 tCTF.
SpeI and EcoRI were used to insert the SDC-4 tCTF sequence [177].
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Figure . Plasmid map of pLVX-mCherry SDC-1 cCTF.
SpeI and NotI were used to insert the SDC-1 cCTF sequence [177].
Figure 53. Plasmid map of pLVX-mCherry SDC-1 cCTF-HA tag.
SpeI and NotI were used to insert the SDC-1 cCTF-HA tag sequence.
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Figure . Plasmid map of pLVX-mCherry full length SDC-1.
NotI and EcoRI were used to insert the full length SDC-1 sequence.
Nucleotide sequences
All  sequences  were  verified  by  sequencing  (MWG  Biotech,  Ebersberg,  Germany)  and 
showed no mutations.
Green: Kozak sequence
Gray: signal peptide sequence
No colure: gene sequence 
Yellow: HA-tag
SDC-1 tCTF
GTGACTTCCGGGCAGATGAGACGCGCGGCGCTCTGGCTCTGGCTCTGCGCGCTGGCGCTGAGCCTG
CAGCCGGCCCTGCCGCTGGGAGCTGGGAGGGGTCATTGCCGGAGGCCTCGTGGGGCTCATCTTTGC
TGTGTGCCTGGTGGGTTTCATGCTGTACCGCATGAAGAAGAAGGACGAAGGCAGCTACTCCTTGGA
GGAGCCGAAACAAGCCAACGGCGGTGCCTACCAGAAACCCACCAAGCAGGAGGAGTTCTACGCCT
GA 
SDC-4 tCTF
GTGACTTCTGGGCAGGTGACTACTAGTGTGACTTGTTGAAGCCATGGCGCCTGCCTGCCTGCTTGC
GCCGCTGCTGCTGCTGCTCCTCGGAGGCTTCCCCTTGGTCCCCGGAACTGAGGTGACTACTAGTGT
GACTTGTTGAAGCCATGGCGCCTGCCTGCCTGCTTGCGCCGCTGCTGCTGCTGCTCCTCGGAGGCTT
CCCCTTGGTCCCCGGAACTGAGGTCTTGGCAGCTCTGATCGTGGGCGGCGTGGTAGGCATCCTCTTT
GCCGTTTTCCTGATCCTGCTGCTGGTGTACCGCATGAAGAAGAAGGACGAAGGCAGTTACGACTTG
GGCAAGAAACCCATCTACAAAAAAGCCCCCACCAATGAGTTCTACGCATGAGTGACTGTGACTATC
GATGTGACTGTGACTGCGGCCGCGTGACT
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SDC-1 cCTF
GTGACTTCCGGGCAGCCTAGTAACGGGCAGCATGAAGAAGAAGGACGAAGGCAGCTACTCCTTGG
AGGAGCCGAAACAAGCCAACGGCGGGGCCTACCAGAAGCCCACCAAACAGGAGGAATTCTATGCC
TGACACTGGC
SDC-1 cCTF-HA-tag
GTGACTTCCGGGCAGCCTAGTAACGGGCAGCATGAAGAAGAAGGACGAAGGCAGCTACTCCTTGG
AGGAGCCGAAACAAGCCAACGGCGGGGCCTACCAGAAGCCCACCAAACAGGAGGAATTCTATGCC
TGACACTGGC TACCCATACGACGTGCCAGACTACGCC
Full length SDC-1
GTGACTTCCGGGCAGCATGAGACGCGCGGCGCTCTGGCTCTGGCTCTGCGCGCTGGCGCTGAGCCT
GCAGCCGGCCCTGCCGCAGCCGGCCCTGCCGCAAATTGTGGCTACTAATTTGCCCCCTGAAGATCA
AGATGGCTCTGGGGATGACTCTGACAACTTCTCCGGCTCAGGTGCAGGTGCTTTGCAAGATATCAC
CTTGTCACAGCAGACCCCCTCCACTTGGAAGGACACGCAGCTCCTGACGGCTATTCCCACGTCTCC
AGAACCCACCGGCCTGGAGGCTACAGCTGCCTCCACCTCCACCCTGCCGGCTGGAGAGGGGCCCA
AGGAGGGAGAGGCTGTAGTCCTGCCAGAAGTGGAGCCTGGCCTCACCGCCCGGGAGCAGGAGGC
CACCCCCCGACCCAGGGAGACCACACAGCTCCCGACCACTCATCAGGCCTCAACGACCACAGCCA
CCACGGCCCAGGAGCCCGCCACCTCCCACCCCCACAGGGACATGCAGCCTGGCCACCATGAGACC
TCAACCCCTGCAGGACCCAGCCAAGCTGACCTTCACACTCCCCACACAGAGGATGAGGTCCTTCTG
CCACCGAGAGGGCTGCTGAGGATGGAGCCTCCAGTCAGCTCCCAGCAGCAGAGGGCTCTGGGGAG
CAGGACTTCACCTTTGAAACCTCGGGGGAGAATACGGCTGTAGTGGCCGTGGAGCCTGACCGCCG
GAACCAGTCCCCAGTGGATCAGGGGGCCACGGGGGCCTCACAGGGCCTCCTGGACAGGAAAGAG
GTGCTGGGAGGGGTCATTGCCGGAGGCCTCGTGGGGCTCATCTTTGCTGTGTGCCTGGTGGGTTTC
ATGCTGTACGCATGAAGAAGAAGGACGAAGGCAGCTACTCCTTGGAGGAGCCGAAACAAGCCAAC
GGCGGGGCCTACCAGAAGCCCACCAAACAGGAGGAATTCTATGCCTGA
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Figure . Quality certificate syndecan-1 cCTF peptide from ThermoScientific.
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Figure . Quality certificate scramble cCTF peptide from ThermoScientific.
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